Current Trends in Cardiovascular Research

Jan Fedacko (Editor)
Department of Internal Medicine, PJ Safaric University, Kosice, Slovakia

Krasimira Hristova (Editor)
National Heart Institute, Sofia, Bulgaria

Germaine Cornelissen (Editor)
Halberg Chronobiology Center, University of Minnesota, Medical School, Minneapolis, USA

Ram B. Singh (Editor)
Halberg Hospital and Research Institute, Moradabad, India
The Tsim Tsoum Institute, Krakow, Poland

Series: Cardiology Research and Clinical Developments
BISAC: TEC012000

Clear

$230.00

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Details

Current Trends in Cardiovascular Research brings evidence to the medical community about the role of metabolic factors in the pathogenesis of cardiovascular function and dysfunction which results in different cardiovascular diseases. (Imprint: Nova Biomedical)

PART I

Chapter 1. Coronary Risk Factors in South West Asia
Abdulla Shehab, Galal Elkilany, R B Singh, Krassimira Hristova, Hilton Chaves, Germaine Cornelissen, Kuniaki Otsuka

Chapter 2. Can Circadian Restriction of Feeding Modulate Autonomic Nervous System Dysfunction and Cardiometabolic Risk?
Ram B Singh, Krasimira Hristova, Tatjana Gligorijevic, Fabien De Meester, Banshi Saboo, Galal Elkilany, Toru Takahashi, Anuj Mahashwari, Germaine Cornelissen, Najah R. Hadi, Bassim I. Mohammad, Sergey Chibisov, Maria Abramova, and Sergey Shastun

Editorial

Chapter 3. Heart Failure Biomarkers: Importance in Prognosis of Disease
Neha Singh, Neelesh Gupta, Rajeev Gupta, Abdulla Shehab, Krasimira Hristova, Galal Elkilany, and Parinita Dherange

Chapter 4. Association of Silent Myocardial Ischemia among Patients with Newly Diagnosed Type 2 Diabetes Mellitus, Detected by 48-Hour Ambulatory Electrocardiographic Monitoring
Laith Abdulhussein Aldabbagh, Abdulhamza Rajooj Hmood, Najah R. Hadi, and Neelesh Gupta

Chapter 5. Diet and Atherosclerosis in Ancient Periods
Geir Bjørklund, Douglas W. Wilson, Fabien De Meester, Toru Takahashi, Agnieszka Wilczynska, Ram B. Singh, and Banshi Saboo

Chapter 6. Management of Type 2 Diabetes and Atherosclerosis with Alternative Therapies
Pradeep Kumar Singh Visen, Aastha Singh Visen, Srishti Singh Visen, Harpal Singh Buttar, and Ram B. Singh

Chapter 7. Cerebral Infarction in Wolff-Parkinson-White Syndrome – A Case Report
N. S. Neki, Divyang M. Shah, Maninder Singh, Kailash Kohle, Shrikant Bollewar, and Monisha Bali

Editorial 1.

Chapter 8. Beyond Drug Therapy: Nutritional Perspectives in the Management of Chronic Heart Failure
Galal El-Kilany, Ram B Singh, Krasimira Hristova, Branislav Milovanovic, Hilton Chaves, Douglas W. Wilson, Banshi Saboo, and Anuj Mahashwari

Chapter 9. Prevalence of Diabetes Mellitus among Known Hypertensive Patients
Ratindra N. Mondal, Shafiul Alam, Ashraful Haque, Shah Md Sarwer Jahan, Abul Kalam Azad, Mahfuzer Rahman, Moni Rani, B. D. Bidhu, AKM Shaheduzzaman, K. Sarker, Amaresh C. Shaha, Ram B. Singh, N. Islam, Devendra N. Sarkar, and Md Z. Hossain

Chapter 10. Ambulatory Blood Pressure Monitoring for Clinical Applications and Basic Science
Germaine Cornelissen, Cathy Lee Gierke, Yoshihiko Watanabe, Larry A Beaty, Jarmila Siegelova, Alain Delcourt, Christian Deruyck, Ram B Singh, Miguel A Revilla, Kuniaki Otsuka, On behalf of the Project on the BIOsphere and the COSmos (BIOCOS)

Chapter 11. Are Mitochondrial Energetics in the Rat under Control of the Solar (24 Hours) and/or Lunar (24.8 Hours) Day?
Miroslav Mikulecký, Sr., Anna Gvozdjáková, Jarmila Kucharská, Viliam Mojto, Miroslav Mikulecký, Jr., Ram B Singh, and Germaine Cornélissen

Chapter 12. Brain-Heart Interactions and Circadian Rhythms in Chronic Heart Failure (Homage to Dr. Franz Halberg on the 2nd Anniversary of his death on 9th June 2013)
Ram B Singh, Germaine Cornelissen, Toru Takahashi, Sergey Shastun, Krasimira Hristova, Sergey Chibisov, Markus Keim, Maria Abramova, Kuniaki Otsuka, Banshi Saboo, RK Singh, NS Verma, Anna Gvozdjakova, Jan Fedacko, Daniel Pella, Ranjana Singh, Anuj Maheshwari, AK Pandey, and Douglas W Wilson

Chapter 13. Case Report: Congenital Absence of Left Circumflex Artery
Mukesh Nathani, Alaa M. J. Al-khafaji, Sherif Ahmed Baathallah, Galal Elkilany, Aula M. Ismael, and Safaa A. Alawi

Chapter 14. Study of the Effects of Isolated Systolic Hypertension versus Those with Isolated Diastolic Hypertension on Atherosclerotic Risk Factors in Young Adults
Hussein Aziz Naser, Rajeev Gupta, and Neelesh Gupta

Chapter 15. New Coronary Risk Factors in Chronic Heart Failure
Ram B Singh, Adarsh Kumar, Krasimira Hristova, Jan Fedacko, Shantanu Singhal, Douglas W Wilson, and Toru Takahashi

PART II

Chapter 16. Angiotensin-Receptor Neprilysin Inhibitor Lcz696: A Novel Therapy for Heart Failure
IM Bassim, NR Hadi, RB Singh, Sergey Shastun, Turegeldy Sharmanov, Shamil Tazhibayev, and Lyazzat Gumarova

Chapter 17. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors
Banshi Saboo, RB Singh, Jan Fedacko, Krasimira Hristova, Galal Elkilany, Telessy Istavan, Mridula Rai, and DW Wilson

Editorial

Chapter 18. Recent Monoclonal Antibody Trials in the Management of Coronary Artery Disease
RB Singh, Krasimira Hristova, Jan Fedacko, Rajeev Gupta, and Hilton Chaves

Chapter 19. Can Halberg's Chronotherapy Approach Increase Efficacy and Safety of PCSK9 Inhibitors and Decrease Their Adverse Effects?
RB Singh, Germaine Cornelissen, Anna Gvozdjáková, Jan Fedacko, Banshi Saboo, and Anuj Mahashwari

Chapter 20. Study Protocol for a New Study: Can Chronotherapy Enhance Efficacy and Diminish Adverse Effects of PCSK9 Inhibitors in the Management of Acute Coronary Syndromes?
Jan Fedacko, Krasimira Hristova, Galal Elkilany, JP Sharma, Germaine Cornelissen, Ram B Singh, Banshi Saboo, and Ramesh K Goyal

Chapter 21. The Challenges of New Guidelines for Management of Hypertension: A View Point of the International College of Cardiology
Krassimira Hristova, RB Singh, Germaine Cornelissen, Jan Fedacko, Daniel Pella, Hilton Chaves, Galal Elkilany, and Kuniaki Otsuka

Chapter 22. In Search of Wonderland: Heparin or Bivalirudin
Rajeev Gupta, Neelesh Gupta, Jan Fedacko, Viola Mechirova, Daniel Pella, and RB Singh

Chapter 23. Mitochondrial Coenzyme Q and Oxidative Phosphorylation in Brain and Myocardium of Control and Diabetic Rats
Anna Gvozdjáková, Jarmila Kucharská, Ol’ga Vanèová, Ol’ga Ulièná, Viliam Mojto, Ram B Singh, and Germaine Cornelissen

Chapter 24. Effect of Maternal Dietary Supplementation on Complications of Pregnancy and Infancy and Metabolic Syndrome in Later Adult Life
Poonam Singh, Rajesh K Singh, Ram B Singh, Banshi Saboo, Galal Elkilany, Krassimira Hristova, DW Wilson, and Fabien De Meester

Review Article

Chapter 25. Can Brain-Derived Neurotrophic Factor Modulate Cardiometabolic Risk for Prevention of Vascular Disease?
Ram B Singh, Anuj Mahashwari,Toru Takahashi, Miki Tokunaga, Agnieszka Wilczynska, Banshi Saboo, Fabien De Meester, Galal Elkilany, Krasimira Hristova, Douglas W Wilson, and Sergey Shastun

PART III

Editorial 1

Chapter 26. Can Improvement in Nutritional Status Decrease Infant and Childhood Mortality As Well As Future Risk of Cardiovascular Diseases?
Toru Takahashi, Fabien De Meester, and Ram B Singh

Editorial 2

Chapter 27. The Ambient Air Pollution and the Heart
RB Singh, Toru Takahashi, Galal Elkilany, Krasimira Hristova, Aparajita Singh, Raina Pal, Zubin Pradeep Sharma, and Sergey Shastun

Editorial 3

Chapter 28. Genetic Risk Factors of Coronary Artery Disease
Ram B Singh, Seithikurippu R. Pandi-Perumal, Jaipaul Singh, Krasimira Hristova, and Galal Elkilany

Chapter 29. Cardiovascular Autonomic Disturbances in Patients with Diabetes Mellitus
N.S.Neki, Jain Ankur, Bajaj Rohit, Manav Mohit, Chavan Vishvanath, and Kumar Harsh

Chapter 30. Antioxidant Vitamins and Oxidative Stress in Chronic Heart Failure
Ram B Singh, Krasimira Hristova, Jan Fedacko, Shantanu Singhal, Shairy Khan, Douglas W Wilson, Toru Takahashi, and Zubin Sharma

Chapter 31. Stress, Peace and the Heart
Abdulla Al Shaibani, Galal Alkilany, and Ram B Singh

Chapter 32. G.S. Katinas (6 October 1925 – 4 September 2014)
Chibisov Sergey, Ram B. Singh, V. Frolov, E. Kharlitskaya, O. Mamontov, M. Dementyev, E. Mitina, O. Schwartzkopff, G. Cornélissen

Index

Chapter 1

[1] http://www.middleeasthealthmag.com/cgi-bin/index.cgi?
http://www. middle east healthmag.com/jan2013/feature11.htm.
[2] Van Gaal LF, Maggioni AP. Overweight, obesity, and outcomes: fat mass and beyond. The Lancet 2014; 383: 935-6, doi:10.1016/S0140-6736(13)62076-0.
[3] MacGregor GA, Hashem KM. Action on sugar—lessons from UK salt reduction programme. The Lancet 2014; 383: 929-31, doi:10.1016/ S0140-6736(14)60200-2.
[4] Singh RB, Verma SP, Niaz MA. Social class and coronary artery disease in India. Lancet 1999; 353: 154.
[5] Pella D, Thomas N, Tomlinson B, Singh RB. Prevention of coronary artery disease: the South Asian paradox. Lancet 2003; 361:79-80.
[6] Janus ED, Postiglione A, Singh RB, Lewis B. on behalf of the council on arteriosclerosis of the International Society and federation of Cardiology. The modernization of Asia: implications for coronary heart disease. Circulation 1996; 94: 2671-2673.
[7] Singh RB, Niaz MA, Ghosh S, Beegum R, Rastogi V, Sharma JP, Dube GK,. Association of trans fatty acids (vegetable ghee) and clarified butter (Indian ghee) intake with higher risk of coronary heart disease in rural and urban populations with low fat consumption. Int J Cardiol 1996; 56: 289-298.
[8] Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004; 364: 937–952.
[9] Hajat C, Harrison O, Al Siksek Z. Weqaya: A Population-Wide Cardiovascular Screening Program in Abu Dhabi, United Arab Emirates. Am J Public Health. 2012 May; 102(5): 909–914. Published online 2012 May. doi: 10.2105/AJPH. 2011.300290.
[10] Loney T, Aw T-C, Handysides DG, Ali R, Blair I, Grivna M, Shah SM, Sheek-Hussein M, El-Sadig M, Sharif AA, El-Obaid Y. An analysis of the health status of the United Arab Emirates: the ‘Big 4’ public health issues. Glob Health Action. 2013; 6: 10.3402/gha.v6i0.20100. Published online Feb 5, 2013. doi: 10.3402/ gha.v6i0.20100.
[11] MacDonald Gibson J, Thomsen J, Launay F, Harder E, DeFelice N. Deaths and medical visits attributable to environmental pollution in the United Arab Emirates. PLoS One. 2013;8(3):e57536. doi: 10.1371/journal.pone.0057536. Epub 2013 Mar 4.
[12] Almahmeed W, Arnaout MS, Chettaoui R, Ibrahim M, Kurdi MI, Taher MA, Mancia G. Coronary artery disease in Africa and the Middle East. Ther Clin Risk Manag. 2012; 8: 65–72. Published online Feb 16, 2012. doi: 10.2147/TCRM.S26414.
[13] World Health Organization. Data and statistics: mortality and health status. [Accessed January 12, 2012]. Available from: http://www. who.int/research/en/.
[14] Okrainec K, Banerjee DK, Eisenberg MJ. Coronary artery disease in the developing world. Am Heart J. 2004; 148: 7-15.
[15] Singh RB, Fedacko J, Vargova V, Kumar A, Mohan A, Pella D, De Meester F, Wilson DW. Singh’s verbal autopsy questionnaire for assessment of causes of death, social autopsy, tobacco autopsy, and dietary autopsy based on medical records and interview. Acta Cardiol 2011; 66: 471-481.
[16] Singh RB, Pella D, Mechirova V, Kumar K et al. Prevalence of obesity, physical inactivity and undernutrition, a triple burden of diseases during transition in developing countries. The Five City Study Group. Acta Cardiol 2007; 62: 119-127.
[17] Singh RB, Fedacko J, Pella D, Macejova Z, Ghosh S, Beegom R, Tumbi ZA, Haque M, Vajpeyee SK, De Meester F, Sergey C, Agarval R, Muthusamy VV, Gupta AA, and the Five City Study Group. Prevalence and risk factors of pre-hypertension and hypertension in five Indian cities. Acta Cardiol. 2011; 66: 29-37.
[18] Singh RB, Sharma JP, Rasogi V, Niaz MA, Ghosh S, Beegom R, Janus ED. Social class and coronary disease in a rural population of north India. Eur Heart J 1997:18; 588-95.
[19] Singh RB, Ghosh S, Niaz MA, Rastogi V. Validation of physical activity and socioeconomic questionnaire in relation to food intakes for the five city study and a proposed classification for Indians. J Assoc Phys India 1997; 45: 603-607.
[20] Singh RB, Rastogi SS, Rastogi V, et al. Blood pressure trends, plasma insulin levels, and risk factors in rural and urban elderly populations of north India. Coron Artery Dis 1997;8: 463-8.
[21] Singh RB, Beegum R, Ghosh S, Niaz MA, Rastogi V, Rastogi SS, Singh NK. Epidemiologic study of hypertension and its determinants in an urban population of north India. J Human Hyper 1997; 11: 679-685.
[22] Singh RB, Beegom R, Rastogi V, Rastogi SS, Madhu V. Clinical characteristics of hypertension among patients of noninsulin dependent diabetes mellitus in North and South India. J Diab Assoc India 1996; 36: 45-50.
[23] Singh RB, Bajaj S, Niaz MA, Rastogi SS, Moshiri M. Prevalence of type 2 diabetes mellitus and risk of hypertension and coronary artery disease in rural and urban population with low rates of obesity. Int J Cardiol. 1998 Sep 1; 66 (1): 65-72.
[24] Singh RB, De Meester F, Wilson DW. Globalization of wealth but not health in the world. WHJ 2013 (in press).
[25] Pellissier S, Dantzer C, Mondillon L, Trocme C, Gauchez AS, Ducros V, Mathieu N, Toussaint B, Fournier A, Canini F, et al. Relationship between Vagal Tone, Cortisol, TNF-Alpha, Epinephrine and Negative Affects in Crohn's Disease and Irritable Bowel Syndrome. PLoS One. 2014; 9(9):e105328. Epub 2014 Sep 10.
[26] Tran BW, Papoiu AD, Russoniello CV, Wang H, Patel TS, Chan YH, Yosipovitch G. Effect of itch, scratching and mental stress on autonomic nervous system function in atopic dermatitis. Acta Derm Venereol. 2010 Jul;90(4):354-61. doi: 10.2340/00015555-0890.
[27] Mendonca GV1, Pereira FD, Fernhall B. Effects of cigarette smoking on cardiac autonomic function during dynamic exercise. J Sports Sci. 2011 Jun;29(9):879-86. doi: 10.1080/02640414. 2011.572991.
[28] Mischel NA, Mueller PJ. (In)activity-dependent alterations in resting and reflex control of splanchnic sympathetic nerve activity. J Appl Physiol (1985). Dec 2011; 111(6): 1854–1862. Published online Oct 6, 2011. doi: 10.1152/jappl physiol.00961.2011.
[29] Marcheva B, Ramsey KM, Buhr ED et al. Disruption of the clock components CLOCK and BMAL1 leads to hypoinsulinaemia and diabetes. Nature 2010; 466: 627–31.
[30] Oishi K, Shirai H, and Ishida N. CLOCK is involved in the circadian transactivation of peroxisome- proliferator-activated receptor a (PPARa) in mice. Biochem J 2005; 386: 575–81.
[31] Turek FW, Joshu C, Kohsaka A et al. Obesity and metabolic syndrome in circadian clock mutant nice. Science 2005; 308: 1043–1045.
[32] Arble DM, Bass J, Laposky AD, Vitaterna MH, and Turek FW. Circadian timing of food intake contributes to weight gain. Obesity 2009; 17: 2100–2102.
[33] Panda S, Hogenesch JB, and Kay SA. Circadian rhythms from flies to human. Nature 2002; 417; 329–35.
[34] Reppert SM, Weaver DR. Coordination of circadian timing in mammals. Nature 2002; 418: 935–941.
[35] Singh RB, Gupta S, Dherange P, De Meester F, Wilczynska A, Alam SE, Pella D, Wilson DW. Metabolic syndrome; a brain disease. Can J physiol Pharmacol 2012; 90: 1171-1183.
[36] Singh RB, Halberg F, Cornelissen G, Siegelova J, Hristova J, Toda E, Takahashi T, Jan Fedacko J, Otsuka K. Personalized circadian timing of exercise. World Heart J 2013; 5: 79-90.
[37] Sherman H, Frumin I, Gutman R et al. Long-term restricted feeding alters circadian expression and reduces the level of inflammatory and disease markers. J Cell Molecul Med 2011; 15: 2745–59.
[38] Sherman H, Genzer Y, Cohen R, Chapnik N, Madar Z, Froy O. Timed high-fat diet resets circadian metabolism and prevents obesity. FASEB J 2012; 26: 3493–502.
[39] Singh RB, Srivastav V, Srivastav SSL, Akhilesh J, Cornélissen G, Halberg F. Circadian variation under conditions of caloric restriction in North India. Abstract 36, 2nd International Symposium: Workshop on Chronoastrobiology and Chronotherapy, Tokyo Kasei University, Tokyo, Japan, November 2001, unpaginated (1 p).
[40] Halberg F, Sullivan B. Meal schedules and their interaction with the body's schedules. Chronobiologia 1976; 3: 75-76.
[41] Nelson W, Cadotte L, Halberg F. Circadian timing of single daily "meal" affects survival of mice. Proc Soc exp Biol (NY) 1973; 144: 766-769.
[42] Halberg F, Cornelissen G, Wang ZR, Wan C, Ulmer W, Katinas G, Singh Ranjana, Singh RK, Singh Rajesh, Gupta BD, Singh RB, Kumar A, Kanabrocki E, Sothern RB, Rao G, Bhatt MLBD, Srivastava M, Rai G, Singh S, Pati AK, Nath P, Halberg Francine, Halberg J, Schwartzkopff O, Bakken E, Shastri VK. Chronomics: circadian and circaseptan timing of radiotherapy, drugs, calories, perhaps nutriceuticals and beyond. J Exp Therapeutics Oncol 2003; 3: 223-260.
[43] Cornelissen G. When you eat matters: 60 years of Franz Halberg's nutrition chronomics. The Open Nutr J 2012; 4: 16-44.
[44] Singh RB, Singh AK, Sharma JP, Singh RK, Kumar A, Rastogi SS, Singh Garima, Kartikey K, Singh S, Fedacko J, Pella D, De Meester F, Wilczynska A, Wilson DW. Nutrition in Chronocardiology: we are indebted Professor Franz Halberg. The Open Nutra J 2012;45-65.
[45] Iqbal R, Anand S, Ounpuu S, et al. INTERHEART Study Investigators. Dietary patterns and the risk of acute myocardial infarction in 52 countries: results of the INTERHEART study. Circulation. 2008;118:1929-1937.
[46] Teo K, Lear S, Islam S, Mony P, Dehghan M, Li W, Rosengren A, Lopez-Jaramillo P, Diaz R, Oliveira G, Miskan M, Rangarajan S, Iqbal R, Ilow R, Puone T, Bahonar A, Gulec S, Darwish EA, Lanas F, Vijaykumar K, Rahman O, Chifamba J, Hou Y, Li N, Yusuf S; on behalf of the PURE Investigators.

Prevalence of a healthy lifestyle among individuals with cardiovascular disease in high-, middle- and low-income countries: The Prospective Urban Rural Epidemiology (PURE) Study. JAMA. 2013; 309: 1613-1621.
[47] Singh RB, Hristova K, Muthusamy VV, Basu TK, Rastogi SS, Toda E, Takahashi T, Fedacko J, Pella D, Wilson DW, De Meester F, Mondal R, Ishaq M, Mohideen MR. The adverse effects of wealth on cardiovascular health: A scientific Statement of the International College of Cardiology. Cardiol Angiol 2013; 1: 9-22.
[48] Singh RB and Indian Consensus Group. Prevalence and prevention of hypertension, diabetes mellitus, and coronary artery disease in India. A scientific statement of the Indian Society of Hypertension, International College of Nutrition and International College of Cardiology. World Heart J 2010; 2: 31-44.
[49] Singh RB, De Meester F, Wilczynszka A, Takahashi T, Juneja L, Watson RR. Can a changed food industry prevent cardiovascular diseases? World Heart J 2013; 5: 1-8.
[50] World Health Organization. The 2008-2013 Action Plan for the Global Strategy for the Prevention and Control of Noncommunicable Diseases (Accessed via: http://www.who.int/nmh/Actionplan-PC-NCD-2008.pdf).
[51] Shroufi A, Chowdhury R, Anchala R, Stevens S, Blanco P, Han T, Niessen L, Franco OH. Cost effective interventions for the prevention of cardiovascular disease in low and middle income countries: a systematic review. BMC Public Health 2012; 13: 285. doi: 10.1186/1471-2458-13-285.
[52] Hristova K, Shiue I, Pella D, Singh RB, Chaves H, Basu TK, Ozimek L, Rastogi SS, Takahashi T, Wilson D, DeMeester F, Cheema S, Garg M, Buttar HS, Milovanovic B, Kumar A, Handjiev S, Cornélissen G, Petrov I. Prevention strategies for cardiovascular diseases and diabetes mellitus in developing countries: World Congress of Clinical Nutrition 2013. Nutrition 2014; doi: 10.1016/j.nut.2013.12.013.
[53] Singh RB, Takahashi T, Nakaoka T, Otsuka K, Toda E, Shin HH, Kyu Lee M, Beeharry V, Hristova K, Fedacko J, Pella D, De Meester F, Wilson DW, Juneja LR. Nutrition in transition from Homo sapiens to Homo economicus. The Open Nutra J 2013; 6: 6-17.
[54] The "Heart Disease and Stroke Statistics - 2014 Update" Circulation. 2014; 129: e28-e292. Published online before print December 18, 2013, doi: 10.1161/ 01.cir.0000441139.02102.80.
[55] Moodie R, Stuckler D, Monteiro C, Sheron N, Neal B, Thamarangsi T, Lincoln P, Casswel S on behalf of the Lancet NCD Group. Profits and pandemics: prevention of harmful effects of tobacco, alcohol, and ultra-processed food and drink industries. The Lancet 2013 (doi:10.1016/S0140-6736(12)62089).
[56] Bantle JP. Dietary fructose and metabolic syndrome and diabetes. J. Nutr. 2009; 139, 1263S–1268S.
[57] Naghavi M, Wang H, Lozano R, Davis A et al. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet. 2014 Dec 17. doi: 10.1016/S0140-6736(14)61682-2.
[58] Saboo B, Fedacko J, Singh RB. Proprotein convertase subtilisin/kexin type 9 inhibiters. World Heart J 2015;7: (in press).

Chapter 2

[1] Van Gaal LF, Maggioni AP. Overweight, obesity, and outcomes: fat mass and beyond. The Lancet 2014; 383: 935-6, doi:10.1016/S0140-6736(13)62076-0.
[2] Yang Q, Zhang Z, Gregg EW, et al. Added sugar intake and cardiovascular diseases mortality among US adults. JAMA Intern Med 2014; DOI:10.1001/jamainternmed. 2013.13563.
[3] Singh RB, Verma SP, Niaz MA. Social class and coronary artery disease in India. Lancet 1999; 353: 154.
[4] Pella D, Thomas N, Tomlinson B, Singh RB. Prevention of coronary artery disease: the South Asian paradox. Lancet 2003; 361: 79-80.
[5] Janus ED, Postiglion A, Singh RB, Lewis B. on behalf of the council on arteriosclerosis of the International Society and federation of Cardiology. The modernization of Asia: implications for coronary heart disease. Circulation 1996; 94: 2671-3.
[6] Singh RB, Niaz MA, Ghosh S, Beegum R, Rastogi V, Sharma JP, Dube GK. Association of trans fatty acids (vegetable ghee) and clarified butter (Indian ghee) intake with higher risk of coronary heart disease in rural and urban populations with low fat consumption. Int J Cardiol 1996; 56: 289-98.
[7] Marcheva B, Ramsey KM, Buhr ED et al. Disruption of the clock components CLOCK and BMAL1 leads to hypoinsulinaemia and diabetes. Nature 2010; 466: 627–31.
[8] Muntzel MS, Ali S O. Naimi A, Barclay A, Ajasin D. Cafeteria diet increases fat mass and chronically elevates lumbar sympathetic nerve activity in rats. Hypertension 2012; 60: 1498-1502. doi: 10.1161/HYPERTENSIONAHA. 112.194886.
[9] Turek FW, Joshu C, Kohsaka A et al. Obesity and metabolic syndrome in circadian clock mutant mice. Science 2005; 308: 1043–5.
[10] Arble DM, Bass J, Laposky AD, Vitaterna MH, and Turek FW. Circadian timing of food intake contributes to weight gain. Obesity 2009; 17: 2100–2.
[11] Panda S, Hogenesch JB, and Kay SA. Circadian rhythms from flies to human. Nature 2002; 417; 329–35.
[12] Reppert SM and Weaver DR. Coordination of circadian timing in mammals. Nature 2002; 418: 935–41.
[13] Singh RB, Takahashi T, Hristova K, Milovanovic B. Effects of circadian restricted feeding and low energy intake, on risk of cardiovascular disease and type 2 diabetes mellitus. Nutrition Res (in press).
[14] Singh RB, Anjum B, Garg R, Verma N, Singh R, Mahdi AA, Singh RK, De Meester F, Wilczynska A, Dharwadkar S, Takahashi T, Wilson DW. Association of circadian disruption of sleep and night shift work with risk of cardiovascular disease. World Heart J 2012;4:23-34.
[15] Storch KF, Lipan O, Leykin I, et al. Extensive and divergent circadian gene expression in liver and heart. Nature 2002; 417: 78–83.
[16] Herzog ED, Takahashi JS and Block GD. Clock controls circadian period in isolated suprachiasmatic nucleus neurons. Nature Neuroscience 1998; 1, 708–13.
[17] Cassone VM, Stephan FK. Central and peripheral regulation of feeding and nutrition by the mammalian circadian clock: implications for nutrition during manned space flight. Nutrition 2002; 18: 814–9.
[18] Eerola K, Rinne P, Penttinen AM, Vähätalo L, Savontaus M, Savontaus E. α-MSH overexpression in the nucleus tractus solitarius decreases fat mass and elevates heart rate. J Endocrinol. 2014 Jul;222(1):123-36. doi: 10.1530/JOE-14-0064.
[19] Mischel NA, Mueller PJ. (In)activity-dependent alterations in resting and reflex control of splanchnic sympathetic nerve activity. J Appl Physiol (1985). Dec 2011; 111(6): 1854–1862 doi: 10.1152/japplphysiol. 00961.2011.


[20] Mendonca GV, Pereira FD, Fernhall B. Effects of cigarette smoking on cardiac autonomic function during dynamic exercise. J Sports Sci. 2011 Jun;29(9):879-86. doi: 10.1080/02640414.2011.572991.
[21] Monforte R, Estruch R, Valls-Solé J, Nicolás J, Villalta J, Urbano-Marquez A. Autonomic and peripheral neuropathies in patients with chronic alcoholism: a dose-related toxic effect of alcohol. Arch Neurol. 1995; 52(1): 45-51. doi:10.1001/archneur.1995.00540250049012.
[22] Tran BW, Papoiu AD, Russoniello CV, Wang H, Patel TS, Chan YH, Yosipovitch G. Effect of itch, scratching and mental stress on autonomic nervous system function in atopic dermatitis. Acta Derm Venereol. 2010 Jul;90(4):354-61. doi: 10.2340/00015555-0890.


[23] Huang W, Zhu T, Pan X, Hu M, Lu SE, Lin Y, Wang T, Zhang Y, Tang X. Air pollution and autonomic and vascular dysfunction in patients with cardiovascular disease: interactions of systemic inflammation, overweight, and gender. Amer J Epidemiol 2012; 176 (2): 117-126. DOI: 10.1093/aje/kwr511.
[24] Sherman H, Frumin I, Gutman R et al. Long-term restricted feeding alters circadian expression and reduces the level of inflammatory and disease markers. J Cell Molecul Med 2011; 15: 2745–59.
[25] Sherman H, Genzer Y, Cohen R, Chapnik N, Madar Z, Froy O. Timed high-fat diet resets circadian metabolism and prevents obesity. FASEB J 2012; 26: 3493–3502.
[26] Singh RB, Srivastav V, Srivastav SSL, Akhilesh J, Cornélissen G, Halberg F. Circadian variation under conditions of caloric restriction in North India. Abstract 36, 2nd International Symposium: Workshop on Chronoastrobiology and Chronotherapy, Tokyo Kasei University, Tokyo, Japan, November 2001, unpaginated (1 p).
[27] Halberg F, Sullivan B. Meal schedules and their interaction with the body's schedules. Chronobiologia 1976; 3: 75-76.
[28] Nelson W, Cadotte L, Halberg F. Circadian timing of single daily "meal" affects survival of mice. Proc Soc exp Biol (NY) 1973; 144: 766-769.
[29] Halberg F, Cornelissen G, Wang ZR, Wan C, Ulmer W, Katinas G, Singh Ranjana, Singh RK, Singh Rajesh, Gupta BD, Singh RB, Kumar A, Kanabrocki E, Sothern RB, Rao G, Bhatt MLBD, Srivastava M, Rai G, Singh S, Pati AK, Nath P, Halberg Francine, Halberg J, Schwartzkopff O, Bakken E, Shastri VK. Chronomics: circadian and circaseptan timing of radiotherapy, drugs, calories, perhaps nutriceuticals and beyond. J Exp Therapeutics Oncol 2003; 3: 223-260.
[30] Cornelissen G. When you eat matters: 60 years of Franz Halberg's nutrition chronomics. The Open Nutr J 2012; 4: 16-44.
[31] Singh RB, Singh AK, Sharma JP, Singh RK, Kumar A, Rastogi SS, Singh Garima, Kartikey K, Singh S, Fedacko J, Pella D, De Meester F, Wilczynska A, Wilson DW. Nutrition in Chronocardiology: we are indebted Professor Franz Halberg. The Open Nutra J 2012; 4: 45-65.
[32] Stote KS, Baer DJ, Mattson MP. A controlled trial of reduced meal frequency without caloric restriction in healthy, normal-weight, middle-aged adults. Am J Clin Nutr 2007; 85: 981-988.
[33] Froy O. Circadian Rhythms and Obesity in Mammals. ISRN Obesity. 2012; 12, doi.org/ 10.5402/2012/437198.
[34] Cornelissen G, Halberg F, Otsuka K, Singh RB, Chen CH. Chronobiology predicts actual and proxy outcomes when dipping fails. Hypertension 2007; 49:237-39.
[35] Singh RB, Niaz MA, Cornelissen G, Otsuka K, Siegelova J, Fiser B, Halberg F. Circadian rhythmicity of circulating vitamin concentrations. Scripta Medica (Brno) 2001,74: 93-96.
[36] Singh RB, Cornelissen G, Kumar A, Bathina S, Halberg F. Larger circadian amplitude of heart rate associated with active prayer in Hindu Indians in Asia. World Heart J 2009; 1: 219-222.
[37] Singh RB, Halberg F, Cornelissen G, Siegelova J, Hristova J, Toda E, Takahashi T, Jan Fedacko J, Otsuka K. Personalized circadian timing of exercise. World Heart J 2013; 5: 79-90.
[38] Gal D, Pella D, Singh RB. The effect of an alpha-linolenic acid rich diet on the circadian rhythm of cardiac events. World Heart J 2008; 1: 49-56.
[39] Oishi K, Shirai H, and Ishida N. CLOCK is involved in the circadian transactivation of peroxisome- proliferator-activated receptor (PPAR gamma) in mice. Biochem J 2005; 386: 575–581.
[40] Boulamery-Velly A, Simon N, Vidal J, Mouchet J, Bruguerolle B. Effects of three-hour restricted food access during the light period on circadian rhythms of temperature, locomotor activity, and heart rate in rats. Chronobiol Internat 2005; 22: 489–98.
[41] Grasl-Kraupp B, Bursch W, Ruttkay-Nedecky B, Wagner A, Lauer B, Schulte-Hermann R. Food restriction eliminates preneoplastic cells through apoptosis and antagonizes carcinogenesis in rat liver. Proc Natl Acad Sci USA 1994; 91: 9995–9999.
[42] Hara R, Wan K, Wakamatsu H et al. Restricted feeding entrains liver clock without participation of the suprachiasmatic nucleus. Genes to Cells 2001; 6: 269–78.


[43] Gaspar, L., Hlinstakova, S., Dukat, A. et al.: Holter ECG monitoring during gastroscopy in patients with chronic atrial fibrillation. Bratisl Lek Listy 2010, 102 (5): 266-267.
[44] Gaspar, L., Makovnik, M., Bendzala, M. et al.: Medial calcinosis - a marker of increased cardiovascular risk. Gazzetta Medica Italiana, 2013, 172 (4): 247-252.
[45] Filipovic B,Gajic M,Krstic M,Milinic N,Milovanovic B,Filipovic B, Cvetkovic M. The comparison of two Nutritional Assessment Methods in Gastroenterology Patients. World Journal of Gastroenterology 2010; 16(16):1999-04.
[46] Milovanovic B,Trifunovic D, Djuric D. Autonomic Nervous System Adjustment(ANSA)in patients with hypertension treated with Enalapril. Acta Physiologica Hungarica 2011;98:71-84.
[47] Milutinovic Z,Milicevic D, Milovanovic B, Perunici-Pekovic G, Pencic B. Do components of metabolic syndrome contribute to cardiac autonomic neuropathy in non-diabetic patients? Saudi Medical Journal, 2010;31:650-657.
[48] Bjelakovic B, Ilic S, Dimitrijevic L, Milovanovic B, Kostic G, Bjelakovic L, Lukic S. Heart rate variability in in infants with central coordination disturbance. Early Human Development 2010; 86: 77-81.
[49] Milovanovic B, Milinic N, Trifunovic D, Krotin M, Filipovic B, Bisenic Djuric D. Autonomic dysfunction in alcoholic cirrhosis and its relation to sudden cardiac death risk predictors. General Physiology and Biophysics 2009; 28: 251-261.
[50] Pavlovic S, Stevic Z, Milovanovic B, Milicic B, Rakocevic V, Lavrniv D, Apostolski S. Impairment of cardiac autonomic control in patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis 2009; 10: 1-5.
[51] Mironova T, Mironov V, Antufiv V, Safronova E, Mironov M, Davydova E. Heart rate variability analysis in coronary artery disease and angina pectoris. Recent Patent in Cardiovas Drug Discov. 2009; 4:45-54.
[52] Tatyana Mironova, Vladimir Mironov, Yury Shamurov, Tatyana Barikova, Olga Toropova. J Electrocardiol 2011; 44:41-43.
[53] The Duck Egg Infant Milk Trial (DEIM TRIAL) Investigators). Effect of duck egg -infant milk on body weight in babies with undernutrition. A randomized, double blind, controlled trial. (under consideration).

Chapter 3

[1] Singh RB, Rai AN, Dube DP, Srivastav DK, Somani PN, Katiyar BC. Radioimmunoassay of serum digoxin in relation to digoxin intoxication. Br Heart J. 1975;37:619-23.
[2] Hristova K, Singh RB, Fedacko J, Toda E, Kumar A, Saxena M, et al. Causes and risk factors of congestive heart failure in India. World Heart J. 2013;5:13-20.
[3] Fedacko J, Singh RB, Gupta A, Hristova K, Toda E, Kumar A, et al. Inflammatory mediators in chronic heart failure in North India. Acta Cardiol. 2014;69:391-8.
[4] Ahmad T, Fiuzat M, Pencina MJ, Geller NL, Zannad F, Cleland JG, et al. Charting a roadmap for heart failure biomarker studies. JACC: Heart Failure. 2014;2:477-88.
[5] McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004.
[6] Singh R, Dube K, Srivastav P. Hypomagnesemia in relation to digoxin intoxication in children. Am Heart J. 1976;92:144-7.
[7] Singh R, Cameron E. Relation of myocardial magnesium deficiency to sudden death in ischemic heart disease. Am Heart J. 1982;103:449-50.
[8] Cameron E, Singh R. Magnesium and sudden death from heart disease. The Lancet. 1979;314:1084-5.
[9] Kumar A, Singh RB, Saxena M, Niaz MA, Joshi SR, Chattopadhyay P, et al. Effect of carni Q-gel (ubiquinol and carnitine) on cytokines in patients with heart failure in the Tishcon study. Acta Cardiol. 2007;62:349.
[10] Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008;358:2148-59.
[11] Matsumoto M, Tsujino T, Lee-Kawabata M, Naito Y, Sakoda T, Ohyanagi M, et al. Serum interleukin-6 and C-reactive protein are markedly elevated in acute decompensated heart failure patients with left ventricular systolic dysfunction. Cytokine. 2010;49:264-8.
[12] Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation. 2003;107:1486-91.
[13] Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation. 2003;108:2317-22.
[14] Dunlay SM, Weston SA, Redfield MM, Killian JM, Roger VL. Tumor necrosis factor-alpha and mortality in heart failure: a community study. Circulation. 2008;118:625-31.
[15] van Kimmenade RR, Januzzi JL, Jr. Emerging biomarkers in heart failure. Clin Chem. 2012;58:127-38.
[16] Maisel A, Mueller C, Nowak R, Peacock WF, Landsberg JW, Ponikowski P, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol. 2010;55:2062-76.
[17] Shah RV, Truong QA, Gaggin HK, Pfannkuche J, Hartmann O, Januzzi JL, Jr. Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. Eur Heart J. 2012;33:2197-205.
[18] Masson S, Anand I, Favero C, Barlera S, Vago T, Bertocchi F, et al. Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials. Circulation. 2012;125:280-8.
[19] deFilippi CR, de Lemos JA, Christenson RH, Gottdiener JS, Kop WJ, Zhan M, et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA. 2010;304:2494-502.
[20] Fonarow GC, Peacock WF, Horwich TB, Phillips CO, Givertz MM, Lopatin M, et al. Usefulness of B-type natriuretic peptide and cardiac troponin levels to predict in-hospital mortality from ADHERE. Am J Cardiol. 2008;101:231-7.
[21] Reichlin T, Socrates T, Egli P, Potocki M, Breidthardt T, Arenja N, et al. Use of myeloperoxidase for risk stratification in acute heart failure. Clin Chem. 2010;56:944-51.
[22] Tang WH, Brennan ML, Philip K, Tong W, Mann S, Van Lente F, et al. Plasma myeloperoxidase levels in patients with chronic heart failure. Am J Cardiol. 2006;98:796-9.
[23] Chatterjee K. Neurohormonal activation in congestive heart failure and the role of vasopressin. Am J Cardiol. 2005;95:8b-13b.
[24] Neuhold S, Huelsmann M, Strunk G, Stoiser B, Struck J, Morgenthaler NG, et al. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. J Am Coll Cardiol. 2008;52:266-72.
[25] Yu CM, Cheung BM, Leung R, Wang Q, Lai WH, Lau CP. Increase in plasma adrenomedullin in patients with heart failure characterised by diastolic dysfunction. Heart. 2001;86:155-60.
[26] Yildirim E, Keles I, Cakmak HA, Cosansu K, Can G, Ikitimur B. Evaluation of the clinical utility of urocortin 1 in systolic heart failure. Kardiol Pol. 2014;72:452-8.
[27] Gruson D, Ahn SA, Ketelslegers JM, Rousseau MF. Circulating levels of stress associated peptide Urocortin in heart failure patients. Peptides. 2010;31:354-6.
[28] Zile MR, Desantis SM, Baicu CF, Stroud RE, Thompson SB, McClure CD, et al. Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ Heart Fail. 2011;4:246-56.
[29] Ky B, French B, McCloskey K, Rame JE, McIntosh E, Shahi P, et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail. 2011;4:180-7.
[30] Weir RA, Miller AM, Murphy GE, Clements S, Steedman T, Connell JM, et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol. 2010;55:243-50.
[31] Kempf T, Eden M, Strelau J, Naguib M, Willenbockel C, Tongers J, et al. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res. 2006;98:351-60.
[32] Kempf T, von Haehling S, Peter T, Allhoff T, Cicoira M, Doehner W, et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol. 2007;50:1054-60.
[33] Wollert KC, Kempf T. Growth differentiation factor 15 in heart failure: an update. Curr Heart Fail Rep. 2012;9:337-45.
[34] Oliveira-Carvalho V, da Silva MM, Guimaraes GV, Bacal F, Bocchi EA. MicroRNAs: new players in heart failure. Mol Biol Rep. 2013;40:2663-70.
[35] Goren Y, Kushnir M, Zafrir B, Tabak S, Lewis BS, Amir O. Serum levels of microRNAs in patients with heart failure. Eur J Heart Fail. 2012;14:147-54.
[36] Singh RB, Hristova K, El-Kilany G, Takahashi T, Shehab A, Chaves H, Wilson DW, Rupini D, Gupta N, Gupta R. Nutritional modulators in chronic heart failure. The Open Nutra J. 2015;8:(In press).

Chapter 4

[1] Otel I, Ledru F, and Danchin N. Ischemic Heart Disease in Type2 Diabetes. Metabolism, 2003 Aug;52 (8 Suppl 1): pp 6-12.
[2] Chiha M, Njeim M, Chedrawy EG. Diabetes and Coronary Heart Disease: A Risk Factor for the Global Epidemic. Hindawi Publishing Corporation Int J Hypertension, 2012, Article ID 697240, 7 pages doi:10.1155/2012/697240.
[3] The DIAD Investigators. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes. The DIAD Study: A Randomized Controlled Trial. JAMA. 2009; 301: 1547–1555.
[4] Young LH, Chyun DA: Heart disease in patients with diabetes. In Ellenberg and Rifkin’s Diabetes Mellitus: Theory and Practice. 6th ed. Porte DJ, Baron A, Sherwin RS, Eds. New York, McGraw-Hill, 2002.
[5] Cohn PF, Fox KM, Daly C.Silent Myocardial Ischemia. Circulation. 2003; 108:1263-1277.
[6] BARI Investigators: Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. J Am Coll Cardiol 2000;35: 1122–1129.
[7] American Diabetes Association: Standards of medical care for patients with diabetes mellitus. Diabetes Care 2003; 26 (1):S33-S50.
[8] American Diabetes Association: Standards of Medical Care in Diabetes 2014. Diabetes Care Volume 37, Supplement 1, January 2014.doi: 10.2337/dc14-S014 Diabetes Care January 2014 vol. 37 no. Supplement 1 S14-S80.
[9] American Heart Association: Prevention Conference VI: diabetes and cardiovascular disease. Circulation 2002; 105:2231–2239.
[10] Gazzaruso C, Garzaniti A, Giordanetti S, Falcone C, De Amici E, Geroldi D, Fratino P: Assessment of asymptomatic coronary artery disease in apparently uncomplicated type 2 diabetic patients. Diabetes Care 2002; 25:1418–1424.
[11] Singh RB, Rastogi SS, Rao PV, Das S, Madhu SV, Das AK, Sahay BK, Fuse SM, Beegom R, Sainani GS, Shah NA. Diet and lifestyle guidelines and desirable levels of risk factors for the prevention of diabetes and its vascular complications in Indians: a scientific statement of the International College of Nutrition. J Cardiovas Risk 1997; 4:201-208.
[12] Singh RB, Rastogi SS, Niaz MA, Postiglion A. Association of central obesity and insulin resistance with high prevalence of diabetes and cardiovascular disease in an elderly population with low fat intake and lower than normal prevalence of obesity. The Indian paradox. Coro Art Dis 1998; 9: 559-65.
[13] Singh RB, Bazaz S, Niaz MA, Rastogi SS, Moshiri M. Prevalence of type 2 diabetes mellitus and risk of hypertension and coronary artery disease in rural and urban population with low rates of obesity. Int J Cardiol 1998; 66:65-72.
[14] Valensi P1, Sachs RN, Harfouche B, et al. Predictive value of cardiac autonomic neuropathy in diabetic patients with or without silent myocardial ischemia. Diabetes Care. 2001; 24:339-43.
[15] Deedwania PC. Silent myocardial ischemia: Epidemiology and pathogenesis. Up to Date, Website, Accessed Oct 28, 2013.http://pmtwww.uptodate.com/contents/silent-myocardial-ischemia-epidemiology-and pathogenesis?source = search_result&search
= Asymptomatic+coronary+heart+disease.
[16] ICC-ICN Expert Group. Sofia declaration for prevention of cardiovascular diseases and type 2 diabetes mellitus: a scientific statement of the international college of cardiology and international college of nutrition. World Heart J 2014;6: 89-106.
[17] Mondal RN, Haque MA, Md S, Jahan S, Azad AK, Md. Rahman MM, Rani M et al; Validity of verbal autopsy questionnaire for assessment of causes of death among patients with hypertension. World Heart J 2014; 6: 107-116.
[18] Dai JI, Krasnow RE, Liu L, Sawada SG, Reed T. The association between post load plasma glucose levels and 38-year mortality risk of coronary heart disease: the prospective NHLBI Twin Study. PLoS One. 2013 Jul 19; 8(7):e69332.
[19] Iciar Martín-Timón, Cristina Sevillano-Collantes, Amparo Segura-Galindo, and Francisco Javier delCañizo-Gómez. Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength. World J Diabetes. 2014; 5: 444–470.
[20] Mondal RN, Haque MA, Jahan SMS, Azad AK, Rahman MM, Rani Moni, Saha AC. Nurslam M, Hossain MJ. Frequency of causes of dropout among patients with hypertension, World Heart J 2012;4: 293-300.
[21] Lip GYH, Felmeden DC, Li-Saw-Hee FL, et al. Hypertensive heart disease: a complex syndrome or a hypertensive ‘cardiomyopathy’? Eur Heart J. 2000; 21: 1653–1665.
[22] Singh RB, Sharma JP, Rastogi V, Raghuvanshi RS, Moshiri M, Verma SP, Janus ED. Prevalence of coronary artery disease and coronary risk factors in rural and urban populations of north India. Eur Heart J. 1997; 18: 728-735.
[23] Tsujimoto T, Kajio H, Takahashi Y, et al. Asymptomatic coronary heart disease in patients with type 2 diabetes with vascular complications: a cross sectional study. BMJ Open 2011; 1:e000139. doi:10.1136/bmjopen-2011-000139.
[24] Singh RB, Beegom R, Ghosh S, Niaz MA, Rastogi V, Rastogi SS, Singh NK. Epidemiologic study of hypertension and its determinants in an urban population of north India. J human Hyper 1997; 11:679-685.
[25] Leung DY, Leung M. Significance and assessment of coronary microvascular dysfunction. Heart 2011; 97:587e595. doi:10.1136/hrt.2009.183327.
[26] Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med 2007; 356:830-40.
[27] Scognamiglio R, Negut C, Ramondo A, et al. Detection of coronary artery disease in asymptomatic patients with type 2 diabetes mellitus. J Am Coll Cardiol 2006; 47:65e71.
[28] Five City Study Group; Singh RB, Fedacko J, Pella D, Macejova Z, Ghosh S, De AK, Begom R, Tumbuis ZA, Haque M, Vajpeyee SK, De Meester F, Sergey C, Agarwalo R, Muthusamy VV, Gupta AK. Prevalence and risk factors of prehypertension and hypertension in five Indian cities. Acta Cardiol 2011; 66:29-37.
[29] Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358:580-591.
[30] Solomon H, DeBusk RF. Contemporary management of silent ischemia: the role of ambulatory monitoring. Int J Cardiol.2004;96:311-319.
[31] Stern S. Symptoms other than chest pain may be important in the diagnosis of “silent ischemia” or “the sounds of silence”. Circulation. 2005;111:e435-e437.

Chapter 5

[1] Flynn, SM; Carr, SM. Interspecies hybridization on DNA resequencing microarrays: efficiency of sequence recovery and accuracy of SNP detection in human, ape, and codfish mitochondrial DNA genomes sequenced on a human-specific MitoChip. BMC Genomics, 2007, 8, 339.
[2] Cann, RL; Stoneking, M; Wilson, AC. Mitochondrial DNA and human evolution. Nature, 1987, 325, 31-6.
[3] Chesner, CA; Westgate, JA; Rose, WI; Drake, R; Deino, A. Eruptive history of Earth’s largest Quaternary caldera (Toba, Indonesia) clarified. Geology, 1991, 19, 200–3.
[4] Mallory, JP; Mair, VH. The Tarim mummies: ancient China and the mystery of the earliest peoples from the West. London: Thames and Hudson, 2000.
[5] Gao, S; Cui, Y; Yang, Y; Duan, R; Abuduresule, I; Mair, VH; Zhu, H; Zhou, H. Mitochondrial DNA analysis of human remains from the Yuansha site in Xinjiang, China. Sci China C Life Sci, 2008, 51, 205-13.
[6] Chen, G. Number one cemetery at Charwighul Hotunsunbul Pass of Xinjiang (in Chinese; English abstract). Kaogu Xuebao (Acta Archaeologica Sinica), 1988, No. 1, 75-99.
[7] Zhou, J. The Chawuhu Culture in Xinjiang. Circle of Inner Asian Art Newsletter, 1998 April 7, 3-6.
[8] Possehl, GL. The Indus civilization: A contemporary perspective. Walnut Creek, CA: AltaMira Press, 2002.
[9] Skelton, PW; editor. Evolution: a biological and palaeontological approach. Wokingham: Addison-Wesley, 1993.
[10] Howard, BV; Lisse, JR; Knowler, WC; Davis, MP; Pettitt, DJ; Bennett, PH. Diabetes and atherosclerosis in the Pima Indians. Mt Sinai J Med, 1982, 49, 169-75.
[11] Aufderheide, AC. The scientific study of mummies. Cambridge: Cambridge University Press, 2003.
[12] Singh, RB; Reddy, KK; Fedacko, J; De Meester, F; Wilczynska, A; Wilson, DW. Ancient concepts of nutrition and diets in hunter-gatherers. Open Nutra J, 2011, 4, 130-5.
[13] Singh, RB; Moshiri, M; De Meester, F; Juneja, L; Muthusamy, V; Manoharan, S. The evolution of low w-6/w-3 ratio dietary pattern and risk of cardiovascular diseases and diabetes. J Altern Med Res, 2011, 3, 45-62.
[14] O’Rourke, RA; Brundage, BH; Froelicher, VF; Greenland, P; Grundy, SM; Hachamovitch, R. et al. American College of Cardiology/American Heart Association Expert Consensus document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. Circulation, 2000, 102, 126-40.
[15] Allam, AH; Thompson, RC; Wann, LS; Miyamoto, MI; Thomas, GS. Computed tomographic assessment of atherosclerosis in ancient Egyptian mummies. JAMA, 2009, 302, 2091-4.
[16] Wann, S; Thomas, GS. What can ancient mummies teach us about atherosclerosis? Trends Cardiovasc Med, 2014, 24, 279-84.
[17] Thompson, RC; Allam, AH; Lombardi, GP; Wann, LS; Sutherland, ML; Sutherland, JD. et al. Atherosclerosis across 4000 years of human history: the Horus study of four ancient populations. Lancet, 2013, 381, 1211-22.
[18] Allam, A. Atherosclerosis is common in ancient humans: Results of the Horus study of ancient Egyptian mummies. Cairo: Al Azhar University, 2011. Internet: http://www.cardioletter.ch/fileupload/Mummy_ Presentation_Slides.pdf (accessed 9 January 2015).
[19] Ruffer, MA. On arterial lesions found in Egyptian mummies (1580B.C.-525A.D.). J Pathol Bacteriol, 1911, 15, 453-62.
[20] Sandison, AT. Sir Marc Armand Ruffer (1859-1917) pioneer of palaeopathology. Med Hist, 1967, 11, 150-6.
[21] Stout, C. Atherosclerosis in exotic carnivora and pinnipedia. Am J Pathol, 1969, 57, 673-87.
[22] Ratcliffe, HL; Cronin, MT. Changing frequency of arteriosclerosis in mammals and birds at the Philadelphia Zoological Garden; review of autopsy records. Circulation, 1958, 18, 41-52.
[23] Fox, H. Arteriosclerosis in lower mammals and birds: its relation to the disease in man. In: Cowdry EV, editor. Arteriosclerosis. New York, NY: MacMillan, 1933, 153-93.
[24] Lindsay, S; Chaikoff, IL. Naturally occurring arteriosclerosis in animals: a comparison with experimentally induced lesions. In: Sandler M, Bourne GH, editors. Atherosclerosis and its Origin. New York, NY: Academic Press, 1963, 349-437.
[25] McGill, HC; Jr. Strong, JP; Holman, RL; Werthessen, NT. Arterial lesions in the Kenya baboon. Circ Res, 1960, 8, 670–9.
[26] Gresham, GA; Howard, AN; McQueen, J; Bowyer, DE. Atherosclerosis in primates. Br J Exp Pathol, 1965, 46, 94-103.
[27] Lindsay, S; Chaikoff, IL. Naturally occurring arteriosclerosis in nonhuman primates. J Atheroscler Res, 1966, 6, 36-61.
[28] Andrus, SB; Portman, OW; Riopelle, AJ. Comparative studies of spontaneous and experimental atherosclerosis in primates. II. Lesions in chimpanzees including myocardial infarction and cerebral aneurysms. Progr Biochem Pharm, 1968, 4, 393-419.
[29] Strong, JP; Tappen, NC. Naturally occurring lesions in African monkeys: Comparison of sudanophilic aortic lesions in Cercocebus albigena and Cercopithecus ascanius. Arch Path, 1965, 79, 199-205.
[30] Stout, C; Lemmon, WB. Predominant coronary and cerebral atherosclerosis in captive nonhuman primates. Exp Mol Pathol, 1969, 10, 312-22.
[31] Clarkson, TB; Prichard, RW; Netsky, MG; Lofland, HB. Atherosclerosis in pigeons. Its spontaneous occurrence and resemblance to human atherosclerosis. Arch Path, 1959, 68, 143-7.
[32] Bragdon, JH. Spontaneous atherosclerosis in the rabbit. Circulation, 1952, 5, 641-6.
[33] Roberts, JC; Jr. Distribution and severity of spontaneous atherosclerosis in the dog. Circulation, 1961, 24, 1101.
[34] Wilens, SL; Sproul, EE. Spontaneous cardiovascular disease in the rat. II. Lesions of the vascular system. Amer J Path, 1938, 14, 201-16.
[35] Vastesaeger, MM; Gillot, PH; Mortelmans, J. Etude histochimique des lipidesdans les lesions atherosclereuses des ruminants. Bull Soc Roy Zool (Anvers) 1966, 38, 43-58.
[36] Stout, C; Bohorquez, F. Aortic atherosclerosis in hoofed mammals. J Atheroscler Res, 1969, 9, 73-80.
[37] McKinney, B. Atherosclerosis in wild animals. Lancet, 1962, 2, 281.
[38] Clarke, EM; Thompson, RC; Allam, AH; Wann, LS; Lombardi, GP; Sutherland, ML; et al. Is atherosclerosis fundamental to human aging? Lessons from ancient mummies. J Cardiol, 2014, 63, 329-34.
[39] Heagerty, AM. Scanning ancient history for evidence of modern diseases. Lancet, 2013, 381, 1165-6.
[40] Shattock, SG. A report upon the pathological condition of the aorta of King Menephtah, traditionally regarded as the Pharaoh of the Exodus. Proc R Soc Med, 1909, 2, 122-7.
[41] Harris, JE; Wente, EF; editors. An X-ray atlas of the royal mummies. Chicago: University of Chicago Press, 1980.
[42] O’Connor, S; Taylor, C; Campbell, LA; Epstein, S; Libby, P. Potential infectious etiologies of atherosclerosis: a multifactorial perspective. Emerg Infect Dis, 2001, 7, 780-8.
[43] Schillinger, T; Kluger, W; Exner, M; Mlekusch, W; Sabeti, S; Amighi, J; Wagner, O; Minar, E; Schillinger, M. Dental and periodontal status and risk for progression of carotid atherosclerosis: the inflammation and carotid artery risk for atherosclerosis study dental substudy. Stroke, 2006, 37, 2271-6.
[44] Li, X; Kolltveit, KM; Tronstad, L; Olsen, I. Systemic diseases caused by oral infection. Clin Microbiol Rev, 2000, 13, 547-58.
[45] Christophersen, OA. Peroxynitrite, selenoproteins, toxic heavy metals and the etiopathogenesis of coronary heart disease. In: Lewis BS, Flugelman MY, Halon DA (Eds.). Coronary Artery Disease: 2011 Update. Proceedings of the 9th International Congress on Coronary Artery Disease. Venice (Italy), October 23-26, 2011. Bologna: Medimond International Proceedings, 2011, 69-73.
[46] Simopoulos, AP. Evolutionary aspects of the dietary omega-6: omega-3 fatty acid ratio: medical implications. World Rev Nutr Diet, 2009, 100, 1-21.
[47] Allison, MA; Criqui, MH; Wright, CM. Patterns and risk factors for systemic calcified atherosclerosis. Arterioscler Thromb Vasc Biol, 2004, 24, 331-6.
[48] McConnell, EE; Basson, PA; de Vos, V; Myers, BJ; Kuntz, RE. A survey of diseases among 100 free-ranging baboons (Papio ursinus) from the Kruger National Park. Onderstepoort J Vet Res, 1974, 41, 97-167.
[49] Migaki, G; Seibold, HR; Wolf, RH; Garner, FM. Pathologic conditions in the patas moneky. J Am Vet Med Assoc, 1971, 159, 549-56.
[50] de Lorgeril, M; Renaud, S; Mamelle, N; Salen, P; Martin, JL; Monjaud, I; Guidollet, J; Touboul, P; Delaye, J. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet, 1994, 343, 1454-9.
[51] Trichopoulou, A; Bamia, C; Trichopoulos, D. Anatomy of health effects of Mediterranean diet: Greek EPIC prospective cohort study. BMJ, 2009, 338, b2337.
[52] Baroldi, G; Scomazzoni, G. Coronary Circulation in the Normal and the Pathologic Heart. Washington, DC: Office of the General Surgeon, Department of the Army, 1967.
[53] Leder, O; Döring, HJ; Reindell, A; Fleckenstein, A. Protective effect of organic Ca antagonists (iproveratril, D 600, prenylamine) against isoproterenol-induced myocardial necrosis (in German). Pflugers Arch, 1969, 312, R9-10.
[54] Fleckenstein, A; Janke, J; Döring, HJ; Leder, O. Intracellular overloading with calcium as a decisive causative factor in the pathogenesis of noncoronary myocardial necroses (in German). Verh Dtsch Ges Kreislaufforsch, 1971, 37, 345-53.
[55] Varley, KG; Dhalla, NS. Excitation-contraction coupling in heart. XII. Subcellular calcium transport in isoproterenol-induced myocardial necrosis. Exp Mol Pathol, 1973, 19, 94-105.
[56] Yates, JC; Taam, GM; Singal, PK; Beamish, RE; Dhalla, NS. Modification of adrenochrome-induced cardiac contractile failure and cell damage by changes in cation concentrations. Lab Invest, 1980, 43, 316-26.
[57] Schroeder, HA. The Poisons Around Us. Bloomington, IN: Indiana University Press, 1974.
[58] Takahashi, T; Singh, RB; De Meester, F; Wilson, D. How the ― “West” can overcome unhealthy behaviours to prevent chronic diseases. J Socialomics, 2013, 2, e114.

Chapter 6

[1] Cavaghan MK, Ehrmann DA, Polonsky KS. Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest 2000; 106: 329-333.
[2] Bertoni AG, Geoff DC Jr, et al. Diabetic cardiomyopathy and subclinical CVD: the multiethnic study of Atherosclerosis (MESA). Diabetes Care 2006; 29: 588-594.
[3] Eckel RH, Kahn R, Robertson RM, Rizza, RA. Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. Diabetes Care 2006; 29: 1697-99.
[4] Dey L, Attele AS, Yuan CS. Alternative therapies for Type 2 diabetes. Altern Med Rev 2002; 7: 45-58.
[5] Eisenberg DM, Davis RB, Ettner SI, Apple S, Wilkey S, Van Rompay M, Kessler RC. Trends in Alternative medicine use in the United States, 1990-1997: Results of a follow-up National Survey. Journal of American Medical Association 1998; 280: 1569-1575.
[6] Grover JK, Yadav S, Vats V. Medicinal plants of India with anti-diabetic potential. Journal of Ethnopharmacology. 2002; 81: 81-100.
[7] Chakraborti BS, Rajagopalan R. Diabetes and insulin resistance associated disorders:disease and the therapy. Current Science 2002; 83:1533-38.
[8] Kameswara Rao B, Kesavulu MM, Apparao C. Evaluation of hypoglycemic effect of Momordica cymbalaria fruit in alloxan-diabetic rats. Fitoterapia 2003; 74: 7-13.
[9] Ferraris RP, Dietary and developmental regulation of intestinal sugar transport. Biochemical Journal 2001; 360: 265-276.
[10] King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numericalestimates and projections. Diabetes Care 1998; 21(9):1414-1419.
[11] Amos A, McCarty D, Zinnet PZ. 1997. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabetic Medicine 1997; 14: 1-85.
[12] Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
[13] Skyler JS. Diabetes mellitus: pathogenesis and treatment strategies. Journal of Medicinal Chemistry 2004; 47: 4113-4117.
[14] Morris CA, Avorn J. Internet marketing of Herbal Products. JAMA 2003; 290:1505-1509.
[15] Health Canada: Diabetes in Canada: national statistics and opportunities or improved surveillance, prevention and control. Diabetes Division, Bureau of Cardio-Respiratory Diaseases and Diabetes, Laboratory Centre for Disease Control, Health Protection Branch, Health Canada: No. H49-121, 1999.


[16] Al Riyami Aa, Afifi M. Clustering of cardiovascular risk factors among Omani adults. East Mediterr Health J 2003; 9: 893-903.
[17] Khamaisi M, Wexler ID etal. Cardiovascular diseases in type 2 diabetes: epidemiology, risk factors and therapeutic modulations. Isr Med Assoc J 2003; 5:801-806.
[18] Vanuzzo D, Pilotto L, Mirolo R, Pirelli S. Cardiovascular risk and cardiometabolic risk: an epidemiological evaluation. G Ital Cardiol 2008; 9(4 Suppl 1): 6S-17S.
[19] Unwin N, Shaw J, Zimmet P, Alberti KG. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 2002; 19(9):708-23.
[20] Zimmet, PZ, Kelly W. Lecture 1991: Challenges in diabetes epidemiology from west to the rest. Diabetes Care 1992; 15: 232-52.
[21] Hegele RA. 2001. Genes, environment and diabetes in Canadian aboriginal communities. Advanced Experimental and Medical Biology. 2001; 498: 11-20.
[22] American Diabetes Association. Diagnosis and Classification of Diabetes mellitus. Daibetes Care 2007a; 30 (suppl 1): S42-47.
[23] Weir GC. Which comes first in non-insulin-dependent diabetes mellitus: insulin resistance or beta cell failure? Both come first. Journal of American Medical Association 1995; 273: 1878-1879.
[24] Young T K, Reading J, Elias B, O’Neil JD. Type 2 diabetes mellitus in Canada’s first nations: status of an epidemic in progress. Canadian Medical Association Journal 2000; 163: 561-566.
[25] American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2006; 29: 4-42.
[26] Leiter LA, Ceriello A, Davidson JA, et al. Postprandial glucose regulation: new data and new implications. Clin Ther 2005; 27 (Suppl B): S42-56.
[27] Segal P, Zimmet PZ. Conference Report 1st International Congress on “Prediabetes” and the Metabolic Syndrome. Medscape Diabetes and Endocrinology, 2005.
[28] Krent AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005; 65(3):385-411.
[29] Juurlink DN, Gomes T, Lipscombe LL, Austin PC, Hux JE, Mamdani MM. Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone : population based cohort study. British Med J 2011; 339: b2942.
[30] Stafylus PC, Sarafidis PA, Lasaridis AN. The controversial effects of thiozolidinediones on cardiovascular morbidity and mortality. Int J Cardiol 2009; 131: 298-304.
[31] Kim Hack-Seang. Do not put too much value on conventional medicines. J Ethnopharmacology 2005; 100: 37-39.
[32] Mukherjee, PK, Wahile, A. Integrated approaches towards drug development from Ayurveda and other Indian system of medicines. J Ethnopharmacology 2005; 103: 25-35.
[33] Kennedy J. Herb and supplement use in the US adult population. Clinical Therapeutics 2005; 27:1847-1858.
[34] Bailey CJ, Day C. Traditional plant medicines as treatments for diabetes. Diabetes Care 1989; 12: 553-64.
[35] Ivorra MD, Paya M, Villar A. A review of natural products and plants as potential antidiabetic drugs. Journal of Ethnopharmacology 1989; 27: 243-75.
[36] Marles RJ,Farnsworth NR. Antidiabetic plants and their active constituents. Phytomedicine 1995; 2:137-189.
[37] Yeh GY, Eisenberg DM, Kaptchuk TJ, Phillips RS. Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care 2003; 26(4): 1277-94.
[38] Pelikánova T, Vintr Lek. Treatment of diabetes in metabolic syndrome 2009; 55(7-8): 637-45.
[39] Shekelle, Paul G, Morton, Sally C, Coulter, Ian, Venuturupalli, Swamy, Favreau, Joya, Hilton, Lara K. Are Ayurvedic herbs for diabetes effective?: Limited evidence shows that some herbs and formulas have glucose- lowering effects, and deserve further study. The Journal of Family Practice 2005; 54(10): 876-886.
[40] Narayana DBA, Katayar CK, Brindavanam NB. Original System: search, research or research. IDMA Bulletin 1998; 29: 413-16.
[41] Mukherjee PK, Maiti K, Mukherjee K, Houghton PJ. Leads from Indian medicinal plants with hypoglycemic potentials. Journal of Ethnopharmacology 2006; 106: 1-28.
[42] Elder C. Ayurveda for diabetes mellitus: a review of the biomedical literature. Altern Ther Health Med. 2004; 10(1):44-50.
[43] Matsuda H, Morikawa T, Yoshikawa M. Antidiabetogenic constituents from several natural medicines. Pure Appl Chem 2002; 74(7): 1301-08.
[44] Ungar G. Pharmacological studies of a new oral hypoglycemic drug. Proc Soc Exp Biol Med 1957; 95: 190–92.
[45] Dekker JM, Hein RJ. Beyond postprandial hyperglycemia: metabolic factors associated with cardiovascular disease. Diabetologia 2002; 45 (4): 461-475.
[46] Lebovitz HE.

A new oral therapy for diabetes management: alpha-glucosidase inhibition with acarbose. Clinical Diabetes 1995; 13:99-103.
[47] American Diabetes Association. Postprandial blood glucose. Diabetes Care 2001; 24 (4): 775-8.
[48] Gahche J, Bailey R, Burt V, et al. Dietary supplement use among U.S. adults has increased since NHANES III (1988–1994). NCHS data brief, no 61. Hyattsville, MD: National Center for Health Statistics, 2011.
[49] Rizzo NS, Sabate J, Jaceldo-Siegl K, Fraser GE. Vegetarian dietary patterns are associated with a lower risk of metabolic sybdrome. Diabetes Care 2011; 34(5):1225-7.
[50] De Biase SG, Fernandes SF, Gianini RJ, Duarte JL. Vegetarian diet and cholesterol and triglycerides levels. Arq Bras Cardiol 2007; 88:35–39.
[51] Teixeira RdeC, Molina Mdel C, Zandonade E, Mill JG. Cardiovascular risk in vegetarians and omnivores: a comparative study. Arq Bras Cardiol 2007; 89:237–244.
[52] Wolever TM, Jenkins DJ, Jenkins AL, Josse RG, The Glycemic index: methodology and clinical implications. Am J Clin Nutr 1991; 54(5): 846-854.
[53] DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131:281-303.
[54] American Diabetes Association Clinical Education Series. Medical management of Type 2 Diabetes. 4thed. 1998.
[55] Clissold SP, Edwards C.

Acarbose. A preliminary review of its pharmacodynamics and pharmacokinetic properties, and therapeutic potential. Drugs 1988; 35:214 -43.
[56] Rahelić D, Bozikov V, Pavić E, Jurić K, Fairgrieve C, Romić D, Kokic, S, Vuksan V. Glycemic index in diabetes. Coll Antropol 2011; 35: 1363-1368.
[57] Collier GR, Wolever TM, Wong GS, Josse RG. Prediction of glycemic response to mixed meals in noninsulin-dependent diabetic subjects. Am J Clin Nutr 1986; 44(3): 349-352.
[58] Ciok, J., Dolna, A. The role of glycemic index concept in carbohydrate metabolism. Przegl Lek 2006; 63:287-91.
[59] Schafer G, Schenk U, Ritzel U, Ramadori G, Leonhardt U. Comparison of the effects of dried peas with those of potatoes in mixed meals on postprandial glucose and insulin concentrations in patients with type 2 diabetes. Am J Clin Nutr 2003; 78(1):99-103.
[60] Chew I, Brand JC, Thorburn AW, Truswell AS. Application of glycemic index to mixed meals. Am J Clin Nutr 1988;47(1):53-56.
[61] Bornet FR, Costagliola D, Rizkalla SW, Blayo A, Fontvielle AM, Haardt MJ, Letanoux M, Tchobroutsky G, Slama G. Insulinemic and glycemic indexes of six starch-rich foods taken alone and in a mixed meal by type 2 diabetics. Am J Clin Nutr 1987; 45(3):588-595.
[62] Wolever TM, Jenkins DJ. The use of the glycemic index in predicting the blood glucose response to mixed meals. Am J Clin Nutr 1986; 43(1):167-172.
[63] Wolever TM, Nuttall FQ, Lee R, Wong GS, Josse RG, Csima A, Jenkins DJ. Prediction of the relative blood glucose response of mixed meals using the white bread glycemic index. Diabetes Care 1985; 8(5): 418-428.
[64] Kendall CW, Josse AR, Esfahani A, Jenkins DJ. Eu J clin Nutr 2011;65(6):696-702.
[65] Runchey SS, Pollak MN, Valsta LM, Coronado GD, Schwarz Y, Breymeyer KL, Wang C, Wang CY, Lampe JW, Neuhouser ML. Eur J clin Nutr 2012; 66:1146-52.
[66] Freeland KR, Anderson GH, Wolever TM. Appetite 2009; 52(1):58-64.
[67] Jenkins DJ, Kendall CW, McKeown-Eyssen G, Josse RG, Silverberg J, Booth GL, Vidgen E, Josse AR, Nguyen TH, Corrigan S, Banach MS, Ares S, Mitchell S, Emam A, Augustin LS, Parker TL, Leiter LA. JAMA 2008;300(23):2742-53.
[68] Wolever TM, Gibbs AL, Spolar M, Hitchner EV, Heimowitz C. Nutr Metab (Lond) 2006;3:33.
[69] Chauhan B, Kumar G, kalam N, Ansari SH. Current concepts and prospects of herbal Nutraceutical: A review. J Adv Phar Technol Res 2013; 4(1):4-8.
[70] Das L, Bhaumik E, raychudhary U, and Chakraborty, R. Role of Nutraceuticals in human health. J Food Sci Technology 2012; 49(2): 173-183.
[71] Massaro M, Scoditti E, Carluccio MA, De Caterina R. Nutraceuticals and prevention of atherosclerosis: focus on omega-3 polyunsaturated fatty acids and Mediterranean diet polyphenols. Cardiovasc Ther 2010; 28(4):e13-9.
[72] Badimon L, Vilahaur G, Padro T. Nutraceutical and atherosclerosis: human trial. Cardiovasc Ther 2010; 28(4): 202-15.
[73] Ramaa CS, Shirode AR, Mundada, AS and Kadam VJ. Nutraceuticals- an emerging era in the treatment and prevention of cardiovascular disease. Curr Pharm Biotechnol 2006; 7(1): 15-23.
[74] Venn VJ, Mann GI. Cereal, grains, legumes and diabetes. Eur J Clin Nutr 2004; 58: 1443-61.
[75] Truswell AS. Cereal grains and coronary heart disease. Eur J Clin Nutr 2002; 56(1):1-14.
[76] Lee T, Dogoua J J. Nutritional supplements and their effect on glucose control. Adv Exp Med Biol 2012; 771: 381-95.
[77] Lee T, DogouaJ J. Nutritional supplements and their effect on glucose control. Curr Diab Ret 2011; 11: 142-8.
[78] Scazzina F, Siebenhandl-Ehn S, Pellegrini N. Br J Nutr 2013; 109(7):1163-74.
[79] Grooms K M, Omarborne M J, Fan do Q, Djousse L, Clarke C R. Dietary fibre intake and cardiometabolic risks among US adults, NHANES 1999-2010. Am J Med 2013; 126:1059-1067.
[80] Pavlovich-Abril A, Rouzaud-Sández O, Torres P, Robles-Sánchez RM. Int J Food Sci Nutr 2012; 63(7):882-92.
[81] Pal S, Radavelli-Bagatini S. Effect of Sileum on metabolic syndrome risk factors. Obes Rev 2012; 13: 1034-47.
[82] Pal S, Khossousi A, Binns C, Dhaliwal S, Ellis V. The effect of fibre supplement compared to a healthy diet on body composition, lipids, glucose, insulin and other metabolic syndrome risk factors in overweight and obese individuals. Br J Nutra 2011; 105: 90-100.
[83] Bodinham CL, Frost GS, Robertson MD. Acute ingestion of resistant starch reduces food intake in healthy adults. Br J Nutra 2010; 103(6): 917-21.
[84] Bodinham CL, Smith L, Wright J, Frost GS, Robertson MD. Dietary fibre improves first-phase insulin secretion in overweight individuals. PLoS One 2012; 7(7):e40834.
[85] Giacosa, A., Rondanelli, M. The right fibre for the right disease: An update on the Sileum seed husk and the metabolic syndrome. J Clin Gastro Enterol 2010; 44(1): S58-60.
[86] Anderson JW, Baird P, Davis RH Jr, Ferreri S, Knudtson M, Koraym A, Waters V, Williams CL. Nutr Rev 2009;67(4):188-205.
[87] Vuksan V, Rogovik AL, Jovanovski E, Jenkins AL. Curr Diab Rep. 2009; (5):405-11.
[88] Brand-Miller JC, Atkinson FS, Gahler RJ, Kacinik V, Lyon MR, Wood S. Br J Nutr 2012; 108(2):245-8.
[89] Jenkins AL, Kacinik V, Lyon M, Wolever TM. Nutr J 2010; 22:9-58.
[90] Jenkins AL, Kacinik V, Lyon MR, Wolever TM. J Am Coll Nutr 2010; 29(2):92-8.
[91] Jenkins DJ, Kendall CW, McKeown-Eyssen G, Josse RG, Silverberg J, Booth GL, Vidgen E, Josse AR, Nguyen TH, Corrigan S, Banach MS, Ares S, Mitchell S, Emam A, Augustin LS, Parker TL, Leiter LA. JAMA 2008; 300(23):2742-53.
[92] Maragoni F, Poli A. Glycemic index of bread and biscuits is markedly reduced by the addition of a propeitry fibre mixture to the ingredients. Nutr Metab Cardiovasc Dis 2008; 18(9): 602-5.
[93] Riccardi G, Rivellese AA, Giacco R. Am J Clin Nutr 2008; 87(1):269S-274S.
[94] Ryan EA, Pick ME, Marceau C. Use of alternative medicines in diabetes mellitus. Diabet Med 2001;18: 242-5.
[95] Johnson L, Strich H, Taylor A, Timmermann B, Malone D, Teufel-Shone N, Drummond R, Woosley, R, Pereira E, Martinez A. Use of herbal remedies by diabetic Hispanic women in the southwestern United States. Phytotherapy Research 2006; 20: 250-255.
[96] Matsui T, Ogunwande IA, Abesundara KJM, Matsumoto K. Antihyperglycemic potential of natural products. Mini Reviews in Medicinal Chemistry 2006; 6: 109-120.
[97] Vuksan V, Sievenpiper JL. Herbal remedies in the management of diabetes: lessons learned from the study of ginseng. Nutrition, Metabolism and Cardiovascular Diseases 2005; 15:149-160.
[98] Anonymous. Complementary medicine: time for critical engagement. Lancet 2000; 356:2023-2026.
[99] Ernst E. Herbal medicines: where is the evidence? Bristish Medical Journal 2000; 321:395-396.
[100] Angell M, Kassirer JP. Alternative medicine-the risks of untested and unregulated remedies. New England Journal of Medicine 1998;339:839-841.
[101] Kim HJ, Yoon KH, Kang MJ, Yim HW, Lee KS, Vuksan V, Sung MK. A six-month supplementation of mulberry, korean red ginseng, and banaba decreases biomarkers of systemic low-grade inflammation in subjects with impaired glucose tolerance and type 2 diabetes. Evidenced based complementary and alternative medicine 2012; 2012:735191.
[102] Mucalo I, Rahelić D, Jovanovski E, Bozikov V, Romić Z, Vuksan V. Coll Antropol 2012; 36(4):1435-40.
[103] Jenkins AL, Kacinik V, Lyon M, Wolever TM. Reduction of postprandial

glycemia by the novel viscous polysaccharide PGX, in a dose-dependent manner,

independent of food form. Nutr J 2010; 22:9-58.
[104] Jenkins Al, Jenkins DJA, Wolever TM, Rogovik AL, E, Božikov V, Rahelić D, VuksanV. Comparable Postprandial Glucose Reductions with Viscous Fiber Blend Enriched Biscuits in Healthy Subjects and Patients with Diabetes Mellitus: Acute Randomized Controlled Clinical Trial. Croat Med J 2008; 49(6): 772–782.
[105] Vuksan V, Peeva V, Rogovik A, Beljan-Zdravkovic U, Stavro M, Jenkins A, Dias AG, Devanesen S, Sievenpiper J, Hanna A; little s.h.a.r.e. Can J Cardiol. 2010; 26(3):e128-32.
[106] Vuksan V, Sung MK, Sievenpiper JL, Stavro PM, Jenkins AL, Di Buono M, Lee KS, Leiter LA, Nam KY, Arnason JT, Choi M, Naeem A. Nutr Metab Cardiovasc Dis. 2008;18(1):46-56.
[107] Vuksan V, Sievenpiper JL, Xu Z, et al. Konjac-Mannan and American ginseng: emerging alternative therapies for type 2 diabetes mellitus. J Am Coll Nutr 2001; 20:370S-380S.
[108] Vuksan V, Sievenpiper JL, Wong J, et al. American ginseng (Panax quinquefolius L.) attenuates postprandial glycemia in a time dependent but not dose-dependent manner in healthy individuals. Am J Clin Nutr 2001; 73: 753-758.
[109] Vuksan V, Stavro MP, Sievenpipe JL, et al. American ginseng improves glycemia in individuals with normal glucose tolerance: effect of dose and time escalation J Am Coll Nutr 2000; 19:738-744.
[110] Vuksan V, Sievenpiper JL. The variable effects of whole-leaf digitalis is a paradigm of the glycemic effects of ginseng. Arch Intern Med 2000;160;3330-1.
[111] Vuksan V, Stavro MP, Sievenpipe JL, et al. Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes. Diabetes Care 2000; 23: 1221-6.
[112] Vuksan V, Sievenpiper JL. Koo VY, et al. American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects with type 2 diabetes mellitus. Arch Intern Med 2000; 160: 1009-13.
[113] Petersen BL, Ward LS, Bastian ED, Jenkins AL, Campbell J, Vuksan V. A whey protein supplement decreases post-prandial glycemia. Nutr J 2009; 8: 47.
[114] Visen P, Saraswat B, Visen A, Roller M, Bily A, et al. Acute effects of Fraxinus excelsior L. seed extract on postprandial glycemia and insulin secretion on healthy volunteers. Journal of Ethnopharmacology 2009; 126:226–232.
[115] Sievenpiper JL, Ezatagha A, Dascalu A, Vuksan V. When a placebo is not a 'placebo': a placebo effect on postprandial glycaemia. Br J Clin Pharmacol 2007; 64:546-9.
[116] Sievenpiper JL, Sung MK, Di Buono, M, Lee KS, Nam KY, Arnason JT, Choi M, Naeem A. Korean red ginseng rootlets decrease acute postprandial glycemia: results from sequential preparation- and dose-finding studies. Journal of the American College of Nutrition 2006; 25:100–107.
[117] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V. Decreasing, null and increasing effects of eight popular types of ginseng on acute postprandial glycemic indices in healthy humans: the role of ginsenosides. Journal of American College of Nutrition 2004; 23: 248–258.
[118] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V. Null and opposing effects of Asian ginseng (panax ginseng C.A. Meyer) on glycemia: results of two acute dose escalation studies. Journal of the American College of Nutrition 2003; 22: 524–532.
[119] Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362 (6423): 801–9.
[120] Finn AV, Nakano M, Narula J, Kolodgie FD, Virmani R Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol 2010; 30 (7): 1282–92.
[121] Williams KJ, Tabas I. Arteriosclerosis, thrombosis, and vascular biology 1995; 15 (5): 551–61.
[122] Sparrow CP, Olszewski J. Cellular oxidation of low density lipoprotein is caused by thiol production in media containing transition metal ions. Journal of lipid research 1993; 34 (7): 1219–28.
[123] Blankenhorn DH, Hodis HN. Atherosclerosis--reversal with therapy. The Western journal of medicine 1993; 159 (2): 172–9.
[124] Mitchell RS, Kumar V, Abbas AK, Fausto N. Robbins Basic Pathology: With STUDENT CONSULT Online Access (8th ed.). Philadelphia: Saunders. p.345. 2007.
[125] Nie L, Wise ML, Peterson DM, Meydani M. Avenanthramide, a polyphenol from oats, inhibits vascular smooth muscle cell proliferation and enhances nitric oxide production. Atherosclerosis 2006; 186 (2): 260–6.
[126] de Oliveira Otto MC, Wu JH, Baylin A, Vaidya D, Rich SS et al. Circulating and Dietary Omega-3 and Omega-6 Polyunsaturated Fatty Acids and incidence of CVD in the Multi-Ethenic Study of Athereosclerosis. J Am Heart Assoc 2013; 2(6):e000506.
[127] Bertoia ML, Triche EW, Michaud DS, Baylin A, Hogan JW, Neuhouser ML, Tinker LF, Van Horn L, Waring ME, Li W, Shikany JM, Eaton CB. Am J Clin Nutr. Mediterranean and Dietary Approaches to Stop Hypertension dietary patterns and risk of sudden cardiac death in postmenopausal women. 2013; Dec 18.
[128] Robinson JG, Stone NJ Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids. Am J Cardiol. 2006; 98(4A):39i-49i.
[129] Spagnoli LG, Orlandi A, Marino B, Mauriello A, De Angelis C, Ramacci MT. Propionyl-L-carnitine prevents the progression of atherosclerotic lesions in aged hyperlipemic rabbits. Atherosclerosis.1995; 114(1):29-44.
[130] Ghanbarzadeh S, Garjani A, Ziaee M, Khorrami A. CoQ10 and L-Carnitine Attenuate the Effect of High LDL and Oxidized LDL on Spermatogenesis in Male Rats. Drug Res (Stuttg) 2013; Dec 10.
[131] Shargorodsky M, Debby O, Matas Z, Zimlichman R. Effect of long-term treatment with antioxidants (vitamin C, vitamin E, coenzyme Q10 and selenium) on arterial compliance, humoral factors and inflammatory markers in patients with multiple cardiovascular risk factors. Nutr Metab 2010;7:55.
[132] Jakubowski H. Protein N-homocysteinylation: implications for atherosclerosis. Biomed Pharmacother 2001;55(8):443-7.
[133] Packer L, Kraemer K, Rimbach G. Molecular aspects of lipoic acid in the prevention of diabetes complications. Nutrition 2001;17(10):888-95.
[134] Orekhov AN, Tertov VV, Sobenin IA, Pivovarova EM. Direct anti-atherosclerosis-related effects of garlic. Ann Med 1995; 27(1):63-5.
[135] Williams MJ, Sutherland WH, McCormick MP, Yeoman DJ, de Jong SA. Aged garlic extract improves endothelial function in men with coronary artery disease. Phytother Res 2005;19(4):314-9.
[136] Ou HC, Lee WJ, Lee IT, Chiu TH, Tsai KL, Lin CY, Sheu WH. Ginkgo biloba extract attenuates oxLDL-induced oxidative functional damages in endothelial cells. J Appl Physiol (1985) 2009;106(5):1674-85.
[137] Tsai JY, Su KH, Shyue SK, Kou YR, Yu YB, Hsiao SH, Chiang AN, Wu YL, Ching LC, Lee TS. EGb761 ameliorates the formation of foam cells by regulating the expression of SR-A and ABCA1: role of haem oxygenase-1. Cardiovasc Res 2010; 88(3):415-23.
[138] Ungvari Z, Orosz Z, Rivera A, Labinskyy N, Xiangmin Z, Olson S, Podlutsky A, Csiszar A. Resveratrol increase vascular oxidative stress resistance. Am J Physiol Heart Circ Physiol 2007;292(5):H2417-24.
[139] Kuhlmann CR, Schaefer CA, Kosok C, Abdallah Y, Walther S, Lüdders DW, Neumann T, Tillmanns H, Schäfer C, Piper HM, Erdogan A. Quercetin-induced induction of the NO/cGMP pathway depends on Ca2+- activated K+ channel-induced hyperpolarization-mediated Ca2+-entry into cultured human endothelial cells. Planta Medica 2005; 71(6):520-4.
[140] Reiterer G, Toborek M, Hennig B. Quercetin protects against linoleic acid-induced porcine endothelial cell dysfunction. J Nutr 2004; 134(4):771-5.
[141] Lee W, Min WK, Chun S, Lee YW, Park H, Lee DH, Lee YK, Son JE. Long-term effects of green tea ingestion on atherosclerotic biological markers in smokers. Clin Biochem 2005; 38(1):84-7.
[142] Fang JC, Kinlay S, Beltrame J, Hikiti H, Wainstein M, Behrendt D, Suh J, Frei B, Mudge GH, Selwyn AP, Ganz P. Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial. Lancet 2002; 359:1108-13.
[143] Munteanu A, Zingg JM, Azzi A. Anti-atherosclerotic effects of vitamin E--myth or reality? J Cell Mol Med 2004; 8: 59-76.
[144] Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med 2005; 258(2):94-114.
[145] Fan JS, Liu DN, Huang G, Xu ZZ, Jia Y, Zhang HG, Li XH, He FT. Panax notoginseng saponins attenuate atherosclerosis via reciprocal regulation of lipid metabolism and inflammation by inducing liver X receptor alpha expression. J Ethnopharmacol 2012; 142(3):732-8.
[146] Gaweł E. Chemical composition of lucerne leaf extract (EFL) and its applications as a phytobiotic in human nutrition. Acta Sci Pol Technol Aliment 2012; 11(3):303-10.
[147] Chen JH, Wang CJ, Wang CP, Sheu JY, Lin CL, Lin HH. Hibiscus sabdariffa leaf polyphenolic extract inhibits LDL oxidation and foam cell formation involving up-regulation of LXRα/ABCA1 pathway. Food Chem 2013; 141(1):397-406.
[148] Park SH, Kim JL, Kang MK, Gong JH, Han SY, Shim JH, Lim SS, Kang YH. Sage weed (Salvia plebeia) extract antagonizes foam cell formation and promotes cholesterol efflux in murine macrophages. Int J Mol Med 2012; 30(5):1105-12.
[149] Liu LK, Lee HJ, Shih YW, Chyau CC, Wang CJ. Mulberry anthocyanin extracts inhibit LDL oxidation and macrophage-derived foam cell formation induced by oxidative LDL. J Food Sci 2008; 73(6):H113-21.

Chapter 7

[1] Rosner MH, Brady WJ Jr, Kefer MP, et al. Electrocardiography in the patient with the Wolff–Parkinson–White syndrome: diagnostic and initial therapeutic issues. American Journal of Emergency Medicine.1999; 17 (7): 705–14.
[2] Sorbo MD, Buja GF, Miorelli M, et al. The prevalence of the Wolff–Parkinson–White syndrome in a population of 116,542 young males. Giornale Italiano di Cardiologia (in Italian).1995; 25 (6): 681–7.
[3] Munger TM, Packer DL, Hammill SC, et al. A population study of the natural history of Wolff–Parkinson–White syndrome in Olmsted County, Minnesota,1953 1989. Circulation. 1993; 87 (3): 866–73.
[4] Sethi KK, Dhall A, Chadha DS, et al. WPW and preexcitation syndromes. J. Assoc. Physicians India.2007;55:10-5.
[5] Gollob MH, Green MS, Tang AS, et al. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N. Engl. J. Med. 2001;344(24):1823-31.
[6] Ghosh S, Avari JN, Rhee EK, et al. Hypertrophic cardiomyopathy with preexcitation: insights from noninvasive electrocardiographic imaging (ECGI) and catheter mapping. J. Cardiovasc. Electrophysiol. 2008;19(11):1215-7.
[7] Fengler BT, Brady WJ, Plautz CU, et al. Atrial fibrillation in the Wolff–Parkinson–White syndrome: ECG recognition and treatment in the ED. Am. J. Emerg. Med. 2007; 25 (5): 576–83.
[8] Hogenhuis W, Stevens SK, Wang P, et al. Cost-effectiveness of radiofrequency ablation compared with other strategies in Wolff-Parkinson-White syndrome. Circulation 1993; 88:437.

Chapter 8

[1] Singh RB, Hristova K, El-Kilany G, Takahashi T, Shehab A, Chaves H, Wilson DW, Rupini D, Gupta N, Gupta R. Nutritional modulators of chronic heart failure. The Open Nutra J 2015;8: 1-4.
[2] Witte KKA, Clark AL, Cleland JCF. Chronic heart failure and micronutrients. JACC 2001;37:1765-74.
[3] Hristova K, Singh RB, Fedacko J, Toda E, Kumar A, Saxena M, Baby A, Takahashi T, De Meester F, Wilson DW.

Causes and risk factors of congestive heart failure in India. World Heart J 2013; 5: 13-20.
[4] Fedacko J, Singh RB, Gupta A, Hristova K, Toda E, Kumar A, Saxena M, Baby A, Singh R, Takahashi T, Wilson DW. Inflammatory mediators in chronic heart failure in north India. Acta Cardiol 2014; 69: 391-984.
[5] Lee JH, Jarreau T, Prasad A, Lavie C, O Keefe J, Ventura H. Nutritional assessment in heart failure patients. Cong Heart F 2011; 17: 199-203. doi: 10.1111/j.1751-7133.2011.00239.x.
[6] Abbate A. The heart on fire: inflammasome and cardiomyopathy. Exp Physiol 2013; 98: 385.
[7] Singh RB, Dube KP, Srivastav PK. Hypomagnesemia in relation to digoxin intoxication in children. Am Heart J 1976; 92: 144-147.
[8] Singh RB, Rastogi SS, Verma R, Laxmi B, Singh Reema, Ghosh S, Niaz MA. Randomized, controlled trial of cardioprotective diet in patients with recent acute myocardial infarction: results of one year follow up. BMJ 2002; 304: 1115-1119.
[9] Singh RB, Dubnov G, Niaz MA, Ghosh S, Singh R, Rastogi SS, Manor O, Pella D, Berry EM. Effect of an Indo-Mediterranean diet on progression of coronary disease in high risk patients: a randomized single blind trial. Lancet 2002; 360: 1455-1461.
[10] Singh RB, Cameron EA. Relation of myocardial magnesium deficiency to sudden death in ischemic heart disease. Am Heart J 1982; 103: 899.
[11] Cameron EA, Singh RB. Magnesium and sudden death from heart disease. Lancet 1979; 2: 1084.
[12] Kumar A, Singh RB, Saxena M, Niaz MA, Josh SR, Chattopadhyay P, Mechirova V, Pella D, Chopra R. Effect of carni Q-gel (ubiquinol and carnitine) on cytokines in patients with heart failure in the Tishcon study. Acta Cardiol 2007; 62: 349-354.
[13] Wang Y, Seto SW, Golledge J. Angiotensin II, sympathetic nerve activity and chronic heart failure. Heart Fail Rev. 2014;19:187-98. doi: 10.1007/s10741-012-9368-1.
[14] Florea VG, Cohn JN, The Autonomic Nervous System and Heart Failure. Circulation Research. 2014; 114: 1815-1826. doi 10.1161/CIRCRESAHA. 114. 302589.
[15] Dai J, Lampert R, Wilson PW, Goldberg J, Ziegler TR, Vaccarino V. Mediterranean dietary pattern is associated with improved cardiac autonomic function among middle-aged men: a twin study. Circ Cardiovasc Qual Outcomes. 2010; 3(4): 366-373. doi: 10.1161/CIRCOUTCOMES. c109.905810.
[16] Hristova K, Nakaoka T, Otsuka K, Fedacko J, Singh R, Singh RB, De Meester F, Wilczynska A, Wilson DW. Perspectives on chocolate consumption and risk of cardiovascular diseases and cognitive function. The Open Nutra J 2012; 5: 207-212.
[17] Gal D, Pella D, Singh RB. The effect of an alpha-linolenic acid rich diet on the circadian rhythm of cardiac events. World Heart J 2008; 1: 49-56.
[18] Wang S, Moustaid-Moussa N, Chen L, Mo H, et al. Novels insights of dietary polyphenols and obesity. J Nutr Biochem 2014; 25: 1-18.
[19] McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, et al. for the PARADIGM-HF Investigators and Committees. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993-1004 doi: 0.1056/NEJMoa1409077.
[20] 20. Ahmad T, Fiuzat M, Pencina MJ, et al. Charting a roadmap for heart failure biomarker studies. JACC Heart Failure 2014; 2 (5): 477-488.
[21] Singh RB. Biochemical aspects of arrhythmiogenesis and ventricular fibrillation. Am J Cardiol 1980; 46: 899.
[22] Hristova K, Cornelissen G, Fedacko J, Singh RB. Echocardiographic study of circadian myocardial function among clinically healthy subjects. World Heart J 2014; 6 (4): 241-259.

Chapter 9

[1] Sowers JR, Epstein M, Frohlich ED: Diabetes, hypertension, and cardiovascular disease. Hypertension 2001, 37:1053–1059.
[2] Lawes CM, Vander Hoorn S, Rodgers A, International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet 2008; 371:1513.
[3] Mondal RN, Haque MA, Jahan SMS, Azad AK, Rahman MM, Rani Moni et al. Validity of verbal autopsy questionnaire for assessment of causes of death among patients with hypertension. World Heart Journal 2014; 6 (2): 107-115.
[4] WHO. The world health report 2002: reducing risks, promoting healthy life. Geneva: World Health Organization, 2002.
[5] WHO. WHO Global Report. Preventing chronic disease: a vital investment. Geneva: World Health Organization, 2005.
[6] MM Zaman and MA Rouf. Journal of Human Hypertension (1999) 13, 547–549.
[7] WHO/BANGLADESH Regional Office for South-East Asia. NCD risk factor survey 2010 report published and disseminated. Published on 7th August 2011. http://www.ban.searo.who.int/EN/Section31_295.htm.
[8] Mondal RN, Haque MA, Jahan SMS, Azad AK, Rahman MM, Rani Moni et al. Prevalence and risk factors of hypertension in Rangpur, Bangladesh. World Heart J, 2013; 5: 91-100.
[9] Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De SG, Ferguson TB, et al. Heart disease and stroke statistics: 2010 update: a report from the American Heart Association. Circulation. 2010; 121: e46–e215.
[10] Pirola L, Balcerczyk A, Okabe J, El-Osta A: Epigenetic phenomena linked to diabetic complications. Nat Rev Endocrinol 2010, 6:665–675.
[11] Ehud GFH, Messerlib EZ, Tenenbaum A: Hypertension and diabetes (eds): cardiovascular diabetology: clinical, metabolic and inflammatory facets. Adv Cardiol Basel, Karger 2008, 45:82–106.
[12] Hirose H, Saito I. Trends in blood pressure control in hypertensive patients with diabetes mellitus in Japan. Hypertens Res 2003; 26:717–22.
[13] Conen D, Ridker PM, Mora S, et al. Blood pressure and risk of developing type 2 diabetes mellitus: the women’s health study. Eur Heart J 2007; 28:2937–43.
[14] American Diabetes Association. Hypertension management in adults with diabetes. Diabetes Care 2004;27(Suppl):S65–7.
[15] Hayashi T, Tsumura K, Suematsu C, et al.: High normal blood pressure, hypertension and the risk of type 2 diabetes in Japanese men. Diabetes Care 1999, 22:1683–1687.
[16] Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomized controlled trials. Lancet 2009; 373:1765–72.
[17] Mohan V, Seedat YK, Pradeepa R. The rising burden of diabetes and hypertension in southeast Asian and African regions: need for effective strategies for prevention and control in primary health care settings. Int J Hypertens. Published Online First: 14 Mar 2013. doi:10.1155/2013.409083.
[18] Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375: 2215–22.
[19] Epstein M: Diabetes and hypertension: the bad companions. J Hypertension 1997, 15: 55–62.
[20] Sahay BK: API-ICP guidelines on DM. J Assoc Physicians India 2007, 55:1–50.
[21] Liu J, Zhao D, Liu J, et al. Prevalence of diabetes mellitus in outpatients with essential hypertension in China: a cross-sectional study BMJ Open 2013;3:e003798. doi:10.1136/bmjopen-2013-003798.
[22] Singh RB, Bazaz S, Niaz MA, Rastogi SS, Moshiri M. Prevalence of type 2 diabetes mellitus and risk of hypertension and coronary artery disease in rural and urban population with low rates of obesity. Int J Cardiol 1998; 66: 65-72.
[23] Freemantle N, Holmes J, Hockey A, Kumar S: How strong is the association between abdominal obesity and the incidence of type 2 diabetes? Int J Clin Pract 2008, 62:1391–1396.
[24] Wassink AM, Van Der Graaf Y, Soedamah-Muthu SS, Spiering W, Visseren FLj:Smart study group: metabolic syndrome and incidence of type 2 diabetes in patients with manifest vascular disease. Diab Vasc Dis Res 2008, 5:114–122.
[25] Singh RB, Rastogi SS, Niaz MA, Postiglion A. Association of central obesity and insulin resistance with high prevalence of diabetes and cardiovascular disease in an elderly population with low fat intake and lower than normal prevalence of obesity. The Indian paradox. Coro Art Dis 1998; 9: 559-65.
[26] Singh RB, Rastogi SS, Rao PV, Das S, Madhu SV, Das AK, Sahay BK, Fuse SM, Beegum R, Sainani GS, Shah NA. Diet and lifestyle guidelines and desirable levels of risk factors for the prevention of diabetes and its vascular complications in Indians: a scientific statement of the International College of Nutrition. J Cardiovas Risk 1997; 4:201-208.
[27] Hansson L, Lindholm LH, Niskanen L et al. for the Captopril Prevention Project (CAPPP) study group. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611–616.
[28] Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomized trials. BMJ 2003; 326:1427.
[29] Eberly LE, Cohen JD, Prineas R, et al. Impact of incidence diabetes and incidence of non-fatal cardiovascular disease on 18-year mortality: the Multiple Risk Factor Intervention Trail Experience. Diabetes Care 2003; 26:848-854.
[30] Opie LH, Schall R. Old antihypertensive and new diabetes. J Hypertension 2004; 22:1453-1458.
[31] Eberly LE, Cohen JD, Prineas R, et al. Impact of incidence diabetes and incidence of non-fatal cardiovascular disease on 18-year mortality: the Multiple Risk Factor Intervention Trail Experience. Diabetes Care 2003; 26:848-854.
[32] Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertensive study (LIFE): a randomized trial against atenolol. Lancet 2002; 359:1004-1010.
[33] Hansson L, Lindholm L, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354:1751-1756.
[34] Gu P, Jiang W, Cheng M, et al. Glucose metabolism in outpatients with new-onset hypertension in Chinese Han population. Clin Exp Hypertens 2012;34: 474–81.
[35] Mancia G. The association of hypertension and diabetes: prevalence, cardiovascular risk and protection by blood pression reduction. Acta Diabetol 2005; 42(Suppl.1):S17-S25.
[36] Singh RB, Fedacko J, Pella D, Hristova K, Chaves H, Milovanovic B, Handjiev S, Takahashi T, De Meester F, Wilson DW, Elkilany G, Baathallah S. Angiotensin converting enzyme; a possible risk promotor during transition from under-nutrition to chronic diseases of affluence. World Heart J 2014; 6: 209-215.
[37] Ye M, Wysocki J, Naaz P, Salabat MR,LaPointe MS, Batlle D. Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice. Hypertension 2004; 43: 1120-1125. doi: 10.1161/01.HYP. 0000126192. 27644.76.
[38] Nagi DK, Foy CA, Mohammad Ali V, Yudkin JS, Grant PJ, Knowler WC. Angiotensin-1-converting enzyme (ACE) gene polymorphism, plasma ACE levels, and their association with the metabolic syndrome and electrocardiographic coronary artery disease in Pima Indians. Metabolism 1998; 47: 622–626.
[39] Park SF, Kim WJ, Park SW, Park JW, Lee N, Park CY, Youn BS. High urinary ACE2 concentrations are associated with severity of glucose intolerance and microalbuminuria. Eur J Endocrinol. 2013; 168: 203-210.
[40] Singh RB, Gupta S, Dherang P, De Meester F, et al. Metabolic syndrome; a brain disease. Cand J Physiol Pharmacol 2012;90:1171-83.

Chapter 10

[1] Halberg F, Cornelissen G, Carandente A, Bakken E, Young E. Chronobiologic perspectives of international health care reform for the future of children. Chronobiologia 1993; 20: 269-275.
[2] Cornelissen G, Delmore P, Bingham C, Rutledge G, Kumagai Y, Kuwajima I, Suzuki Y, Kuramoto K, Otsuka K, Scarpelli PT, Tarquini B, Cagnoni M, Garcia L, Zaslavskaya RM, Syutkina E, Carandente F, Rapoport SI, Romanov YA, Tamura K, Bakken E, Halberg F. A response to the health care crisis: a "health start" from "womb to tomb". Chronobiologia 1993; 20: 276-291.
[3] Halberg F, Cornelissen G, Otsuka K, Siegelova J, Fiser B, Dusek J, Homolka P, Sanchez de la Pena S, Singh RB, BIOCOS project. Extended consensus on means and need to detect vascular variability disorders (VVDs) and vascular variability syndromes (VVSs). Leibniz-Online Nr. 5, 2009 (http://www2.hu-berlin.de/leibniz-so zietaet/journal/archiv_5_09.html).
[4] Halberg F, Cornelissen G, Schwartzkopff O. Self-surveillance assesses strain, vascular variability anomalies, VVAs, or disorders, VVDs, optimizes treatment and societal health. Sovremennaya medicinskaya nauka 2012: 123-156.
[5] Halberg F, Powell D, Otsuka K, Watanabe Y, Beaty LA, Rosch P, Czaplicki J, Hillman D, Schwartzkopff O, Cornelissen G. Diagnosing vascular variability anomalies, not only MESOR-hypertension. Am J Physiol Heart Circ Physiol 2013; 305: H279-H294. doi: 10.1152/ajpheart.00212.2013.
[6] Cornelissen G, Siegelova J, Watanabe Y, Otsuka K, Halberg F. Chronobiologically-interpreted ABPM reveals another vascular variability anomaly (VVA): excessive pulse pressure product (PPP) updated conference report. World Heart J 2012; 4 (4): 237-245.
[7] Otsuka K, Cornelissen G, Halberg F. Predictive value of blood pressure dipping and swinging with regard to vascular disease risk. Clinical Drug Investigation 1996; 11: 20-31.
[8] Otsuka K, Cornelissen G, Halberg F, Oehlert G. Excessive circadian amplitude of blood pressure increases risk of ischemic stroke and nephropathy. J Medical Engineering and Technology 1997; 21: 23-30.
[9] Schaffer E, Cornelissen G, Rhodus N, Halhuber M, Watanabe Y, Halberg F. Blood pressure outcomes of dental patients screened chronobiologically: a seven-year follow-up. JADA 2001; 132: 891-899.
[10] Müller-Bohn T, Cornelissen G, Halhuber M, Schwartzkopff O, Halberg F. CHAT und Schlaganfall. Deutsche Apotheker Zeitung 2002; 142: 366-370 (January 24).
[11] Cornelissen G, Halberg F, Otsuka K, Singh RB, Chen CH. Chronobiology predicts actual and proxy outcomes when dipping fails. Hypertension 2007; 49: 237-239. doi:10.1161/01.HYP.0000250392.51418.64.
[12] Cornelissen G, Halberg F, Otsuka K, Singh RB. Separate cardiovascular disease risks: circadian hyper-amplitude-tension (CHAT) and an elevated pulse pressure. World Heart J 2008; 1 (3): 223-232.
[13] Halberg F, Cornélissen G, Otsuka K, Siegelova J, Fiser B, Dusek J, Homolka P, Sanchez de la Peña S, Singh RB, BIOCOS project. Extended consensus on need and means to detect vascular variability disorders (VVDs) and vascular variability syndromes (VVSs). World Heart J 2010; 2 (4): 279-305.
[14] Halberg F, Cornelissen G, Wilson D, Singh RB, De Meester F, Watanabe Y, Otsuka K, Khalilov E. Chronobiology and chronomics: detecting and applying the cycles of nature. Biologist 2009; 56 (4): 209-214.
[15] Halberg F, Cornelissen G, International Womb-to-Tomb Chronome Initiative Group: Resolution from a meeting of the International Society for Research on Civilization Diseases and the Environment (New SIRMCE Confederation), Brussels, Belgium, March 17-18, 1995: Fairy tale or reality? Medtronic Chronobiology Seminar #8, April 1995, 12 pp. text, 18 figures. http://www.msi.umn.edu/~halberg/
[16] Bartter FC. Periodicity and medicine. In: Scheving LE, Halberg F, Pauly JE. (Eds.) Chronobiology. Igaku Shoin Ltd., Tokyo 1974; 6-13.
[17] Halberg F, Cornelissen G, Halberg J, Fink H, Chen C-H, Otsuka K, Watanabe Y, Kumagai Y, Syutkina EV, Kawasaki T, Uezono K, Zhao ZY, Schwartzkopff O. Circadian Hyper-Amplitude-Tension, CHAT: a disease risk syndrome of anti-aging medicine. J Anti-Aging Med 1998; 1: 239-259.
[18] Cornelissen G, Rigatuso J, Wang ZR, Wan CM, Maggioni C, Syutkina EV, Schwartzkopff O, Johnson DE, Halberg F, International Womb-to-Tomb Chronome Group: Case report of an acceptable average but overswinging blood pressure in Circadian Hyper-Amplitude-Tension, CHAT. Neuroendocrinol Lett 2003; 24 (Suppl 1): 84-91.
[19] Halberg F, Cornelissen G, Wall D, Otsuka K, Halberg J, Katinas G, Watanabe Y, Halhuber M, Müller-Bohn T, Delmore P, Siegelova J, Homolka P, Fiser B, Dusek J, Sanchez de la Peña S, Maggioni C, Delyukov A, Gorgo Y, Gubin D, Carandente F, Schaffer E, Rhodus N, Borer K, Sonkowsky RP, Schwartzkopff O. Engineering and governmental challenge: 7-day/24-hour chronobiologic blood pressure and heart rate screening: Biomed Instrumentation and Technol - Part I: 2002; 36: 89-122; Part II: 2002; 183-197.
[20] Cornelissen G, Halberg F. Impeachment of casual blood pressure measurements and the fixed limits for their interpretation and chronobiologic recommendations. Ann NY Acad Sci 1996; 783: 24-46.
[21] Portela A, Cornelissen G, Halberg F, Menéndez JC. Can blood pressure variability be reconciled with the interpretation of single measurements versus fixed thresholds? EuroRehab 1996; 6: 33-48.
[22] Halberg F, Cornelissen G, Otsuka K, Katinas GS, Schwartzkopff O, Halpin C, Mikulecky M, Revilla M, Siegelova J, Homolka P, Dusek J, Fiser B, Singh RB. Chronomics detects altered vascular variabilities constituting risks greater than hypertension: with an illustrative case report. In: Mitro P, Pella D, Rybar R, Valocik G. (Eds.) Proceedings, 2nd Congress on Cardiovascular Diseases, Kosice, Slovakia. Monduzzi Editore, Bologna 2002; 223-258.
[23] Halberg F, Cornelissen G, Schwartzkopff O. In memoriam Howard Burchell: Lifetime chronobiologically-interpreted (C-)ABPM for strain assessment for everybody with diagnostic dividends. World Heart J 2010; 2 (3): 177-196.
[24] Halberg F, Cornelissen F, Halberg Francine, Kessler T, Otsuka K. Measuring mental strain by duration of blood pressure overswing (CHAT): case report. World Heart J 2010; 2 (2): 141-167.
[25] Katinas G, Halberg F, Cornelissen G, Otsuka K, Tarquini R, Perfetto F, Maggioni C, Schwartzkopff O, Bakken E. Transient circadian hyper-amplitude-tension (CHAT) may be intermittent: case reports illustrating gliding spectral windows. Biomed and Pharmacother 2003; 57 (Suppl 1): 104s-109s.
[26] Kenner T. An essay on some aspects of physiology: presented by an every-day physiologist in honour of Franz Halberg. In: Halberg F, Kenner T, Fiser B, Siegelova J. (Eds.) Proceedings, Noninvasive Methods in Cardiology. Faculty of Medicine, Masaryk University, Brno, Czech Republic 2009; 318-324.
[27] Halberg F, Cornelissen G, Halberg E, Halberg J, Delmore P, Shinoda M, Bakken E. Chronobiology of human blood pressure. Medtronic Continuing Medical Education Seminars, 4th ed. Medtronic Inc., Minneapolis 1988; 242 pp.
[28] Levine H, Saltzman W, Yankaskas J, Halberg F. Circadian state-dependent effect of exercise upon blood pressure in clinically healthy men. Chronobiologia 1977; 4: 129-130.
[29] Scarpelli PT, Livi R, Scarpelli L, Croppi E, Germano G, Cagnoni S, Halberg F. Cigarette-smoking effects on circadian rhythm parameters of blood pressure. Proc. 2nd Ann. IEEE Symp. on Computer-Based Medical Systems. Computer Society Press, Washington DC 1989; 267-272.
[30] Singh RB, Cornelissen G, Otsuka K, Juneja L, Halberg F. Coronary risk factors and ambulatory blood pressure and heart rate in Asian Indians. The Open Nutraceuticals J 2012; 5 (Suppl. 1-M5): 79-80.
[31] Cornelissen G, Otsuka K, Uezono K, Siegelova J. Salt, blood pressure, and cardiovascular disease risk. In: Kenner T, Cornélissen G, Siegelova J, Dobsak P. (Eds.) Noninvasive Methods of Cardiology. Faculty of Medicine, Masaryk University, Brno, Czech Republic 2014; 125-132.
[32] Cornelissen G, Otsuka K, Watanabe Y, Siegelova J. Alcohol consumption and vascular variability disorders. In: Kenner T, Cornélissen G, Siegelova J, Dobsak P. (Eds.) Noninvasive Methods of Cardiology. Faculty of Medicine, Masaryk University, Brno, Czech Republic 2014; 9-18.
[33] Watanabe Y, Otsuka K, Siegelova J, Cornelissen G. Decadal change in heart rate variability. In: Kenner T, Cornélissen G, Siegelova J, Dobsak P. (Eds.) Noninvasive Methods of Cardiology. Faculty of Medicine, Masaryk University, Brno, Czech Republic 2014; 59-64.
[34] Watanabe Y, Halberg F, Otsuka K, Cornelissen G. Toward a personalized chronotherapy of high blood pressure and a circadian overswing. Clin Exp Hypertens 2013; 35 (4): 257-266. doi: 10.3109/10641963.2013.780073.
[35] Cornelissen G, Halberg F, Bakken EE, Singh RB, Otsuka K, Tomlinson B, Delcourt A, Toussaint G, Bathina S, Schwartzkopff O, Wang ZR, Tarquini R, Perfetto F, Pantaleoni GC, Jozsa R, Delmore PA, Nolley E. 100 or 30 years after Janeway or Bartter, Healthwatch helps avoid "flying blind". Biomed and Pharmacother 2004; 58 (Suppl 1): S69-S86.
[36] Lee Gierke C. Analysis of rhythms using R: Chronomics Analysis Toolkit (CAT). Master thesis submitted to the Graduate Faculty of the University of Minnesota, July 2013, 63 pp.
[37] Halberg F. Chronobiology: methodological problems. Acta med rom 1980; 18: 399-440.
[38] Cornelissen G, Halberg F. Chronomedicine. In: Armitage P, Colton T. (Eds.) Encyclopedia of Biostatistics, 2nd ed. John Wiley and Sons Ltd., Chichester, UK 2005; 796-812.
[39] Refinetti R, Cornelissen G, Halberg F. Procedures for numerical analysis of circadian rhythms. Biological Rhythm Research 2007; 38 (4): 275-325. http://dx.doi.org/10.1080/09291010600903692.
[40] Cornelissen G. Cosinor-based rhythmometry. Theoretical Biology and Medical Modelling 2014; 11: 16. doi:10.1186/1742-4682-11-16. 24 pp.
[41] Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; i: 307-310.
[42] Wu J, Halberg F, Nomura T, Yamaguchi M, Iwata N, Weber M, Drayer JIM, Shinoda M. Intraindividual comparison for novelty effect of two “ambulatory” 24-hour blood pressure and heart rate profiles in healthy human adults. 1st International Conference of Chronobiology and Chronomedicine, Chengdu, People's Republic of China, 1988; 21-23.
[43] Tamura K, Wu J, Cornelissen G, Halberg F. Agreement between consecutive ambulatory 24-hour blood pressure and heart rate profiles in Japanese hospital staff. Progress in Clinical and Biological Research 1990; 341A: 263-272.
[44] Otsuka K, Okajima K, Yamanaka T, Oinuma S, Sasaki J, Taniwaki Y, Otsuka K, Cornelissen G. Aging and the novelty pressor effect in men on the first day of 7-day/24-hour ambulatory blood pressure monitoring. J Am Geriatrics Soc 2014; 62 (8): 1602-1605.
[45] Cornelissen G, Otsuka K, Halberg F. Week-long ABPM records are a prerequisite for a reliable diagnosis of vascular variability disorders (VVDs). In: Proceedings, Natural Cataclysms and Global Problems of the Modern Civilization, Istanbul. SWB International Publishing House, London 2012; 250-255.
[46] Gumarova LZ, Cornelissen G, Halberg F, Mansharipova AT, Otsuka K, Syutkina EV, Masalov AV, Chibisov SM, Frolov VA. Duration of ABPM as an important prerequisite for a reliable diagnosis of vascular variability disorders (VVDs). Vestnik PFUR, seria Meditsina, 2013; 1: 27-33.
[47] Singh RB, Halberg F, Siegelova J, Cornelissen G. What is the best time to exercise? In: Halberg F, Kenner T, Fiser B, Siegelova J. (Eds.) Noninvasive Methods in Cardiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic 2012; 163-164.
[48] Singh RB, Halberg F, Cornelissen G, Siegelova J, Hristova K, Toda E, Takahashi T, Fedacko J, Otsuka K. Personalized circadian timing of exercise. World Heart J 2013; 5 (2): 79-90.
[49] Singh RB, Cornelissen G, Kumar A, Bathina S, Halberg F. Larger circadian amplitude of heart rate associated with active prayer in Hindu Indians in Asia. World Heart J 2008; 1 (3): 219-221.
[50] Watanabe Y, Halberg F, Kikuchi T, Mitsuhashi T, Otsuka K, Sakura H, Cornelissen G. Earthquake and ambulatory blood pressure monitoring. J Phys Fitness Sports Med 2014; 3 (5): 507-508.
[51] Delyukov A, Gorgo Y, Cornelissen G, Otsuka K, Halberg F. Infradian, notably circaseptan testable feedsidewards among chronomes of the ECG and air temperature and pressure. Biomed and Pharmacother 2001; 55 (Suppl 1): 84-92.

Chapter 11

[1] Langmesser S, Albrecht U: Life time - circadian clocks, mitochondria and metabolism. Chronobiol Int 2006, 23(1-2): 151-157.
[2] Mikulecký M: Methods of chronobiometric analysis of mitochondrial function. In: Mitochondrial Medicine, ed. A. Gvozdjáková, Springer, Netherlands, 2008; 93-102.
[3] Palmer JD: The clocks controlling the tide-associated rhythms of intertidal animals. Bioassay 2000; 22:32-37.
[4] Barlow PW, Klingelé E, Mikulecký M. The influence of the lunar-solar tidal acceleration on trees gives a glimpse of how the plant neurobiological system came into being. 5th Symposium Plant Neurobiology 25-29 May 2009, Firenze, Italy, abstract book: 11-13.
[5] Zuercher E, Cantiani M-G, Sorbetti-Guerri F, Michel D. Tree stem diameters fluctuate with tide. Nature 1998; 392:665-666.
[6] Barlow PW, Mikulecký M Sr, Střeštík J: Tree stem diameter fluctuates with the lunar tides and perhaps with geomagnetic activity. Protoplasma 2010; DOI 10.1007/s00709-010-0136-6.
[7] Mikulecký M: Circa(ultra)dian and –lunidian periodicity in arrhythmia attacks. Eur J Int Med 2001; 12:195/P245.
[8] Halberg E, Halberg F. Chronobiologic study design in everyday life, clinic and laboratory. Chronobiologia 1980; 7: 95-120.
[9] Palmer JW, Tandler B, Hoppel CL: Canine myocardial ischemia: defect in mitochondrial electron transfer complex I. J Mol Cell Cardiol 1977; 12: 639-645.
[10] Lowry DH, Rosenbrough NY, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-276.
[11] Estabrook RW: Mitochondrial respiratory control and the polarographic measurements of the ADP:O ratios. Methods Enzymol 1967; 10: 41-47.
[12] Lang JK, Gohil K, Packer L: Simultaneous determination of tocopherols, ubiquinols, and ubiquinones in blood, plasma, tissue homogenates, and subcellular fractions. Anal Biochem 1986; 157:106-116.
[13] Kucharská J, Gvozdjáková A, Mizera S, Braunová Z, Schreinerová Z, Schrameková E, Pecháň I, Fabián J: Participation of coenzyme Q10 in the rejection development of the transplanted heart: a clinical study. Physiol Res 1998; 47/6: 399-204.
[14] Halberg F. Chronobiology: methodological problems. Acta med rom 1980; 18: 399-440.
[15] Cornélissen G, Halberg F. Chronomedicine. In: Armitage P, Colton T. (Eds.) Encyclopedia of Biostatistics, 2nd ed. Chichester, UK: John Wiley and Sons Ltd; 2005; 796-812.
[16] Refinetti R, Cornélissen G, Halberg F. Procedures for numerical analysis of circadian rhythms. Biological Rhythm Research 2007; 38 (4): 275-325. http://dx.doi.org/10.1080/09291010600903692. PMCID: PMC3663600.
[17] Cornélissen G. Cosinor-based rhythmometry. Theoretical Biology and Medical Modelling 2014; 11: 16. doi:10.1186/1742-4682-11-16. 24 pp.
[18] Diem K, Seldrup J, Lentner C. (Ed.) Geigy Scientific tables. Vol. 2. Introduction in statistics. Statistical tables, Mathematical Formulae. Basle 1982; 240 pp.
[19] Mikulecký M sr, Gvozdjáková A, Kucharská J, Tkačov M, Mikulecký M jr. Intracellular energetics in rats is under control of the solar (24 hours) and lunar (24.8 hours) day? Conference of Man in his Terrestrial and Cosmic Environment. Úpice, Czech Republic 2010; abstract book: 15-18.
[20] Mikulecký M, Gvozdjáková A, Kucharská J, Singh RB: Circa(semi)dian periodicity of coenzyme „Q10-CLOCK” and cascade of ocidative phosphorylation in control and diabetic rat heart mitochondria. In: Mitochondrial Medicine, ed. A. Gvozdjáková, Springer, Netherlands, 2008; 151-160.
[21] Gvozdjáková A, Mikulecký M, Crane FL, Kucharská J, Cornelissen G, Kumar A, Palacka P, Singh RB: Mitochondrial cardiomyopathy and coenzyme Q10. World Heart Journal 2014, 6/1:29-46.
[22] Kujaník Š, Mikulecký M: Circadian and ultradian extrasystole rhythms in healthy individuals at elevated versus lowland altitude. Int J Biometeorol 2010; 54: 531-538.
[23] Mikulecký M. Farewell to the internal clock. A contribution in the field of chronobiology. By G. Klein. Review. Biologia 2009; Bratislava http://www. springerlink.com/openurl.asp?genre=article&id=doi:10.2478/s11756-009-0057-Z.
[24] Aschoff J, Wever R. Spontanrhythmik des Menschen bei Ausschluss aller Zeitgeber. Naturwissenschaften 1962; 49:337-342.
[25] Klein G, Farewell to the internal clock, A contribution in the field of chronobiology. Springer New York 2007.
[26] Evstafyev VK. How solar activity influences Earth´s molecular processes. Open Biol J 2009; 2:32-37.
[27] Buchachenko AL, Kuznetsov DA, Arkhangelsky SE, Orlova MA, Markarian AA. Spin biochemistry: intramitochondrial nucleotide phosphorylation is a magnesium nuclear spin controlled process. Mitochondrion 2005; 5: 67-69.
[28] Buchachenko Al et al. Proc USSR Acad Sci 1976; 228: 379.
[29] Ohnishi T, Salerno JC. Conformation-driven and semiquinone-gated proton-pump mechanism in the NADH-ubiquinone oxidoreductase (complex I). FEBS Lett 2005; 579 (21): 4555-4561.
[30] Cornélissen G, Halberg F, Siegelova J, Galvagno A. The moon's image in prolonged human isolation. In: Halberg F, Kenner T, Fiser B, Siegelova J. (Eds.) Noninvasive Methods in Cardiology. Faculty of Medicine, Masaryk University, Brno, Czech Republic 2010; 69-74.
[31] Halberg F, Cornélissen G, Hillman D, Ilyia E, Cegielski N, el-Khoury M, Finley J, Thomas F, Brandes V, Kino T, Papadoupoulou A, Chrousos GP, Costella JF, Mikulecky M. Multiple circadian periods in a lady with recurring episodes of adynamic depression: case report. In: Halberg F, Kenner T, Fiser B, Siegelova J. (Eds.) Noninvasive Methods in Cardiology. Faculty of Medicine, Masaryk University, Brno, Czech Republic 2011; 45-67.
[32] Marquardt DW. An algorithm for least-squares estimation of nonlinear parameters. J Soc Indust Appl Math 1963; 11: 431-441.

Chapter 12

[1] Hristova, K; Singh, RB; Fedacko, J; Toda, E; Kumar, A; Saxena, M; Baby, A; Takahashi, T; De Meester, F; Wilson, DW. Causes and risk factors of congestive heart failure in India. World Heart J, 2013, 5, 13-20.
[2] Fedacko, J; Singh, RB; Gupta, A; Hristova, K; Toda, E; Kumar, A; Saxena, M; Baby, A; Singh Ranjana, Takahashi, T; Wilson, DW. Inflammatory mediators in chronic heart failure in north India. Acta Cardiol, 2014, 69, 391-984.
[3] Wang, Y; Seto, SW; Golledge, J. Angiotensin II, sympathetic nerve activity and chronic heart failure. Heart Fail Rev, 2014, 19, 187-198. doi: 10.1007/s10741-012-9368-1.
[4] Florea, VG; Cohn, JN. The autonomic nervous system and heart failure. Circulation Research, 2014, 114, 1815-1826. doi: 10.1161/ CIRCRESAHA.114.
[5] Wadugu, B; Kühn, B. The role of neuregulin/ErbB2/ErbB4 signaling in the heart with special focus on effects on cardiomyocyte proliferation. Am J Physiol Heart Circ Physiol, 2012, 302(11), H2139-H2147.
[6] Yan, X; Morgan, JP. Neuregulin1 as novel therapy for heart failure. Curr Pharm Des, 2011, 17(18), 1808-1817.
[7] Abbate, A. The heart at fire: inflammasome and cardiomyopathy. Exp Physiol, 2013, 98, 385.
[8] Yan, X; Morgan, JP. Neuregulin1 as novel therapy for heart failure. Curr Pharm Des., 2011, 17(18), 1808-1817.
[9] Mendes-Ferreira, P; De Keulenaer, GW; Leite-Moreira, AF; Brás-Silva, C. Therapeutic potential of neuregulin-1 in cardiovascular disease. Drug Discov Today, 2013, 18(17-18), 836-842.
[10] Galindo, CL; Ryzhov, S; Sawyer, DB. Neuregulin as a heart failure therapy and mediator of reverse remodeling. Curr Heart Fail Rep, 2014, 11(1), 40-49.
[11] Dzida, G; Prystupa, A; Lachowska-Kotowska, P; Kadas, T; Kamienski, P; Kimak, E; Halabis, M; Kicinski, P. Alteration in diurnal and nocturnal melatonin serum level in patients with chronic heart failure. Annals of Agricul and Environ Med, 2013, 20(4), 745-748.
[12] Kim, SG; Yum, MK. Decreased RR interval complexity and loss of circadian rhythm in patients with congestive heart failure. Japanese Circulation Journa., 2000, 64(1), 39-45.
[13] Carson, PA; O’Connor, CM; Miller, AB; Anderson, S; Belkin, R; Neuberg, GW; Wertheimer, JH; Frid, D; Cropp, A; Packer, M. Circadian rhythm and sudden death in heart failure: results from prospective randomized amlodipine survival trial. J Amer Coll Cardiol, 2000, 36(2), 541-546.
[14] Yamazaki, T; Asanoi, H; Ueno, H; Yamada, K; Takagawa, J; Kameyama, T; Hirai, T; Nozawa, T; Inoue, H. Circadian dynamics of heart rate and physical activity in patients with heart failure. Clinical and Experimental Hypertension, 2005, 27(2-3), 241-249.
[15] Watanabe, E; Arakawa, T; Uchiyama, T; Tong, M; Yasui, K; Takeuchi, H; Terasawa, T; Kodama, I; Hishida, H. Prognostic significance of circadian variability of RR and QT intervals and QT dynamicity in patients with chronic heart failure. Heart Rhythm, 2007, 4(8), 999-1005.
[16] Yee, KM; Pringle, SD; Struthers, AD. Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. Journal of the American College of Cardiology, 2001, 37, 1800-1807.
[17] Bublil, EM; Yarden, Y. The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol., 2007, 19(2), 124-134.
[18] Cornelissen, G. When you eat matters: 60 years of Franz Halberg’s nutrition chronomics. The Open Nutr J, 2012, 4, 16-44.
[19] Singh, RB; Singh, AK; Sharma, JP; Singh, RK; Kumar, A; Rastogi, SS; Singh Garima, Kartikey K; Singh, S; Fedacko, J; Pella, D; De Meester, F; Wilczynska, A; Wilson, DW. Nutrition in Chronocardiology: we are indebted Professor Franz Halberg. The Open Nutra J, 2012, 4, 45-65.
[20] Wang, S; Moustaid-Moussa, N; Chen, L; Mo, H. et al. Novels insights of dietary polyphenols and obesity. J Nutr Biochem, 2014, 25, 1-18.
[21] Halberg, F. Some physiological and clinical aspects of 24-hour periodicity. J-Lancet (Minneapolis), 1953, 73, 20-32.
[22] Cornélissen, G; Halberg, E; Halberg, Francine. et al. Chronobiology: a frontier in biology and medicine. Chronobiologia, 1989, 16, 383-408.
[23] Halberg, F. Physiologic 24-hour periodicity; general and procedural considerations with reference to the adrenal cycle. Z Vitamin-, Hormon- u Fermentforsch, 1959, 10, 225-296.
[24] Halberg, F. Chronobiology. Ann Rev Physiol, 1969, 31, 675-725.
[25] Halberg, F. Quo vadis basic and clinical chronobiology: promise for health maintenance. Am J Anat, 1983, 168, 543-594.
[26] Halberg, F; Cornélissen, G; Bakken, E. Caregiving merged with chronobiologic outcome assessment, research and education in health maintenance organizations (HMOs). Progr Clin Biol Res, 1990, 341B, 491-549.
[27] Halberg, F; Cornélissen, G; Katinas, G. et al. Transdisciplinary unifying implications of circadian findings in the 1950s. J Circadian Rhythms, 2003, 1, 2. 61 pp., 2003. www.J Circadian Rhythms.com/content/
pdf/1740-3391/1/2.pdf.
[28] Halberg, F; Gupta, BD; Haus, E; Halberg, E; Deka, AC; Nelson, W; Sothern, RB; Cornélissen, G; Lee, JK; Lakatua, DJ; Scheving, LE; Burns, ER. Steps toward a cancer chronopolytherapy. In: Proc. XIV International Congress of Therapeutics. Montpellier, France: L'Expansion Scientifique Française; 1977. p. 151-196.
[29] Cornelissen, G; Halberg, F; Halberg, J; Schwartzkopff, O. Franz Halberg, MD (5 July 1919-9 June 2013): In Appreciation. Chronobiol Int, 2013, 30(10), 1205-1207.
[30] Halberg, F; Tong, YL; Johnson, EA. Circadian system phase -- an aspect of temporal morphology; procedures and illustrative examples. Proc. International Congress of Anatomists. In: Mayersbach H v. (Ed.) The Cellular Aspects of Biorhythms, Symposium on Biorhythms. New York: Springer-Verlag, 1967, pp. 20-48.
[31] Willis, MS; Patterson, C. Proteotoxicity and cardiac dysfunction — Alzheimer's Disease of the Heart? N Engl J Med, 2013, 368, 455-464 DOI: 10.1056/NEJMra1106180.
[32] Duarte, JH. Vagal stimulation in patients with HF. Nature Reviews Cardiology, 2014, 11, 621. doi:10.1038/nrcardio.2014.150.
[33] Zannad, F; De Ferrari, GM; Tuinenberg, AE; Wright, D. et al. Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the neural cardiac therapy for heart failure (NECTAR-HF), a randomized controlled trial. Euro Heart J 2014; DOI: http://dx.doi.org/ 10.1093/eurheartj/ehu345.
[34] Singh, RB; Cameron, EA. Relation of myocardial magnesium deficiency to sudden death in ischemic heart disease. Am Heart J, 1982, 103, 899.
[35] Cameron, EA; Singh, RB. Magnesium and sudden death from heart disease. Lancet, 1979, 2, 1084.
[36] Dai, J; Lampert, R; Wilson, PW; Goldberg, J; Ziegler, TR; Vaccarino, V. Mediterranean dietary pattern is associated with improved cardiac autonomic function among middle-aged men: a twin study. Circ Cardiovasc Qual Outcomes., 2010, 3(4), 366-373. doi: 10.1161/CIRCOUTCOMES. c109.905810.
[37] Singh, RB; Rastogi, SS; Verma, R; Laxmi, B; Singh Reema, Ghosh, S; Niaz, MA. Randomized, controlled trial of cardioprotective diet in patients with recent acute myocardial infarction: results of one year follow up. BMJ, 1992, 304, 1115-1119.
[38] Singh, RB; Dubnov, G; Niaz, MA; Ghosh, S; Singh, R; Rastogi, SS; Manor, O; Pella, D; Berry, EM. Effect of an Indo-Mediterranean diet on progression of coronary disease in high risk patients: a randomized single blind trial. Lancet, 2002, 360, 1455-1461.
[39] Gal, D; Pella, D; Singh, RB. The effect of an alpha-linolenic acid rich diet on the circadian rhythm of cardiac events. World Heart J, 2008, 1, 49-56.
[40] Lee, JH; Jarreau, T; Prasad, A; Lavie, C; O Keefe, J; Ventura, H. Nutritional assessment in heart failure patients. Cong Heart F, 2011, 17, 199-203. DOI: 10.1111/j.1751-7133.2011.00239.
[41] Witte, KKA; Clark, AL; Cleland, JCF. Chronic heart failure and micronutrients. JACC, 2001, 37, 1765-1774.
[42] Singh, RB; Rai, AN; Dube, KP; Srivastav, DK; Somani, PN; Katiyar, BC. Radioimmunoassay of serum digoxin in relation to digoxin intoxication. Brit Heart J, 1975, 37, 619-623.
[43] Singh, RB; Dube, KP; Srivastav, PK. Hypomagnesemia in relation to digoxin intoxication in children. Am Heart J, 1976, 92, 144-147.
[44] Kumar, A; Singh, RB; Saxena, M; Niaz, MA; Josh, SR; Chattopadhyay, P; Mechirova, V; Pella, D; Chopra, R. Effect of carni Q-gel (ubiquinol and carnitine) on cytokines in patients with heart failure in the Tishcon study. Acta Cardiol, 2007, 62, 349-354.
[45] McMurray, JJV; Packer, M; Desai, AS; Gong, J; Lefkowitz, MP; Rizkala, AR; Rouleau, JL; Shi, VC; Solomon, SD; Swedberg, K; Zile, MR; for the PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med, 2014, 371, 993-1004.
[46] Wilkinson, IB; McEniery, CM; Bongaerts, KH; MacCallum, H; Webb, DJ; Cockcroft, JR. Adrenomedullin (ADM) in the human forearm vascular bed: effect of neutral endopeptidase inhibition and comparison with proadrenomedullin NH2-terminal 20 peptide (PAMP). Br J Clin Pharmacol, 2001, 52, 159-164.
[47] Cruden, NL; Fox, KA; Ludlam, CA; Johnston, NR; Newby, DE. Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition. Hypertension, 2004, 44, 913-918.
[48] Oghenerukevwe Odiete, O; Hill, MF; Sawyer, DB. Neuregulin in cardiovascular development and disease. Circulation Research., 2012, 111:10 , 1376-1385.
[49] Hristova, K; Cornelissen, G; Fedacko, J; Singh, RB. Echocardiographic study of circadian myocardial function among clinically healthy subjects. World Heart J, 2014, 6 (in press).

Chapter 13

[1] Hongsakul K, Suwannanon R. Congenital absence of left circumflex artery detected by computed tomography coronary angiography: a case report. Case Reports in Vascular Medicine 2012; Article ID 204657. 3 pp.
[2] Yamanaka O, Hobbs RE. Coronary artery anomalies in 126,595 patients undergoing coronary arteriography. Catheterization and Cardiovascular Diagnosis 1990; 21: 28–40.
[3] Srinivasan KG, Gaikwad A, Kannan BRJ, Ritesh K, Ushanandini KP. Congenital coronary artery anomalies: diagnosis with 64 slice multidetector row computed tomography coronary angiography: a single-centre study. Journal of Medical Imaging and Radiation Oncology 2008; 52 (2): 148–154.
[4] Erol C, Seker M. Coronary artery anomalies: the prevalence of origination, course, and termination anomalies of coronary arteries detected by 64-detector computed tomography coronary angiography. Journal of Computer Assisted Tomography 2011; 35 (5): 618–624.
[5] Shriki JE, Shinbane JS, Rashid MA, Hindoyan A, Withey JG, DeFrance A, Cunningham M, Oliveira GR, Warren BH, Wilcox A. Identifying, characterizing, and classifying congenital anomalies of the coronary arteries. Radiographics 2012; 32 (2): 453–468.
[6] Gentzler RD II, Gault JH, Liedtke AJ, McCann WD, Mann RH, Hunter AS. Congenital absence of the left circumflex coronary artery in the systolic click syndrome. Circulation 1975; 52 (3): 490–496.
[7] Tzeng YH, Lan GY, Yin WH, Huang CC, Wu YC. Cardiac computed tomography of congenital absent left circumflex coronary artery: a case report. Chinese Journal of Radiology 2009; 34 (4): 273–276.
[8] Majid Y, Warade M, Sinha J, Kalyanpur A, Gupta T. Superdominant right coronary artery with absent left circumflex artery. Biomedical Imaging and Intervention Journal 2011; 7 (1): e2.

Chapter 14

[1] Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Goto S, Liau CS, Richard AJ, Röther J, Wilson PW, REACH Registry Investigators. International prevalence recognition and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295 (2): 180-189.
[2] Kasiwal RR, Bansal M, Desai D, Sharma M. Carotid intima media thickness: Current evidence, practice and Indian experience, Indian J Endocrinol Metab 2014; 18: 13-22.
[3] Silisen H, Muntendam A, Adourian A, Entrekin R, Garcia M, Falk E, Fuster V. Carotid plaque burden as a measure of subclinical atherosclerosis: comparison with other tests for subclinical arterial plaques in the High Risk Plaque BioImage Study. J Am Coll Cardiol Img 2012; 5 (7): 681-689.
[4] Haider AW, Larson MG, Franklin SS, Levy D. Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med 2003; 138: 10-16.
[5] Gepner A, Keevil JG, Wyman RA, Korcarz CE, Aeschlimann SE, Busse KL, Stein JH. Use of carotid intima-media thickness and vascular age to modify cardiovascular risk prediction. J Am Soc Echocardiogr 2006; 19: 1170-1174.
[6] Eigenbrodt ML, Evans GW, Rose KM, Bursac Z, Tracy RE, Mehta JL, Couper DJ. Bilateral common carotid artery ultrasound for prediction of incident strokes using intima-media thickness and external diameter: an observational study. Cardiovascular Ultrasound 2013, 11: 22.
[7] Oparil S, Zaman A, Calhoun DA. Pathogenesis of hypertension. Ann Int Med 2009; 139: 761-776.
[8] Domanski MJ, Davis BR, Pfeffer MA, Kastantin M, Mitchell GF. Isolated systolic hypertension: prognostic information provided by pulse pressure. Hypertension 1999; 34: 375-380.
[9] Salomaa V, Riley W, Kark JD, Nardo C, Folsom AR. Non-insulindependent diabetes mellitus and fasting glucose and insulin concentrations are associated with arterial stiffness indexes: the ARIC study. Circulation. 1995; 91: 1432–1443.
[10] Avolio AP, Clyde KM, Beard TC, Cooke HM, Ho KKL, O’Rourke MF. Improved arterial distensibility in normotensive subjects on a low salt diet. Arteriosclerosis. 1986; 6: 166-169.
[11] Kannel WB, Wolf PA, McGee DL, Dawber TR, McNamara P, Castelli WP. Systolic blood pressure, arterial rigidity, and risk of stroke: the Framingham study. JAMA 1981; 245: 1225-1229.
[12] Nielsen WB, Lindenstrom E, Vestbo J, Jensen GB. Is diastolic hypertension an independent risk factor for stroke in the presence of normal systolic blood pressure in the middle-aged and elderly? Am J Hypertens. 1997; 10: 634-639.
[13] Abernethy J, Borhani NO, Hawkins CM, Crow R, Entwisle G, Jones JW, Maxwell, MH, Langford H, Pressel S. Systolic blood pressure as an independent predictor of mortality in the Hypertension Detection and Follow-Up Program. Am J Prev Med. 1986; 2: 123-132.
[14] Rosenson RS. Modulation of atherosclerosis through inhibition or blockade of angiotensin. Clin Cardiol 2003, 26: 305-311.
[15] Serviace S, Ivey ME, Nigro J, Osman N, Little PJ. Action of calcium channel blocker on vascular proteoglycan endothelium relation to atherosclerosis. Vascular Health and Risk Management 2005; 1 (3): 199-208.
[16] Janic M, Lunder M, Sabovic M. Arterial stiffness and cardiovascular therapy. BioMed Research International 2014; volume 2014, article ID 621437. 11 pages.

Chapter 15

[1] Gerber Y, Weston SA, Redfield MM, Chamberlain AM, Manemann SM, Jiang R, Killian JM, Roger VL. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010.

JAMA Intern Med. doi:10.1001/ jamainternmed.2015.0924.
[2] Singh RB, De Meester F, Juneja F, Mechirova V, Pella D. New risk factors of heart failure. Eur. Heart J 2007 doi: 10.1093/ eurheartj/ehm006.
[3] Luca F, Perry GH, Di Rienzo A. Evolutionary adaptations to dietary changes. Annu Rev Nutr 2010; 30: 291–314.
[4] Esposito K, Glugliano D. Diet and inflammation: a link to metabolic and cardiovascular diseases. Eur. Heart J 2006; 27: 15-20.
[5] Handjieva-Darlenska T, Hristova K, Singh RB. Antioxidant vitamins and the heart. World Heart J 2014; 6: 179-184.
[6] Singh RB, Niaz MA, Ahmad S, Rastogi SS, Singh U, Agarwal P. Dietary and serum levels of antioxidants and minerals in patients with acute myocardial infarction. Trace Elem Electro 1995; 12: 148-152.
[7] Singh RB, Niaz MA, Sharma JP, Kumar R, Bishnoi I, Begum R. Plasma levels of antioxidant vitamins and oxidative stress in patients with acute myocardial infarction. Acta Cardiol 1994; 49: 441-452.
[8] Singh RB, Ghosh S, Niaz MA, Singh R, Beegum R, Chibo H, Shoumin Z, Postiglione A. Dietary intake, plasma levels of antioxidant vitamins and oxidative stress in relation to coronary artery disease in elderly subjects. Am J Cardiol 1995; 76: 1233-1238.
[9] Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 1993; 153: 937–942.
[10] Riordan JF. Angiotensin-I-converting enzyme and its relatives. Genome Biol 2003; 4: 225.
[11] Burns KD, Homma T, Harris RC. The intrarenal renin-angiotensin system. Semin Nephrol 1993; 13: 13-28.
[12] Nagi DK, Foy CA, Mohammad Ali V, Yudkin JS, Grant PJ, Knowler WC. Angiotensin-1-converting enzyme (ACE) gene polymorphism, plasma ACE levels, and their association with the metabolic syndrome and electrocardiographic coronary artery disease in Pima Indians. Metabolism 1998; 47: 622–626.
[13] van de Wal RM, Plokker HW, Lok DJ, Boomsma F, van der Horst FA, van Veldhuisen DJ, van Gilst WH, Voors AA. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int J Cardiol 2006; 26; 106 (3): 367-372.
[14] Ormerod JOM, Arif S, Mukadam M, Evans JDW et al. Short-term intravenous sodium nitrite infusion improves cardiac and pulmonary hemodynamics in heart failure patients. Circ Heart Fail 2015; 8: 265-271. doi:10.1161/CIRCHEART FAILURE.114.001716.
[15] Calvert JW, Lefer DJ. Myocardial protection by nitrite. Cardiovascular Research 2009; 83: 195–203 doi:10.1093/cvr/cvp079.
[16] Singh RB, Niaz MA, Rastogi SS, Rastogi S. Usefulness of antioxidant vitamins in suspected acute myocardial infarction. Am J Cardiol 1996; 77: 232-236.
[17] Singh RB, Niaz MA, Agarwal P, Beegum R, Rastogi SS, Sachan DS. A randomized, double blind, placebo controlled trial of L-carnitine in suspected acute myocardial infarction. Postgrad Med J 1996; 72: 45-50.
[18] United States Preventive Services Task Force. Vitamin, mineral, and multivitamin supplements for the primary prevention of cardiovascular disease and cancer: USPSTF statement. Ann Intern Med 2014; 160 (8): 1-24 http://annals.org.
[19] Calvert JW, Lefer DJ. Myocardial protection by nitrite. Cardiovascular Research 2009; 83: 195–203. doi:10.1093/cvr/cvp079.
[20] Singh RB, Jan Fedacko J, Pella D, Hristova K, Chaves H, Milovanovic B, Handjiev S, Takahashi T, De Meester F, Wilson DW.

Angiotensin converting enzyme; a possible risk promotor during transition from undernutrition to chronic diseases of affluence. World Heart J 2014; 6: 209-215.
[21] Ye M, Wysocki J, Naaz P, Salabat MR, LaPointe MS, Batlle D. Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice. Hypert 2004; 43: 1120-1125.
[22] Fedacko J, Singh RB, Gupta A, Hristova K, Toda E, Kumar A, Saxena M, Baby A, Singh A, Takahashi T, Wilson DW. Inflammatory mediators in chronic heart failure in north India. Acta Cardiol 2014; 69: 391-398.
[23] Hristova K, Singh RB, Fedacko J, Toda E, Kumar A, Saxena M, Baby A, Takahashi T, De Meester F, Wilson DW.

Causes and risk factors of congestive heart failure in India. World Heart J 2013; 5: 13-20.
[24] Esterbaur H, Cheeseman K. Determination of aldehyde peroxidation products malonaldehyde and 4-hydroxynonenal. Methods Enzyme 1990; 186: 407-421.
[25] Niato C. Kawamura M, Yamamoto Y. Lipid peroxides as the initiating factor of atherosclerosis. NY Acad Sci 1993; 676: 27-45.
[26] Ronca-Testoni S. Direct spectrophotometric assay for angiotensin-converting enzyme in serum. Clin Chem 1983; 29: 1093-1096.
[27] Green LC, Wagner DA, Gologowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem 1982; 126: 131-138.
[28] Chopra RK, Goldman R, Sinatra ST, Bhagavan HN. Relative bioavailability of coenzyme Q formulations in human subjects. Int J Vit Nutr Res 1998; 68: 109-113.
[29] Edlund PO. Determination of coenzyme Q, alpha-tocopherol and cholesterol in biological samples by coupled-column liquid chromatography with colorimetric and ultraviolet detection. J Chromatogr 1988; 425: 87-97.
[30] Singh RB, Hristova K, El-Kilany G, Takahashi T, Shehab A, Chaves H, Wilson DW, Rupini D, Gupta N, Gupta R.

Nutritional modulators of chronic heart failure. The Open Nutra J 2015; 8: 1-4.
[31] El-Kilany G, Singh RB, Hristova K, Milovanovic B. Chaves H, Wilson DW, Saboo B, Maheshwari A. Beyond drug therapy, nutritional perspectives in the management of chronic heart failure. Editorial, World Heart J 2015; 7 (in press).
[32] Kumar A, Singh RB, Saxena M, Niaz MA, Josh SR, Chattopadhyay P, Mechirova V, Pella D, Chopra R. Effect of carni Q-gel (ubiquinol and carnitine) on cytokines in patients with heart failure in the Tishcon study. Acta Cardiol 2007; 62: 349-354.
[33] Singh RB, Cornelissen G, Takahashi T, Shastun S, Hristova K, Chibisov S, Keim M, Abramova M, Otsuka K, Saboo B, Singh RK, Verma NS, Gvozdjakova A, Fedacko J, Pella D, Maheshwari A, Pandey AK, Wilson DW. Brain-heart interactions and circadian rhythms in chronic heart failure. (Homage to Dr. Franz Halberg, on the 2nd Anniversary of his death on 9th June 2013). World Heart J 2015; 7 (in press).
[34] The "Heart Disease and Stroke Statistics - 2015 Update" Circulation. 2015; 131: Published online before print January 30, 2015, doi: 10.1161/01.CIR. 0000000000000152.
[35] Singh RB, Takahashi T, Nakaoka T, Otsuka K,Toda E, Shin HH, Kyu Lee M, Beeharry V, Hristova K, Fedacko J, Pella D, De Meester F, Wilson DW, Juneja LR. Nutrition in transition from Homo sapiens to Homo economicus. The Open Nutra J 2013; 6: 6-17.

Chapter 16

[1] The "Heart Disease and Stroke Statistics - 2014 Update" Circulation. 2014; 129: e28-e292 Published online before print December 18, 2013, doi: 10.1161/ 01.cir.0000441139.02102.80.
[2] Krasimira Hristova (1), Ram B. Singh (2), Jan Fedacko (3), Eri Toda (4), Adarsh Kumar (5), Manoj Saxena (2), Anjum Baby (6), Takahashi Toru (7), Fabien De Meester (8), Douglas W. Wilson (9).

Causes and risk factors of congestive heart failure in India. World Heart J., 2013; 5:13-20.
[3] Fedacko J., Singh R. B., Gupta A., Hristova K., Toda E., Kumar A., et al. Inflammatory mediators in chronic heart failure in North India. Acta Cardiol., 2014; 69:391-8.
[4] ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail., 2012; 14: 803-869. doi: 10.1093/eurjhf /hfs105.
[5] McMurray J. V., Packer M., Desai A. S., Gong J., Lefkowitz M. P., Rizkala A. R., et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med., 2014; 371:993-1004.
[6] Kumar A., Singh R. B., Saxena M., Niaz M. A., Josh S. R., Chattopadhyay P., Mechirova V., Pella D., Chopra R. Effect of carni Q-gel (ubiquinol and carnitine) on cytokines in patients with heart failure in the Tishcon study. Acta Cardiol., 2007; 62:349-354.
[7] Singh R. B., Hristova K., El-Kilany G., Takahashi T., Shehab A., Chaves H., Wilson D. W., Rupini D., Gupta N., Gupta R.

Nutritional modulators of chronic heart failure. The Open Nutra J., 2015; 8: (in press).
[8] Mortensen S. A., Rosenfeldt F., Kumar A., Dolliner P., Filipiak K. J., Pella D., Alehagen U., Steurer G., Littarru G. P. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from QSYMBIO: a randomized double blind trial. JACC Heart Failure, 2014; 2(6):641-9. doi: 10.1016/j.jchf.2014.06.008.
[9] von Lueder T. G., Sangaralingham S. J., Wang B. H., et al. Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure. Circ. Heart Fail., 2013;6:594-605.
[10] Solomon S. D., Zile M., Pieske B., et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet, 2012; DOI:10.1016/S0140-6736(12)61227-6. Available at: http:// www.thelancet. com.
[11] Jessup, M., Neprilysin Inhibition a novel therapy for heart failure. N. Engl. J. Med., 2014; 371: 11.
[12] von Lueder T. G., Wang B. H., Kompa A. R., Huang L., Webb R., Jordaan P., Atar D., Krum H., the Angiotensin-receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. Circ. Heart Fail., 2014.
[13] Deddish P. A., Marcic B. M., Tan F., Jackman H. L., Chen Z., Erdös E. G., neprilysin inhibitors potentiate effects of bradykinin on B2 receptor. Hypertension, 2002;39:619-623.
[14] Parminder J., Richard H., Martin J. and Colin B., Neprilysin inhibition in chronic kidney disease. Nephrol. Dial. Transplant., 2014; 0: 1–6.
[15] Isaac R. E., Johnson E. C., Audsley N., Shirras A. D., metabolic inactivation of the circadian transmitter, pigment dispersing factor (PDF), by neprilysin-like peptidases in Drosophila. J. Exp. Biol., 2007; 210:4465-4470.
[16] Marr R. A., Rockenstein E., Mukherjee A., Kindy M. S., Hersh L. B., Gage F. H., Verma I. M., Masliah E. Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J. Neurosci., 2003; 23(6):1992-1996.
[17] Meilandt W. J., Cisse M., Ho K., Wu T., Esposito L. A., Scearce K., Cheng I. H., Yu G. Q., Mucke L., Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Aβ oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice. J. Neurosci., 2009; 29(7):1977-1986.
[18] Spencer B., Verma I., Desplats P., Morvinski D., Rockenstein E., Adame A., Masliah E. A neuroprotective brain-penetrating endopeptidase fusion protein ameliorates alzheimer disease. Pathology and restores neurogenesis. J. Biol. Chem., 2014; 289(25):17917-17931.
[19] Joseph L., Dion H., Yan J., Kudsia H., Jack H. Efficacy of LCZ696, an angiotensin receptor-neprilysin inhibitor (ARNI) in patients with stage 1-2 systolic hypertension. JASH, 2014; 8(4): 27–34.
[20] Helisalmi S., Hiltunen M., Vepsäläinen S., Iivonen S., Mannermaa A., Lehtovirta M., Koivisto A. M., Alafuzoff I., Soininen H. Polymorphisms in neprilysin gene affect the risk of Alzheimer's disease in Finnish patients. J. Neurol. Neurosurg. Psych., 2004;75:1746-1748.

Chapter 17

[1] Shehab A., Elkilany G., Singh R. B., Hristova K., Chaves H., Cornelissen G., Otsuka K.

Coronary risk factors in South West Asia. Editorial, World Heart J., 2015; 7 (in press) (novapublishers.com, NY, USA).
[2] http://www.middleeasthealthmag.com/cgi-bin/index.cgi?http:// www.middleeasthealthmag.com/jan2013/feature11.htm.
[3] Singh R. B., Sharma J. P., Rastogi,V. et al. Prevalence of coronary artery diseases and coronary risk factors in rural and urban populations of north India. Euro Heart J., 1997; 18: 1728 - 1735.
[4] Pella D., Thomas N., Tomlinson B., Singh R. B. Prevention of coronary artery disease: the South Asian paradox. Lancet, 2003; 361:79 - 80.
[5] Loney T., AW T. C., Handysides D. G., Ali R., Blair I., Grivna M., Shah S. M., Hussein M. S., El-Sadig M., Sharif A. A., and El-Obaid Y.. An analysis of the health status of the United Arab Emirates: the ‘Big 4’ public health issues. Glob. Health Action, 2013; 6 doi: 10.3402/ gha. v6i0.20100.
[6] Singh R. B., Niaz M. A., Ghosh S., Beegum R., Rastogi V., Sharma J. P., Dube G. K. Association of trans-fatty acids (vegetable ghee) and clarified butter (Indian ghee) intake with higher risk of coronary heart disease in rural and urban populations with low fat consumption. Int. J. Cardiol., 1996; 56: 289 - 98.
[7] Yusuf S., Hawken S., Ounpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet, 2004; 364: 937 – 952.
[8] Cholesterol Treatment Trialists' (CTT) Collaboration; Baigent C., Blackwell L., Emberson J., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 2010; 376: 1670 - 1681.
[9] Cannon C. P., Braunwald E., McCabe C. H., et al.; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med., 2004; 350: 1495 - 1504.
[10] Cannon C. P. IMPROVE-IT trial: a comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Paper presented at: American Heart Association 2014 Scientific Sessions; November 17, 2014; Chicago, IL.
[11] Roth E. M., Taskinen M. R., Ginsberg H. N., et al. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial. Int. J. Cardiol., 2014; 176: 55 - 61.
[12] Duff C. J., Hooper N. M. Expert Opinion Ther. Target, 2011; 15: 157 - 68.
[13] Do R. Q., Vogel R. A., Schwartz G. G. PCSK9 Inhibitors: potential in cardiovascular therapeutics. Curr. Cardiol. Rep., 2013 15 (3): 345. doi: 10.1007/s11886-012-0345-z.
[14] Urban D., Pöss J., Böhm M., Laufs U. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. J. Am. Coll. Cardiol., 2013; 62: 1401 - 8.
[15] Verma D. R., Brinton E. A. Management of hypercholesterolemia for prevention of atherosclerotic cardiovascular disease: focus on the potential role of recombinant anti-PCSK9 monoclonal antibodies. Rev. Cardiovasc. Med., 2014; 15 (2): 86 - 101.
[16] Do R. Q., Nicholls S. J., Schwartz G. G. Evolving targets for lipid-modifying therapy. EMBO Mol. Med., 2014 Aug. 29; 6 (10): 1215 - 30.
[17] Shen L., Peng H., Xu D., Zhao S. The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors. Pharmacol. Res., 2013 Jul.; 73: 27 - 34.
[18] Dias C. S. Shaywitz A. J., Wasserman S. M., Smith B. P., Gao B., Stolman D. S., Crispino C. P., Smirnakis K. V., Emery M. G., Colbert A., Gibbs J. P., Retter M. W., Cooke B. P., Uy S. T., Matson M., Stein E. A. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J. Am. Coll. Cardiol., 2012; 60, 1888 – 1898.
[19] Stein E. A., Mellis S., Yancopoulos G. D., Stahl N., Logan D., Smith W. B., Lisbon E., Gutierrez M., Webb C., Wu R., Du Y., Kranz T., Gasparino E., Swergold G. D. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N. Engl. J. Med., 2012; 366: 1108 - 1118.
[20] Norata G. D., Tibolla G., and Catapano A. L. Targeting PCSK9 for Hypercholesterolemia. Annual Review of Pharmacol. and Toxicol., 2014; 54: 273 - 293.
[21] Sabatine M. S., Guigliano R. P., Wiviott S. D. and The Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators.

Efficacy and safety of evolocumab in reducing Lipids and cardiovascular events. N. Engl. J. Med., 2015; 372: 1500 - 1509. doi 10.1056/NEJMoa1500858.

Chapter 18

[1] Sabatine MS, Guigliano RP, Wiviott SD and The Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing. Lipids and cardiovascular events. N. Engl. J. Med. 2015; 372: 1500-1509. DOI: 10.1056/NEJMoa1500858.
[2] Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJP, for the ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 2015; 372: 1489-1499. DOI: 10.1056/NEJMoa1501031.
[3] Stein, EA, Mellis S, Yancopoulos GD, Stahl N, Logan D, Smith WB, Lisbon E, Gutierrez M, Webb C, Wu R, Du Y, Kranz T, Gasparino E, Swergold GD. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N. Engl. J. Med. 2012; 366: 1108–1118.
[4] Roth EM, Taskinen MR, Ginsberg HN, Kastelein JJ, Colhoun HM, Robinson JG, Merlet L, Pordy R, Baccara-Dinet MT. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial. Int. J. Cardiol. 2014; 176: 55-61.
[5] Saboo B, Singh RB, Fedacko J, Hristova K, Elkilany G, Istavan T, RaiM,Wilson DW. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. World Heart J. 2015; 7 (in press).
[6] Shehab A, Elkilany G, Singh RB, Hristova K, Chaves H, Cornelissen G, Otsuka K. Coronary risk factors in South West Asia. Editorial, World Heart J. 2015; 7: (novapublishers.com, NY, USA)
[7] Singh RB, Sharma JP, Rastogi V, Raghuvanshi RS, Moshiri M, Verma SP, Janus ED. Prevalence of coronary artery diseases and coronary risk factors in rural and urban populations of north India. Euro Heart J. 1997; 18: 1728-1735.
[8] Pella D, Thomas N, Tomlinson B, Singh RB. Prevention of coronary artery disease: the South Asian paradox. Lancet 2003; 361: 79-80.
[9] Loney T, Aw T-C, Handysides DG, Ali R, Blair I, Grivna M, Shah SM, Sheek-Hussein M, El-Sadig M, Sharif AA, El-Obaid Y.. An analysis of the health status of the United Arab Emirates: the ‘Big 4’ public health issues. Glob. Health Action. 2013; 6: doi: 10.3402/gha.v6i0.20100.
[10] Singh RB, Niaz MA, Ghosh S, Beegum R, Rastogi V, Sharma JP, Dube GK. Association of transfatty acids (vegetable ghee) and clarified butter (Indian ghee) intake with higher risk of coronary heart disease in rural and urban populations with low fat consumption. Int. J. Cardiol. 1996; 56: 289-298.

Chapter 19

[1] Halberg F, Cornelissen G, Singh RB. Timing nutriceuticals. World Heart J. 2010; 2: 100-111.
[2] Cornelissen G, Zaslavskaya RM, Kumagai Y, Romanov Y, Halberg F. Chrono-pharmacologic issues in space. J. Clin. Pharmacol. 1994; 34: 543-551.
[3] Sabatine MS, Guigliano RP, Wiviott SD and The Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators.

Efficacy and safety of evolocumab in reducing. Lipids and cardiovascular events. N. Engl. J. Med. 2015; 372: 1500-1509. DOI: 10.1056/NEJMoa 1500858.
[4] Stein EA, Raal FJ. New therapies for reducing low-density lipoprotein cholesterol. Endocrinol Metab Clin North Am 2014; 43: 1007-1033.
[5] Sullivan D, Olsson AG, Scott R, Kim JB, Xue A, Gebski V, Wasserman SM, Stein EA. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 2012; 308: 2497-2506.
[6] Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth, Burgess L, Ceska R, Roth E, Koren MJ, Ballantyne CM, Monsalvo ML, Tsirtsonis K, Kim JB, Scott R, Wasserman SM, Stein EA, for the DESCARTES Investigators. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N. Engl. J. Med. 2014; 370: 1809-1819.
[7] Persson, L, Cao G, Stahle L, Sjöberg BG, Troutt JS, Konrad RJ, Gälman C, Wallén H, Eriksson M, Hafström I, Lind S, Dahlin M, Amark P, Angelin B, Rudling M.. Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans. Arterioscler. Thromb. Vasc. Biol. 2010; 30: 2666–2672.
[8] Cui Q, Ju X, Yang T, Zhang M, Tang W, Chen Q, Hu Y, Haas JV, Troutt JS, Pickard RT, Darling R, Konrad RJ, Zhou H, Cao G. Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population. Atherosclerosis 2010; 213: 632–636.
[9] Lagace TA. PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells. Curr Opin Lipidol. 2014; 25(5): 387–393. doi: 10.1097/MOL.000000000 0000114.
[10] Singh RB, Darlenska TS, Hristova K, Otsuka K, Fedacko J, Pella D, Milovanovic B, Singh R. Chronocardiology and chronotherapy. J. Cardiol. Ther. 2014; 2: 31-36.
[11] Almontashiri NAM, Vilmundarson RO, Ghasemzadeh N, Dandona S, Roberts R, Quyyumi AA, Chen H-H, Steward AFR. Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies. PLoS ONE 2014; 9 (9): e106294. doi: 10.1371/journal.pone.0106294.
[12] Storch KF, Lipan O, Leykin I, Viswanathan N, Davis FC, Wong WH, Weitz CJ. Extensive and divergent circadian gene expression in liver and heart. Nature 2002; 417 (6884): 78–83.

Chapter 20

[1] Sabatine MS, Guigliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA, for The Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing. Lipids and cardiovascular events. N. Engl. J. Med. 2015; 372: 1500-1509. DOI: 10.1056/NEJMoa1500858.
[2] Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJP, for the ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 2015; 372: 1489-1499. DOI: 10.1056/NEJMoa1501031.
[3] Persson, L, Cao G, Stahle L, Sjöberg BG, Troutt JS, Konrad RJ, Gälman C, Wallén H, Eriksson M, Hafström I, Lind S, Dahlin M, Amark P, Angelin B, Rudling M.. Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans. Arterioscler Thromb Vasc Biol. 2010; 30: 2666-2672.
[4] Singh RB, Darlenska TS, Hristova K, Otsuka K, Fedacko J, Pella D, Milovanovic B, Singh R. Chronocardiology and chronotherapy. J. Cardiol. Ther. 2014; 2: 31-36.
[5] Halberg F, Cornelissen G, Wang ZR, Wan C, Ulmer W, Katinas G, Singh Ranjana, Singh RK, Singh Rajesh, Gupta BD, Singh RB, Kumar A, Kanabrocki E, Sothern RB, Rao G, Bhatt MLBD, Srivastava M, Rai G, Singh S, Pati AK, Nath P, Halberg Francine, Halberg J, Schwartzkopff O, Bakken E, Shastri VK. Chronomics: circadian and circaseptan timing of radiotherapy, drugs, calories, perhaps nutriceuticals and beyond. J. Exp. Therapeutics Oncol. 2003; 3: 223-260.
[6] Saboo B, Singh RB, Fedacko J, Hristova K, Elkilany G, Istavan T, Rai M,Wilson DW. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. World Heart J. 2015; 7 (in press).
[7] Cornelissen G. Cosinor-based rhythm-ometry. Theoretical Biology and Medical Modelling 2014; 11: 16. doi:10.1186/1742-4682-11-16. 24 pp.

Chapter 21

[1] James P. A., Oparil S., Carter B. L., Cushman W. C., Dennison-Himmelfarb C., Handler J., Lackland D. T., LeFevre M. L., MacKenzie T. D., Ogedegbe O., Smith Jr. S. C., Svetkey L. P., Taler S. J., Townsend R. R., Wright Jr. J. T., Narva A. S., Ortiz E. 2014 Evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA, 2014; 311 (5): 507-520, DOI:10.1001/jama. 2013.284427. http:// jama.jamanetwork. com/ article.aspx?articleid=1791497.
[2] Singh R. B. and Indian Consensus Group. Prevalence and prevention of hypertension, diabetes mellitus, and coronary artery disease in India. A scientific statement of the Indian Society of Hypertension, International College of Nutrition and International College of Cardiology. World Heart J., 2010; 2: 31-44.
[3] Moran A. E., Odden M. C., Thanataveerat A., Keane Y. Tzong, K. Y., Rasmussen P. W., Guzman D., Williams L., Bibbins-Domingo K., Coxson P. G., Goldman L. Cost-effectiveness of hypertension therapy according to 2014 Guidelines. N. Engl. J. Med., 2015; 372: 447-455. DOI: 10.1056/NEJMsa1406751.
[4] Singh R. B., Fedacko J., Pella D., Macejova Z., Ghosh S., de Amit K., Begom R., Tumbis Z. A., Haque M., Vajpeyee S. K., de Meester F., Sergey C., Agarwalo R., Muthusamy V. V., Five City Study Group, Gupta A. K. Prevalence and risk factors for prehypertension and hypertension in five Indian cities. Acta Cardiol., 2011; 66: 29-37.
[5] Singh R. B., Cornelissen G., Otsuka K., Juneja L., Halberg F. Coronary risk factors and ambulatory blood pressures and heart rate in Asian Indians. The Open Nutr. J., 2012; 5: 79-80.
[6] Luca F., Perry G. H., Di Rienzo A. Evolutionary adaptations to dietary changes. Annu. Rev. Nutr., 2010; 30: 291–314.
[7] Singh R. B., Rastogi S. S., Singh R., Ghosh S., Niaz M. A. Effects of guava intake on serum total and high density lipoprotein cholesterol levels and systemic blood pressures. Amer. J. Cardiol., 1992; 70: 1287-1291.
[8] Singh R. B., Rastogi S. S., Niaz M. A., Ghosh S., Singh R.: Effects of fat modified and fruits vegetable enriched diets on blood lipids in the Indian diet heart study. Amer. J. Cardiol., 1992; 69: 869-874.
[9] Singh R. B., Fedacko J., Vargova V., Pella D., Niaz M. A., Ghosh S. Effect of Low w-6/w-3 fatty acid ratio Paleolithic-Style Diet in patients with acute coronary syndromes: A randomized, single blind, controlled trial, World Heart J., 2012; 4: 71-84.
[10] De Lorgeril M., Renaud S., Mamelle N., Salen P., Martin J. L., Monjaud I., Guidollet J., Touboul P., Delaye J. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. The Lancet, 1994; 343:1454–1459.
[11] Singh R. B., Dubnov G., Niaz M. A., Ghosh S., Singh R., Rastogi S. S., Manor O., Pella D., Berry E. M. Effect of an Indo-Mediterranean diet on progression of coronary disease in high risk patients: a randomized single blind trial. Lancet, 2002; 360: 1455-1461.
[12] PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet. N. Engl. J. Med., 2013 doi: 10.1056/ NEJMoa1200303.
[13] Singh R. B., Sircar A. R., Rastogi S. S., Singh R. Dietary modulators of blood pressures in hypertension. Euro. J. Clin. Nutr., 1990; 44: 319-327.
[14] Hristova K., Shiue I., Pella D., Singh R. B., Chaves H., Basu T. K., Ozimek L., Rastogi S. S., Takahashi T., Wilson D., DeMeester F., Cheema S., Garg M., Buttar H. S., Milovanovic B., Kumar A., Handjiev S., Cornélissen G., Petrov I. Sofia Declaration on transition of prevention strategies for cardiovascular diseases and diabetes in developing and newly industrialized countries. A statement of the International College of Cardiology and International College of Nutrition. Nutrition, 2014; 30 (9): 1085-1089. DOI 10.1016/ j.nut2013.12.013.
[15] Moore T. J., Conlin P. R., Ard J., Svetkey L. P., for DASH Collaborative Research Group. DASH (Dietary Approaches to Stop Hypertension) Diet Is Effective Treatment for Stage 1 Isolated Systolic Hypertension. Hypertension, 2001; 38: 155-158.
[16] Johnson S. A., Figueroa A., Navaei N., Wong A., Kalfon R., Ormsbee L. T., Feresin R. G., Elam M. L., Hooshmand S., Payton M. E., Arjmandi B. H.

Daily blueberry consumption improves blood pressure and arterial stiffness in postmenopausal women with pre- and stage 1-hypertension: a randomized, double-blind, placebo-controlled clinical trial. Acad. Nutr. Diet, 2015; 115: 369-377. doi: 10.1016/j.jand.2014.11.001.
[17] Halberg F., Cornelissen G., Singh R. B. Timing nutriceuticals. World Heart J., 2010; 2: 100-111.

Chapter 22

[1] Lincoff AM, Bittl JA, Harrington RA, et al; REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289(7):853-863.
[2] Kastrati A, Neumann FJ, Mehilli J, et al; ISAR-REACT 3 Trial Investigators. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N. Engl. J. Med. 2008;359(7):688-696.
[3] Stone GW, McLaurin BT, Cox DA, et al; ACUITY Investigators. Bivalirudin for patients with acute coronary syndromes. N. Engl. J. Med. 2006;355 (21):2203-2216.
[4] EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998; 352: 87–92.
[5] ESPRIT investigators. Novel dosing regimen of eptifi batide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000; 356: 2037–44.
[6] Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention.The REPLACE-2 trial. JAMA 2003; 289: 853–63.
[7] Stone G, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N. Engl. J. Med. 2008; 358: 2218–30.
[8] Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 2009;361: 1045–57.
[9] Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrelin patients with acute coronary syndromes. N. Engl. J. Med. 2007;357: 2001–15.
[10] Romagnoli E, Biondi-Zoccai G, Sciahbasi A, et al. Radial versus femoral randomized investigation in ST-segment elevation acute coronary syndrome. J. Am. Coll. Cardiol. 2012; 60: 2481–89.
[11] Cavender MA, Sabatine MS. Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials. Lancet. 2014;384(9943):599-606.
[12] Bangalore S, Toklu B, Kotwal A, et al. Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors. BMJ. 2014;349:g6419.
[13] Han Y, Guo J, Zheng Y, et al; the BRIGHT Investigators. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. JAMA. doi:10.1001/jama. 2015.2323.
[14] Peggy Peck, Editor-in-chief; Medpage Today, ACC meeting coverage 03.18.2015, ACC: MATRIX scores for transradial- But Angiomax again comes up short against unfractionated heparin.

Chapter 23

[1] Samuels MA. The brain-heart connection. Circulation 2007; 116:77-84.
[2] Singh RB, Karlik C, Otsuka K, Pella D, Pella J. Brain-heart connection and the risk of heart attack. Biomed Pharmacother 2002; 56: 257s-265s.
[3] Cornelissen G, Breus TK, Bingham C, Zaslavskaya R, Varshitsky M, Mirsky B, Teibloom M, Tarquini B, Bakken E, Halberg F, International Womb-to-Tomb Chronome Initiative Group: Beyond circadian chronorisk: worldwide circaseptan-circasemiseptan patterns of myocardial infarctions, other vascular events, and emergencies. Chronobiologia 1993; 20: 87-115.
[4] Neki NS, Singh RB, Rastogi SS. How brain influences neuro-cardiovascular dysfunction. JAPI 2004; 52: 223-230.
[5] Isobe Y, Hida H, Nishino H. Circadian rhythm of metabolic oscillation in suprachiasmatic nucleus depends on mitochondrial oxidation state, reflected by cytochrome C oxidase and lactate dehydrogenase. J Neuroscience Res 2011; 89: 929 – 935.
[6] Gvozdjáková A, Mikulecký M, Crane FL, Kucharská J, Cornelissen G, Kumar A, Palacka P, Singh RB. Mitochondrial cardiomyopathy and coenzyme Q10. WHJ 2014; 6(1): 29-46.
[7] Gvozdjáková A,

Takahashi T, Singh RB, De Meester F, Wilson DW, Crane FL. New roles of coenzyme Q10 in cardiovascular diseases, discovered by a single group. In: Circadian Cardiology with focus on both prevention and intervention. Eds: Hristova K, Shehab A, Cornelissen G, Singh RB, Nova Science Publishers, e-book: 2015; Chapter 23: 355–370.
[8] Halberg E, Halberg F. Chronobiologic study design in everyday life, clinic and laboratory. Chronobiologia 1980; 7: 95-120.
[9] Lang JK, Gohil K, Packer L. Simultaneous determination of tocopherols, ubiquinols, and ubiquinones in blood, plasma, tissue homogenates, and subcellular fractions. Anal Biochem 1986; 157:106 – 116.
[10] Kucharská J, Gvozdjáková A, Mizera S, Braunová Z, Schreinerová Z, Schrameková E, Pecháň I, Fabián J. Participation of coenzyme Q10 in the rejection development of the transplanted heart: a clinical study. Physiol Res 1998; 7/6: 399 - 204.
[11] Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95: 351 - 358.
[12] Palmer JW, Tandler B, Hoppel CL. Canine myocardial ischemia: defect in mitochondrial electron transfer complex I. J Mol Cell Cardiol 1977; 12: 639-645.
[13] Lowry DH, Rosenbrough NY, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193:

265–276.
[14] Estabrook RW. Mitochondrial respiratory control and the polarographic measurements of the ADP:O ratios. Methods Enzymol 1967; 10: 41 – 47.
[15] Pereira VH, Cerqueira JJ, Palha JA, Sousa N. Stressed brain, diseased heart: A review on the pathophysiologic mechanisms. Int J Cardiol 2013; 166: 30-37.
[16] Morris CJ, Yang JN, Scheer AJL. The impact of the circadian timing system on cardiovascular and metabolic function. Prog Brain Res 2012; 199:337-358.
[17] Rey G, Reddy AB. Rhythmic respiration. Science 2013; 342: 570 -571.
[18] Peek CB, Affinati AH, Ramsey KM, Kuo HY, Yu W, Sena LA, Ilkayeva O, Marcheva B, Kobayashi Y, Omura C, Levine DC, Bacsik DJ, Gius D, Newgard CB, Goetzman E, Chandel NS, Denu JM, Bass J. Circadian clock NAD+ cycle drives mitochondrial oxidative metabolism in mice. Science 2013; 342: 591-1243417-1-8.
[19] Simon N, Papa K, Vidal J, Boulamery A, Bruguerolle B. Circadian rhythms of oxidative phosphorylation. Effects of rotenone and melatonin on isolated rat brain mitochondria. Chronobiol International 2003; 20/3: 451-461.
[20] Linnane AW, Eastwood H. Cellular redox poise modulation: the role of coenzyme Q10, gene and metabolic regulation. Mitochondrion 2004; 4: 779-789.
[21] Pella D, Pella J, Singh RB, Thomas N, Tomlinson B. Brain-heart connection and the risk of cardiovascular disease. Monduzzi editore S.p.a. – Medimont Inc., 2002; C425R9014: 363-380.
[22] Singh RB, Weydahl A, Otsuka K, Watanabe Y, Yano S, Mori H, Ichimaru Y, Mitsutake G, Sato Y, Fanghong L, Zhao ZY, Karlik C, Gvozdjakova A. Can nutrition influence circadian rhythm and heart rate variability? Biomed J Pharmacol 2001; 55: 115-124.
[23] Gvozdjáková A, Kucharská J, Cornelissen G, Mikulecký M, Singh RB, Halberg F. Heart mitochondrial coenzyme “Q10-chronome” and variations of oxidative phosphorylation in diabetic rats. Mitochondrial Medicine 2005, St. Louis, USA, June 14-19. Mitochondrion 2005; 5/3: 226-227.
[24] Kohsaka A, Das P, Hashimoto I, Nakao T, Deguchi Y, Gourand SS, Waki H, Muragaki Y, Maeda M. The circadian clock maintains cardiac function by regulating mitochondrial metabolism in mice. Plos One 2014; 9/11: e112811.
[25] Reddy AB, O´Neill JS. Healthy clock, healthy body, healthy mind. Trends in cell biology, 2009; 20/1: 36-44.
[26] Haigis MC, Sinclair DA. Mammalian sirtuins: biological insights and disease relevance. Annu rev Pathol 2010; 5: 253-295.
[27] He W, Newman JC, Wang MZ, Ho L, Verdin E. Mitochondrial sirtuins: regulators of protein acylation and metabolism. Trend in Endocrinology and Metabolism 2012; 23/9: 467-476.
[28] Peek CB, Ramsey KM, Levine DC, Marcheva B, Perelis M, Bass J. Circadian regulation oif cellular physiology. Methods in Enzymology 2015; 552: 165-184.

Chapter 24

[1] Singh RB, Niaz MA, Rastogi SS, Bajaj S, Gaoli, Shoumin Z. Current zinc intake and risk of diabetes and coronary artery disease and factors associated with insulin resistance in rural and urban populations of North India. J Amer Coll Nutr. 1999; 17: 564-570.
[2] Singh RB, Niaz MA, Ghosh S, Beegum R, Bishnoi I, Agarwal P, Agarwal A. Dietary intake and plasma levels of antioxidant vitamins in health and disease. A hospital based case control study. J Nutr Environ Med 1995; 5: 235-242.
[3] Singh RB, Beegum R, Rastogi SS, Gaoli Z, Shoumin Z. Association of low plasma concentration of antioxidant vitamins, magnesium and zinc with high body fat percent measured by bioelectrical impedance analysis in Indian men. Mag Res 1998; 11: 3-10.
[4] Christan P, Stewart CP. Maternal micronutrient deficiency, fetal development, and the risk of chronic disease. J Nutr. 2010; 140: 437–435.
[5] Harder T, Rodekamp E, Schellong K, Dudenhausen JW, Plagemann A. Birth weight and subsequent risk of type 2 diabetes: A meta-analysis. Am J Epidemiol. 2007; 165: 849–857.
[6] van Mierlo LA, Arends LR, Streppel MT, Zeegers MP, Kok FJ, Grobbee DE, Geleijnse JM. Blood pressure response to calcium supplementation: A meta-analysis of randomized controlled trials. J Hum Hypertens. 2006; 20: 571–580.
[7] Pan J, Baker KM. Retinoic acid and the heart. Vitam Horm. 2007; 75: 257–283.
[8] McGrath J, Saari K, Hakko H, Jokelainen J, Jones P, Jarvelin M, Chant D, Isohanni M. Vitamin D supplementation during the first year of life and risk of schizophrenia: A Finnish birth cohort study. Schizophr Res. 2004; 67: 237–245.
[9] Ross RG, Hunter SK, McCarthy L, Beuler J, Hutchison AK, Wagner BD, Leonard S, Stevens KE, Freedman R. Perinatal choline effects on neonatal pathophysiology related to later schizophrenia risk. Am J Psychiatry. 2013; 170: 290–298.
[10] Leung BMY, Kaplan BJ, Field CJ, Tough S, Eliasziw M, Gomez MF, McCargar LJ, and the APrON Study Team. Prenatal micronutrient supplementation and postpartum depressive symptoms in a pregnancy cohort. BMC Pregnancy and Childbirth 2013; 13: 2 doi:10.1186/1471-2393-13-2.
[11] McEvoy CT, Schilling D, Clay N, Jackson K, Go MD, Spitale P, Bunten C, Leiva M, Gonzales D, Hollister-Smith J, Durand M, Frei B, Buist AS, Peters D, Morris CD, Spindel ER. Vitamin C supplementation for pregnant smoking women and pulmonary function in their newborn infants: A randomized clinical trial. JAMA 2014; 311 (20): 2074-2082. doi:10.1001/jama.2014.5217.
[12] Pfab T, Slowinski T, Godes M, Halle H, Priem F, Hocher B. Low birth weight, a risk factor for cardiovascular diseases in later life, is already associated with elevated fetal glycosylated hemoglobin at birth. Circulation. 2006; 114: 1687-1692.
[13] Arnesen E, Forsdahl A. The Tromsø heart study: coronary risk factors and their association with living conditions during childhood. J Epidemiol Community Health. 1985; 39: 210-214.
[14] Freedman DS, Khan LK, Dietz WH, Srinivasan SR, Berenson GS. Relationship of Childhood obesity to coronary heart disease risk factors in adulthood: The Bogalusa Heart Study. Pediatrics 2001; 108: 712-718.
[15] Agarwal S. Labrique A. Newborn health on the line the potential mHealth applications. JAMA 2014; 312 (3): 229-230. doi:10.1001./jama.2014.6371.
[16] World Health Organization, UNICEF. Countdown to 2015: Maternal, Newborn and Child Survival. http://countdown2015mnch.org/documents/2012/Report2012-complete.pdf 2012. Accessed July 2014.
[17] Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, Jha P, Campbell H, Walker CF, Cibulskis R, Eesele T, Liu L, Mathers C, for the Child Health Epidemiology Reference Group of WHO and UNICEF. Global, regional and national causes of child mortality in 2008: a systematic analysis. Lancet 2010; 375: 12–27.
[18] Black RE, Allen LH, Bhutta ZA, Caulfield LE, de Onis M, Ezzati M, Mathers C, Rivera J, for the Maternal and Child Undernutrition Study Group. Maternal and child undernutrition: global and regional exposures and health consequences. Lancet 2008; 371: 243–260.
[19] Allen LH: MMN in pregnancy and lactation: an overview. Am J Clin Nutr 2005; 81: 1206S–1212S.
[20] Bhutta ZA, Ahmed T, Black RE, Cousens S, Dewey K, Giugliani E, Halder BA, Kirkwood B, Morris SS, Sachdev HPS, Shekar S, for the Maternal and Child Undernutrition Study Group. What works? Interventions for maternal and child undernutrition and survival. Lancet 2008; 371: 417–440.
[21] Shrimpton R, Shrimpton R, Schultink W. Can supplements help meet the micronutrient needs of the developing world? Proc Nutr Soc 2002; 61: 223–229.
[22] Haider BA, Bhutta ZA. Multiple-micronutrient supplementation for women during pregnancy. Cochrane Database Syst Rev 2006; 4: 4–18.
[23] Handjieva-Darlenska T, Hristova K, Singh RB. Antioxidant vitamins and the heart. World Heart J 2014; 6: 179-184.
[24] Shah PS, Ohlsson A. Knowledge synthesis group on determinants of low birth weight and preterm births. Effects of prenatal MMN supplementation on pregnancy outcomes: a meta-analysis. CMAJ 2009; 180: E99–E108.
[25] Ronsmans C, Fisher DJ, Osmond C, Margetts BM, Fall CH, Maternal Micronutrient Supplementation Study Group. Multiple micronutrient supplementation during pregnancy in low-income countries: a meta-analysis of effects on stillbirths and on early and late neonatal mortality. Food Nutr Bull 2009; 30: S547–S557.
[26] Fall CH, Fisher DJ, Osmond C, Margetts BM, Maternal Micronutrient Supplementation Study Group. Multiple micronutrient supplementation during pregnancy in low-income countries: a meta-analysis of effects on birth size and length of gestation. Food Nutr Bull 2009; 30: S533–S546.
[27] Keith P. West Jr, KP, Shamim AA, Mehra S, Labrique AB, Ali H, Shaikh S, Klemm RDW, Wu LS-F, Mitra M, Haque R, Hanif AAM, Massie AB, Merrill RD, Schulze KJ, Christian P.

Effect of maternal multiple micronutrient vs iron–folic acid supplementation on infant mortality and adverse birth outcomes in rural Bangladesh The JiVitA-3 Randomized Trial. JAMA. 2014; 312 (24): 2649-2658. doi:10.1001/jama.2014.16819.
[28] Singh RB, Visen P, Sharma D, Sharma S, Mondal R, Sharma JP. Study of functional foods consumption patterns among decedents dying due to various causes of death. The Open Nutra J 2015; 8: 16-28.
[29] Sofi F, Abbate R, Gensini GF, Casini A. Accruing evidence about benefits of adherence to Mediterranean diet on health: an updated systematic review with meta-analysis. Am. J. Clin. Nutr. 2010; 92 (5): 1189-1196. doi: 10.3945/ajcn.2010.29673.
[30] Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, Gómez-Gracia E, Ruiz-Gutiérrez V, Fiol M, Lapetra J, Lamuela-Raventos RM, Serra-Majem L, Pintó X, Basora J, Muñoz MA, Sorlí JV, Martínez JA, Martínez-González MA, for the PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013; 368: 1279-1290. doi: 10.1056/NEJMoa1200303.
[31] De Lorgeril M, Renaud S, Mamelle N, Salen P, Martin JL, Monjaud I, Guidollet J, Touboul P, Delaye J. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. The Lancet 1994; 343: 1454–1459.
[32] Singh RB, Dubnov G, Niaz MA, Ghosh S, Singh R, Rastogi SS, Manor O, Pella D, Berry EM. Effect of an Indo-Mediterranean diet on progression of coronary disease in high risk patients: a randomized single blind trial. Lancet 2002: 360: 1455-1461.
[33] http://www.fda.gov/Food/FoodborneIllnessContaminants/Metals/ucm115644.htm.
[34] Jirtle RL, Skinner MK. Environmental epigenomics and disease susceptibility. Nature Rev Gen 2007; 8: 253-262.
[35] Alam SE, Singh RB, Gupta S, Dherange P, De Meester F, Wilczynska A, Dharwadkar S, Wilson D, Hungin P. Nutritional aspects of epigenetic inheritance. Can J Physiol Pharmacol 2012; 90: 989-994.
[36] Singh RB, Niaz MA, Rastogi V, Beegum R, Singh NK. Diet, antioxidants and risk of cancer; a case control study. J Nutr Environ Med 1997; 7: 267-274.
[37] Singh RB, Gupta UC, Mittal N, Niaz MA, Ghosh S, Rastogi V. Epidemiologic study of trace elements and magnesium and risk of coronary artery disease in the rural and urban populations. J Am Coll Nutr 1997; 16: 62-67.


[38] Singh RB, Rastogi V, Singh R, Niaz MA, Srivastav S, Aslam M, Singh NK. Magnesium and antioxidant vitamins status and risk of complications of ageing in an elderly urban population. Mag Res 1996; 9: 299-306.
[39] UNICEF/WHO/UNU. Composition of multiple micronutrient supplements to be used in pilot programmes among pregnant women in developing countries. New York: NY: UNICEF; 1999.
[40] Singh P, Singh RK, Singh RB, Wilson DW. Can maternal nutrient supplementation prevent complications of pregnancy and infancy? The Open Nutra J 2015; 7 (in press).

Chapter 25

[1] Singh RB, Takahashi T, Tokunaga M, Wilczynska A, Kim CJ, De Meester F, Handjieva-Darlenska T, Cheema SK, Wilson DW. Milovanovic B. Fedacko J, Hristova K, Chaves H.

Effect of brain derived neurotrophic factor, in relation to diet and lifestyle factors, for prevention of neuropsychiatric and vascular diseases and diabetes. The Open Nutra J 2014; 7: 5-14.
[2] Pella D, Otsuka K, Singh RB. Metabolic Syndrome: A Disease of the Brain. The Open Nutraceuticals Journal, 2011; 4: 107-118.
[3] Dubnov G, Pella D, Singh RB. The effect of an alpha-linolenic acid rich diet on the circadian rhythm of cardiac events. World Heart J 2008; 1: 49-56.
[4] Singh RB, Pella D, Otsuka K. Can brain dysfunction be a predisposing factor in metabolic syndrome? Biomed Pharmacother 2004; 58: 52-68.
[5] Pella D, Thomas N, Tomlinson B, Singh RB. Prevention of coronary artery disease: the south Asian paradox. Lancet 2003; 361: 79.
[6] Singh RB, Cornelissen G, Weydahl A, Schwartzkopff O, Katinas G, Otsuka K, Watanabe Y, Yano S, Mori H, Ichimaru Y, Mitsutake G, Pella D, Fanghong L, Zhao Z, Rao RS, Gvozdjakova A, Halberg F. Circadian heart rate and blood pressure variability considered for research and patient care. Int J Cardiol 2003; 87: 9-28.
[7] Singh RB, Weydahl K, Otsuka K, Watanabe Y, Yano S, Mori H, Ichimaru Y, Mitsutake G, Sato Y, Fanghong L, Zhao ZY, Kartik C, Gvozdjakova A. Can nutrition influence heart rate and blood pressure variability. Biomed Pharmacother 2001; 55: 7-18.
[8] Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, Wang H, Abumrad N, Eaton JW, Tracey KJ. Vagal nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000; 405: 458-62.
[9] Singh RB, Gupta S, Dherange P, De Meester F, Wilczynska A, Alam SE, Pella D, Wilson DW. Metabolic syndrome: a brain disease. Can J Physiol Pharmacol 2012; 90: 1171–1183.
[10] 10.Yoshida T, Ishikawa M, Niitsu T, Nakazato M,Watanabe H, Shiraishi T,Shiina A, Hashimoto T,Kanahara N,Hasegawa T, Enohara M, Kimura A, Iyo M, Hashimoto K. Decreased serum levels of mature Brain-Derived Neurotrophic Factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder. PLoS One 2012; 7(8): e42676.
[11] Halberg F, Cornelissen G, Czaplicki J, Hillman D, Sampson M, Schwartzkopff O, Watanabe Y. Beyond a spotcheck-based health care: thank you, Ram Bahadur Singh. The Open Nutr Journal, 2011; 4: 34-44.
[12] Suliman S, Hemmings MJ, Seedat S. Brain-Derived Neurotrophic Factor (BDNF) protein levels in anxiety disorders: systematic review and meta-regression analysis. Front Integr Neurosci 2013; 7: 55 doi: 10.3389/fnint.2013.00055
[13] Ali S, Stone MA, Peters JL, Davies MJ, Khunti K. The prevalence of co-morbid depression in adults with type 2 diabetes: a systematic review and meta-analysis. Diabet Med 2006; 23: 1165–1173.
[14] Feinkohl I, Sattar N, Welsh P, Reynolds RM, Deary IJ: Association of N-terminal pro-brain natriuretic peptide with cognitive function and depression in elderly people with type 2 diabetes. PLoS One 2012; 7: e44569.
[15] Egede LE, Nietert PJ, Zheng D: Depression and all-cause and coronary heart disease mortality among adults with and without diabetes. Diabetes Care 2005; 28: 1339–1345.
[16] Bogner HR, Morales KH, Post EP, Bruce ML. Diabetes, depression, and death: a randomized controlled trial of a depression treatment program for older adults based in primary care. (PROSPECT). Diabetes Care 2007; 30: 3005–3010.
[17] Mattson MP, Maudsley S, Martin B: BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders. Trends Neurosci 2004; 27: 589–594.
[18] Tsai SJ, Hong CJ, Liou YJ. Effects of BDNF polymorphisms on antidepressant action. Psychiatry Investig 2010; 7: 236–42.
[19] Duman RS: Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromolecular Med 2004; 5 (1): 11–25.
[20] Karege F, Perret G, Bondolfi G, Schwald M, Bertschy G. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res 2002; 109: 143–148.
[21] Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 2008; 64 (6): 527–532.
[22] Duman RS. Structural alterations in depression: cellular mechanisms underlying pathology and treatment of mood disorders. CNS Spectr 2002; 7: 140–142.
[23] Kernie SG, Liebl DJ, Parada LF. BDNF regulates eating behavior and locomotor activity in mice. EMBO J 2000; 19 (6): 1290–1300.
[24] Fujinami A, Ohta K, Obayashi H, Fukui M, Hasegawa G, Nakamura N. Serum brain-derived neurotrophic factor in patients with type 2 diabetes mellitus: Relationship to glucose metabolism and biomarkers of insulin resistance. Clin Biochem 2008; 41 (10–11): 812–817.
[25] Rao AA, Sridhar GR, Srinivas B, Das UN. Bioinformatics analysis of functional protein sequences reveals a role for brain-derived neurotrophic factor in obesity and type 2 diabetes mellitus. Med Hypotheses 2008; 70 (2): 424–429.
[26] Arentoft A, Sweat V, Starr V, Oliver S, Hassenstab J. Plasma BDNF is reduced among middle-aged and elderly women with impaired insulin function: evidence of a compensatory mechanism. Brain Cogn 2009; 71: 147–152.
[27] Swift DL, Johannsen NM, Myers VH, Earnest CP, Smits JA. The effect of exercise training modality on serum brain derived neurotrophic factor levels in individuals with type 2 diabetes. PLoS One 2012; 7 (8): e42785.
[28] Das UN. Is type 2 diabetes mellitus a disorder of the brain. Nutrition 2002; 18: 667-672.
[29] Engum A. The role of depression and anxiety in onset of diabetes in a large population-based study. J Psychosom Res 2007; 62 (1): 31–38.
[30] Ventriglia M, BocchioChiavetto L, Benussi L, Binetti G, Zanetti O. Association between the BDNF 196 A/G polymorphism and sporadic Alzheimer's disease. Mol Psychiatry 2002; 7 (2): 136–137.
[31] Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003; 112: 257–269.
[32] Molendijk ML, van Tol MJ, Penninx BW, van der Wee NJ, Aleman A, Veltman DJ. BDNF val66met affects hippocampal volume and emotion-related hippocampal memory activity. Transl Psychiatry. 2012; 31 (2): e74.
[33] Ribeiro L, Busnello JV, Cantor RM, Whelan F, Whittaker P. The brain-derived neurotrophic factor rs6265 (Val66Met) polymorphism and depression in Mexican-Americans. Neuroreport 2007; 18: 1291–1293.
[34] Jiang X, Xu K, Hoberman J, Tian F, Marko AJ. BDNF variation and mood disorders: a novel functional promoter polymorphism and Val66Met are associated with anxiety but have opposing effects. Neuropsychopharmacology 2005; 30 (7): 1353–1361.
[35] Schumacher J, Jamra RA, Becker T, Ohlraun S, Klopp N. Evidence for a relationship between genetic variants at the brain-derived neurotrophic factor (BDNF) locus and major depression. Biol Psychiatry 2005; 58: 307–314.
[36] Carrard A, Salzmann A, Perroud N, Gafner J, Malafosse A, Karege F. Genetic association of the Phosphoinositide-3 kinase in schizophrenia and bipolar disorder and interaction with a BDNF gene polymorphism. Brain Behav 2011; 1 (2): 119–124.
[37] Zhou JX, Li HC, Bai JX, Chang BC, Li CJ, Sun P, Chen LM. Functional Val66Met polymorphism of Brain-derived neurotrophic factor in type 2 diabetes with depression in Han Chinese subjects. Behav Brain Func 2013; 9: 34. http://www. Behavioralandbrainfunctions. com/content/9/1/34
[38] Tsai SJ, Hong CJ, Liou YJ. Effects of BDNF polymorphisms on antidepressant action. Psych Investig 2010; 7 (4):236–242.
[39] Outhred T, Das P, Dobson-Stone C, Griffiths K, Felmingham KL, Bryant RA. The functional epistasis of 5-HTTLPR and BDNF Val66Met on emotion processing: a preliminary study. Brain Behav 2012; 2 (6): 778–788.
[40] Vasant DH, Payton A, Mistry S, Thompson DG, Hamdy S. The val66met polymorphism of brain-derived neurotrophic factor is associated with human esophageal hypersensitivity. Neurogastroenterol Motil 2013; 25 (2): 162–e85.
[41] Smolders R, Rijpkema M, Franke B, Fernández G. BDNF Val66Met polymorphism interacts with sex to influence bimanual motor control in healthy humans. Brain Behav 2012; 2: 726–731.
[42] Hwang JP, Tsai SJ, Hong CJ, Yang CH, Lirng JF. The Val66Met polymorphism of the brain-derived neurotrophic-factor gene is associated with geriatric depression. Neurobiol Aging 2006; 27: 1834–1837.
[43] Hong CJ, Huo SJ, Yen FC, Tung CL, Pan GM, Tsai SJ. Association study of a brain-derived neurotrophic-factor genetic polymorphism and mood disorders, age of onset and suicidal behavior. Neuropsychobiology 2003; 48: 186–189.
[44] Chen ZY, Jing D, Bath KG, Ieraci A, Khan T. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science 2006; 314: 140–143.
[45] Giese M, Unternährer E, Hüttig H, Beck J, Brand S, Calabrese P, Holsboer-Trachsler E, Eckert A. BDNF: an indicator of insomnia? Molecular Psychiatry 2013; 19 (2):151-152. doi: 10.1038/mp.2013.10
[46] Duman RS, Malberg J, Nakagawa S, D'Sa C. Neuronal plasticity and survival in mood disorders. Biol Psychiatry 2000; 48: 732–739.
[47] Faraguna U, Vyazovskiy VV, Nelson AB, Tononi G, Cirelli C. A causal role for brain-derived neurotrophic factor in the homeostatic regulation of sleep. J Neurosci 2008; 28: 4088–4095.
[48] Steiger A, Kimura M. Wake and sleep EEG provide biomarkers in depression. J Psychiatr Res 2010; 44: 242–252.
[49] Molendijk ML, Bus BA, Spinhoven P, Penninx BW, Kenis G, Prickaerts J. BDNF as biomarker for depression. Mol Psychiatry 2011; 16: 1088–1095.
[50] Lang UE, Hellweg R, Gallinat J. BDNF serum concentrations in healthy volunteers are associated with depression related personality traits. Neuropsycho-pharmacology 2004; 29: 795–798.
[51] Bus BA, Molendijk ML, Penninx BJ, Buitelaar JK, Kenis G, Prickaerts J Elzinga BM, Voshaar RC. Determination of serum brain derived neurotrophic factor. Psychoneuroendocrinology 2011; 36: 228–239.
[52] Sartorius A, Hellweg R, Litzke J, Vogt M, Dormann C, Vollmayr B, Danker-Hopfe H, Gass P. Correlations and discrepancies between serum and brain tissue levels of neurotrophins after electroconvulsive treatment in rats. Pharmacopsychiatry 2009; 42: 270–276.
[53] Conti B, Maier R, Barr AM, Morale MC, Lu X, Sanna PP, Bilbe G, Hoyer D, Bartfai T. Region-specific transcriptional changes following the three antidepressant treatments electroconvulsive therapy, sleep deprivation and fluoxetine. Mol Psychiatry 2007; 12: 167–189.
[54] Cattaneo A, Bocchio-Chiavetto L, Zanardini R, Milanesi E, Placentino A, Gennarelli M. Reduced peripheral brain-derived neurotrophic factor mRNA levels are normalized by antidepressant treatment. Int J Neuropsychopharmacol. 2010; 13: 103–108.
[55] D’Sa C, Dileone RJ, Anderson GM, Sinha R. Serum and plasma brain-derived neurotrophic factor (BDNF) in abstinent alcoholics and social drinkers. Alcohol 2012; 46 (3): 253–259.
[56] Singh RB, Chaudhuri J, De Meester F, Wilzynska A, Wilson DW, Hungin APS. The gut, brain and heart connection. World Heart J 2011; 3: 151-174.
[57] Lommatzsch M, Braun A, Mannsfeldet A, Botchkharav NV, Pause R, Fishcher A, Lewin GR, Renz H. Abundant production of brain derived neurotrophic factor by adult visceral epithelia. Am J Pathol. 1999; 155: 1183-1193.
[58] Rost B, Hanf G, Ohnemus U. Monocytes of allergics and non-allergics produce, store and release the neurotrophins NGF, BDNF and NT-3. Regul Pept 2005; 124: 19-25.
[59] Noga O, Englmann C, Hanf G, Grützkau A, Seybold J, Kunkel G. The production, storage and release of the neurotrophins nerve growth factor, brain-derived neurotrophic factor and neurotrophins-3 by human peripheral eosinophils in allergics and non-allergics. Clin. Exp. Allergy 2003; 33: 649-654.
[60] Cai D, Holm JM, Duignan IJ, Zheng J, Xaymardan M, Chin A. BDNF-mediated enhancement of inflammation and injury in the aging heart. Physiol. Genomics 2006; 24: 191-197.
[61] Johansson M, Norrgard O, Frogmen S. Study of expression patterns and levels of neurotrophins and neurotrophin receptors in ulcerative colitis. Inflamm Bowel Dis. 2007; 13: 398-409.
[62] di Mola F, Friess H, Zhu ZW, Koliopanos A, Bley T, Di Sebastiano P, Innocenti P, Zimmermann A, Büchler MW. Nerve growth factor and Trk high affinity receptors (TrkA) gene expression in inflammatory bowel disease.Gut 2000; 46: 670-679.
[63] Raap U, Werfel T, Goltz C, Deneka N, Langer K, Bruder M, Kapp K, Schmid-Ott G, Wedi B. Circulating levels of brain-derived neurotrophic factor correlate with disease severity in the intrinsic type of atopic dermatitis. Allergy 2006; 61: 1416-1418.
[64] Krabbe KS, Nielsen AR, Krogh-Madsen R, Plomgaard P, Rasmussen P, Erikstrup C, Fischer CP, Lindegaard B, Petersen AM, Taudorf S, Secher NH, Pilegaard H, Bruunsgaard H, Pedersen BK. Brain derived neurotrophic factor and type 2 diabetes. Diabetologia 2007; 50: 431-38.
[65] Nonomura T, Tsuchida A, Ono-kishino M, NakagawaT, Taiji M, Noguchi H. Brain derived neurotrophic factor regulates energy expenditure through the central nervous system in obese diabetic mice. Int. J. Exp.Diab. Res. 2001; 2: 201-209.
[66] Ono M, Itakura Y, Nonomura T. Intermittent administration of brain derived neurotrophic factor ameliorates glucose metabolism in the obese diabetic mice. Metabolism 2000; 49: 129-133.
[67] Cao L, Lin EJ, Cahill MC, Wang C, Liu X, During MJ. Molecular therapy of obesity and diabetes by a physiological autoregulatory approach. Nat. Med. 2009; 15: 447-454.
[68] Rao JS, Ertley RN, Lee H, DeMar JC, Arnold JT, Rapoport SI, Bazinet RP. n-3 polyunsaturated fatty acid deprivation in rats decreases frontal cortex BDNF via a p38 MAPK-dependent mechanism. Mol. Psychiatry 2007; 12: 36-46.
[69] Di Marzo V. The endocannabinoid system in obesity and type 2 diabetes. Diabetologia 2008; 51: 1356-1367.
[70] Cho HJ, Kim JK, Zhou XF, Rush RA. Increased brain derived neurotrophic factor immunoreactivity in rat dorsal root ganglia and spinal cord following peripheral inflammation. Brain Res 1997; 764: 269-272.
[71] Komori T, Morikawa Y, Nanjo K, Senba E. Induction of brain-derived neurotrophic factor by leptin in the ventromrdial hypothalamus. Neuroscience 2006; 139: 1107-1115.
[72] Tonra JR, Ono M, Liu X, Garcia K, Jackson C. Brain derived neurotrophic factor improves blood glucose control and alleviates fasting hyperglycemia in C57BLKS-lepr(db)mice. Diabetes 1999; 48: 588-594.
[73] Nakagawa T, Ogawa Y, Ebihara K, Yamanaka M, Tsuchida A, Taiji M, Noguchi H, Nakao K. Antiobesity and antidiabetic effects of brain derived neurotrophic factor in rodent models of leptin resistance. Int J Obesity Rel Meta Disor 2003; 27: 557-565.
[74] Tamura H, Kamegai J,Shimizu T, Ishii S, Sugihara H, Oikawa S. Ghrelin stimulates growth hormones but not food intakes in arcuate nucleus ablated rats. Endocrinology 2002; 143: 3268-3275.
[75] Suwa M, Kishimoto H, Nofuji Y, Nakano H, Sasaki H, Radak Z, Kumagai S. Serum brain-derived neurotrophic factor level is increased and associated with obesity in newly diagnosed female patients with type 2 diabetes mellitus. Metabolism 2006; 55 (7): 852–857.
[76] WHO. Mortality and burden of disease estimates for WHO Member States in 2008. Geneva: World Health Organization, 2010.
[77] Editorial. Wealth but not health in USA. Lancet 2013; 381: 177.
[78] Pucci S, Mazzarelli P, Missiroli F, Regine F, Ricci F. Neuroprotection: VEGF, IL-6, and clusterin: the dark side of the moon. Prog Brain Res 2008; 173: 555–573.
[79] Golden E, Emiliano A, Maudsley S, Windham BG, Carlson OD, Egan JM. Circulating brain-derived neurotrophic factor and indices of metabolic and cardiovascular health: data from the Baltimore Longitudinal Study of Aging. PLoS One. 2010; 5: e10099.
[80] Ferris LT, Williams JS, Shen CL. The effect of acute exercise on serum brain-derived neurotrophic factor levels and cognitive function. Med Sci Sports Exerc 2007; 39: 728–734.
[81] Blann AD, Belgore FM, McCollum CN, Silverman S, Lip PL, Lip GY. Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes. Clin Sci (Lond) 2002; 102: 187–194.
[82] Lieb W, Safa R, Benjamin EJ, Xanthakis V, Yin X, Sullivan LM. Vascular endothelial growth factor, its soluble receptor, and hepatocyte growth factor: clinical and genetic correlates and association with vascular function. Eur Heart J. 2009; 30: 1121–1127.
[83] Wolf PA, D’Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke 1991; 22: 312–318.
[84] Lennmyr F, Ata KA, Funa K, Olsson Y, Terént A. Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) following permanent and transient occlusion of the middle cerebral artery in the rat. J Neuropathol Exp Neurol. 1998; 57: 874–882.
[85] Santhanam AV, Smith LA, Katusic ZS. Brain-derived neurotrophic factor stimulates production of prostacyclin in cerebral arteries. Stroke 2010; 41: 350–356.
[86] Cao L, Zhang L, Chen S, Yuan Z, Liu S, Shen X, Zheng X, Qi X, Li KKH, Chan JYH, Cai D. BDNF-mediated migration of cardiac microvascular endothelial cells is impaired during ageing. J Cell Mol Med 2012; 16: 3105-3115.
[87] Liu Y, Sun L, Huan Y, Zhao H, Deng J. Application of bFGF and BDNF to improve angiogenesis and cardiac function. J Surg Res 2006; 136: 85-91.
[88] Okada S, Yokoyama M, Toko H, Tateno K, Moriya J, Shimizu I, Nojima A, Ito T, Yoshida Y, Kobayashi Y, Katagiri H, Minamino T, Komuro I. BDNF protects against cardiac dysfunction after myocardial infarction via central nervous system mediated pathway. Arterioscler Thromb Vasc Biol 2012; 32: 1902-2009.
[89] Pikula A, Beiser AS, Chen TC, Preis SR, Vorgias D, DeCarli C, Au R, Kelly-Hayes M, Kase CS, Wolf PA, Vasan RS, Seshadri S. Serum brain–derived neurotrophic factor and vascular endothelial growth factor levels are associated with risk of stroke and vascular brain injury. Framingham Study. Stroke 2013; 44: 2768-2775.
[90] Rasmussen P, Brassard P, Adser H, Pedersen MV, Leick L, Hart E, Secher NH, Pedersen BK, Pilegaard H. Evidence for a release of brain-derived neurotrophic factor from the brain during exercise. Experimental Physiology 2009; 94:

1062-1069.
[91] Karczewska-Kupczewska M, Kowalska I, Nikołajuk A, Adamska A, Zielińska M, Kamińska N, Otziomek E, Górska M, Strczkowski M. Circulating brain-derived neurotrophic factor concentration is down regulated by intralipid/heparin infusion or high-fat meal in young healthy male subjects. Diabetes Care 2012; 35: 358–362.
[92] Lee J, Duan W, Long JM, Ingram DK, Mattson MP. Dietary restriction increases the number of newly generated neural cells, and induces BDNF expression, in the dentate gyrus of rats. J Mol Neurosci 2000; 15: 99–108.
[93] Araya AV, Orellana X, Espinoza J. Evaluation of the effect of caloric restriction on serum BDNF in overweight and obese subjects: preliminary evidences. Endocrine 2008; 33: 300–304.
[94] Tang SW, Chu E, Hui T, Helmeste D, Law C. Influence of exercise on serum brain-derived neurotrophic factor concentrations in healthy human subjects. Neurosci Lett 2008; 431: 62–65.
[95] Baydyuk M, Wu XS, He L, Wu LG. Brain-Derived Neurotrophic Factor inhibits calcium channel activation, exocytosis, and endocytosis at a central nerve terminal. The J Neuroscience, 2015, 35: 4676-4682.

Chapter 26

[1] Liu L, Oza S, Hogan D, Perin J, Rudan I, Lawn JE, Cousens S, Mathers C, Black RE. Global, regional, and national causes of child mortality in 2000-13, with projections to inform post-2015 priorities: an updated systematic analysis. The Lancet 2015; 385 (9966): 430-440.
[2] World Health Organization, UNICEF. Countdown to 2015: Maternal, Newborn and Child Survival. http//countdown2015mnch.org/documents/ 2012/Report2012-complete. Pdf.2012. Accessed July 2014.
[3] Shehab A, Elkilany G, Singh RB, Hristova K, Chaves H, Cornelissen G, Otsuka K. Coronary risk factors in South West Asia. Editorial. World Heart J 2015; 7: 21-30.
[4] Barker DJ. The development origins of adult diseases. J Am Coll Nutr 2004; 23 (Suppl 6): 588s-595s.
[5] Singh P, Singh RK, Singh RB. Can maternal nutrient supplementation prevent complications of pregnancy and infancy? The Open Nutr J, 2015: 7 (In press).
[6] Arnesen E, Forsdahl A. The Tromsø heart study: coronary risk factors and their association with living conditions during childhood. J Epidemiol Community Health. 1985; 39(3): 210-214.
[7] Singh RB, Mori H. Risk factors for coronary heart disease: synthesis of a new hypothesis through adaptation. Med Hypoth 1992; 39:334-341.
[8] Freedman DS, Khan LK, Dietz WH, Srinivasan SR, Berenson GS. Relationship of childhood obesity to coronary heart disease risk factors in adulthood: The Bogalusa Heart Study. Pediatrics 2001; 108: 712-718. doi: 10.1542/peds.108.3.712.
[9] Pfab T, Slowinski T, Godes M, Halle H, Priem F, Hocher B. Low birth weight, a risk factor for cardiovascular diseases in later life, is already associated with elevated fetal glycosylated hemoglobin at birth. Circulation 2006; 114 (16): 1687-1692.
[10] Gluckman PD, Hanson MA, Cooper C, Thornburg KL. Effect of in utero and early-life conditions on adult health and disease. N Engl J Med 2008; 359: 61–73.
[11] Mishra S, Singh RB, Dwivedi SP, De Meester F, Rybar R, Pella D, Fedacko J, Juneja LR. Effects of nutraceuticals on gene expression. The Open Nutra J 2009; 2: 70-80.
[12] Froy O. Circadian rhythms and obesity in mammals. ISRN Obesity 2012: volume 2012, Article ID 437198, 12 pages. http://dx.doi.org/ 10.5402/2012/437198.
[13] Singh RB, Srivastav V, Srivastav SSL, Akhilesh J, Cornélissen G, Halberg F. Circadian variation under conditions of caloric restriction in North India. Abstract 36, 2nd International Symposium: Workshop on Chronoastrobiology and Chronotherapy, Tokyo Kasei University, Tokyo, Japan, November 2001, un-paginated (1 p).
[14] Halberg F, Sullivan B. Meal schedules and their interaction with the body’s schedules. Chronobiologia 1976; 3: 75-76.
[15] Cornélissen G. When you eat matters: 60 years of Franz Halberg’s nutrition chronomics. The Open Nutraceuticals J 2012; 5 (Suppl 1-M1): 16-44.
[16] Singh RB, Singh AK, Sharma JP, Singh RK, Kumar A, Rastogi SS, Singh Garima, Kartikey K, Singh S, Fedacko J, Pella D, De Meester F, Wilczynska A, Wilson DW. Nutrition in Chronocardiology: we are indebted Professor Franz Halberg. The Open Nutra J 2012; 45-65.
[17] Hristova K, Nakaoka T, Otsuka K, Fedacko J, Singh R, Singh RB, De Meester F, Wilczynska A, Wilson DW. Perspectives on chocolate consumption and risk of cardiovascular diseases and cognitive function. The Open Nutraceuticals Journal 2012, 5, 207-212.
[18] Atallah R, Filion KB, Wakil S, Genest J, Joseph L, Poirier P, Rinfret S, Schiffrin EL, Eisenberg MJ. Long-term effects of 4 popular diets on weight loss and cardiovascular risk factors: A systematic review of randomized controlled trials. Circ Cardiovasc Qual Outcomes 2014; 7: 815-827.
[19] Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, Hu FB, Hubbard VS, Jakicic JM, Kushner RF, Loria CM, Millen BE, Nonas CA, Pi-Sunyer FX, Stevens J, Stevens VJ, Wadden TA, Wolfe BM, Yanovski SZ. Practice guidelines and the Obesity Society Report of the American College of Cardiology/American Heart Association Task Force on 2013 AHA/ACC/TOS guideline for the management of overweight. Circulation 2014; 129: S102-S138.
[20] Katz DL. Diets, diatribes, and a dearth of data. Circ Cardiovasc Qual Outcomes 2014; 7: 809-811. DOI:10.1161/CIRCOUTCOMES.114. 001458.
[21] Woo Baidal JA, and Taveras EM. Protecting Progress against childhood obesity — The national school lunch program. N Engl J Med 2014; 371 (20): 1862-1865.
[22] Kartikey K, Kumar R, Singh G, Takahashi T, Cornelissen G, De Meester F, Singh RB. Effect of duck egg infant milk on body weight in babies with undernutrition. A randomized, controlled trial. Presented at the 18th World Congress on Clinical Nutrition, Ubon Ratchithani, Thailand, Dec 1-3, 2014.
[23] Harder T, Rodekamp E, Schellong K, Dudenhausen JW, Plagemann A. Birth weight and subsequent risk of type 2 diabetes: A meta-analysis. Am J Epidemiol 2007; 165: 849–857.
[24] Keith P. West Jr, KP, Shamim AA, Mehra S, Labrique AB, Ali H, Shaikh S, Klemm RDW, Wu LS-F, Mitra M, Haque R, Hanif AAM, Massie AB, Merrill RD, Schulze KJ, Christian P.

Effect of maternal multiple micronutrient vs iron–folic acid supplementation on infant mortality and adverse birth outcomes in rural Bangladesh The JiVitA-3 randomized trial. JAMA. 2014;312(24):2649-2658.doi:10.1001/jama. 2014.16819.

Chapter 27

[1] Editorial, Air pollution at the forefront of global health. Lancet 2015; 385: 2224.
[2] Gold DR, Mittleman MA. New insights into pollution and the cardiovascular system: 2010 to 2012. Circulation. 2013;127: 1903–1913
[3] Brook RD, Rajagopalan S, Pope CA III, Brook JR, Bhatnagar A, Diez-Roux AV, Holguin F, Hong Y, Luepker RV, Mittleman MA, Peters A, Siscovick D, Smith SC Jr, Whitsel L, Kaufman JD; on behalf of the American Heart Association Council on Epidemiology and Prevention, Council on the Kidney in Cardiovascular Disease, and Council on Nutrition, Physical Activity and metabolism. Particulate matter air pollution and cardiovascular disease: an update to the scientific statement from the American Heart Association. Circulation. 2010;121:2331–2378.
[4] Sun Q, Hong X, Wold LE. Cardiovascular effects of ambient particulate air pollution exposure. Circulation. 2010;121:2755–2765.
[5] Gold DR, Samet JM. Air pollution, climate, and heart disease. Circulation 2013; 128: e411-e414doi: 10.1161/CIRCULATIONAHA. 113.003988.
[6] Pal R, Mahima, Gupta A, Singh C, Anamika Tripathi A, Singh RB. The effects of fireworks on ambient air and possible impact on cardiac health, during deepawali festival in north India. World Heart J 2013;5:21-32.
[7] Singh RB, Sharma JP, Rastogi V, Raghuvanshi RS, Moshiri M, Verma SP, Janus ED. Prevalence of coronary artery disease and coronary risk factors in rural and urban populations of north India. Eur Heart J 1997; 18: 1728-1735.
[8] Wilhelm M, Schulz C, Schwenk M. Revised and new reference values for arsenic, cadmium, lead, and mercury in blood or urine of children: basis for validation of human biomonitoring data in environmental medicine. Int J Hyg Environ Health. 2006 May; 209(3):301-5.
[9] Mordukhovich I, Wright RO, Hu H, Amarasiriwardena C, Baccarelli A, Litonjua A, Sparrow D, Vokonas P, Schwartz J. Associations of toenail arsenic, cadmium, mercury, manganese, and lead with blood pressure in the normative aging study. Environ Health Perspect. 2012;120:98-104. doi: 10.1289/ehp.1002805.
[10] Horton LM, Mortensen ME, Iossifova Y, Wald MM, Burgess P. What do we know of childhood exposures to metals (arsenic, cadmium, lead, and mercury) in emerging market countries? Int J Pediatr. 2013; 2013:872596. Epub 2013 Jan 8.
[11] Pope CA III, Hansen ML, Long RW, Nielsen KR, Eatough NL, Wilson WE, Eatough DJ. Ambient particulate air pollution, heart rate variability, and blood markers of inflammation in a panel of elderly subjects. Environ Health Perspect. 2004; 112:339-345.
[12] Editorial. Air pollution: Europe’s avoidable health risk. Lancet, 2013;381: 876, doi:10.1016/ S0140-6736(13)60656-X.

Chapter 28

[1] Mega JL, Stitziel NO, Smith JG, Chasman DI, Caulfield MJ, Devlin JJ, Nordio F, Hyde CL, Cannon CP, Sacks FM, Poulter NR, Sever PS, Ridker PM, Braunwald E, Melander O, Kathiresan S, Sabatine MS. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet 2015; 385: 2264-2271.
[2] Huang CC, Fornage M, Lloyd-Jones DM, Wei GS, Boerwinkle E, Liu K. Longitudinal association of PCSK9 sequence variations with low-density lipoprotein cholesterol levels: the Coronary Artery Risk Development in Young Adults Study. Circ Cardiovasc Genet 2009; 2: 354–361.
[3] Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354: 1264–1272.
[4] Cui Q, Ju X, Yang T, Zhang M, Tang W, Chen Q, Hu Y, Haas JV, Troutt JS, Pickard RT, Darling R, Konrad RJ, Zhou H, Cao G. Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population. Atherosclerosis 2010; 213: 632–636.
[5] Benn M, Nordestgaard BG, Grande P, Schnohr P, Tybjaerg-Hansen A. PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. J Am Coll Cardiol 2010; 55: 2833–2842.
[6] Shehab A, Elkilany G, Singh RB, Hristova K, Chaves H, Cornelissen G, Otsuka K. Coronary risk factors in South West Asia. Editorial. World Heart J 2015; 7: 21-30.
[7] Singh RB, Sharma JP, Rastogi V, Raghuvanshi RS, Moshiri M, Verma SP, Janus ED. Prevalence of coronary artery diseases and coronary risk factors in rural and urban populations of north India. Euro Heart J 1997; 18: 1728-1735.
[8] Pella D, Thomas N, Tomlinson B, Singh RB. Prevention of coronary artery disease: the South Asian paradox. Lancet 2003; 361: 79-80.
[9] Singh RB, Niaz MA, Ghosh S, Beegum R, Rastogi V, Sharma JP, Dube GK. Association of trans fatty acids (vegetable ghee) and clarified butter (Indian ghee) intake with higher risk of coronary heart disease in rural and urban populations with low fat consumption. Int J Cardiol 1996; 56: 289-298.
[10] Patel RS, Asselbergs FW, Quyyumi AA, Palmer TM, Finan CI, Tragante V, Dearfield J, Hemingway H, Hingorani AD, Holmes MV. Genetic variants at chromosome 9p21 and risk of first versus subsequent coronary heart disease events. A systematic review and meta-analysis. J Am Coll Cardiol 2014; 63: 2234–2245.
[11] Wauters E, Carruthers KF, Buysschaert I, Dunbar DR, Peuteman G, Belmans A, Budaj A, Van de Werf F, Lambrechts D, Fox KAA. Influence of 23 coronary artery disease variants on recurrent myocardial infarction or cardiac death: the GRACE Genetics Study. Eur Heart J 2013; 34: 993–1001.
[12] CARDIoGRAMplusC4D Consortium. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet 2013; 45: 25–33.
[13] Hughes MF, Saarela O, Stritzke J, Kee F, Silander K, Klopp N, Kontto J, Karvanen J, Willenborg C, Salomaa V, Virtamo J, Amouyel P, Arveiler D, Ferrières J, Wiklund P-G, Baumert J, Thorand B, Diemert P, Trégouët DA, Hengstenberg C, Peters A, Evans A, Koenig W, Erdmann J, Samani NJ, Kuulasmaa K, Schunkert H. Genetic markers enhance coronary risk prediction in men: the MORGAM prospective cohorts. PLoS One. 2012; 7: e40922.
[14] Vaarhorst AA, Lu Y, Heijmans BT. Literature-based genetic risk scores for coronary heart disease: the Cardiovascular Registry Maastricht (CAREMA) prospective cohort study. Circ Cardiovasc Genet 2012; 5:202–209.
[15] Virani SS, Brautbar A, Lee VV, Elayda M, Morrison AC, Grove ML, Nambi V, Frazier L, Wilson JM, Willerson JT, Boerwinkle E, Ballantyne CM. Chromosome 9p21 single nucleotide polymorphisms are not associated with recurrent myocardial infarction in patients with established coronary artery disease. Circ J 2012; 76: 950–956.
[16] Saboo B, Singh RB, Fedacko J, Hristova K, Elkilany G, Istavan T, Rai M, Wilson DW. Proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors. World Heart J 2015; 7 (in press).
[17] Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670–1678.
[18] Pencina MJ, Navar-Boggan AM, D'Agostino RB Sr, Williams K, Neely B, Sniderman AD, Peterson ED. Application of new cholesterol guidelines to a population-based sample. N Engl J Med 2014; 370: 1422–1431.
[19] Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW, American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: 2889–2934.
[20] Horton R. What is medicine’s five sigma? Lancet 2015; 385: 1380.

Chapter 29

[1] Maser RE, Mitchell BD, Vinik AI, Freeman R. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care 2003; 26: 1895–1901.
[2] Ziegler D, Gries FA, Spüler M, Lessmann F, Diabetic Cardiovascular Autonomic Neuropathy Multicenter Study Group. The epidemiology of diabetic neuropathy. J Diabetes and its Complications 1992; 6: 49-57.
[3] Wein TH, Albers JW. Diabetic neuropathies. Phys Med Rehabil Clin N Am 2001; 12: 307-320.
[4] Ziegler D, Gries FA, Muhlen H, Rathmann W, Spüler M, Lessmann F. Prevalence and clinical correlates of cardiovascular autonomic and peripheral diabetic neuropathy in patients attending diabetes centers. The Diacan Multicenter Study Group. Diabetes Metab 1993; 19: 143-151.
[5] Mamatha. Cardiovascular autonomic function test responses in patients with diabetes and non-diabetics. Biomedicine 2011; 31: 31-38.
[6] Khandelwal E, Jaryal AK, Deepak KK. Pattern and prevalence of cardiovascular autonomic neuropathy in diabetics visiting a tertiary care referral center in India. Indian J Physiol Pharmacol 2011; 55: 119-127.
[7] Khatoon N, Santhosh Kumar B, Hazari MAH. Cardiovascular autonomic neuropathy in patients with diabetes mellitus. Int J Pharma and Biosciences 2010; 1 (3): 1-7.
[8] Balcıoğlu AS, Müderrisoğlu H.

Diabetes and cardiac autonomic neuropathy: Clinical manifestations, cardiovascular consequences, diagnosis and treatment. World J Diabetes 2015; 6: 80–91. doi: 10.4239/wjd.v6.i1.80
[9] Low PA, Fealey RD. Sudomotor neuropathy. In: Dyck PJ, Thomas PK, Asbury AK, Winegrad AI, Porte D, eds. Diabetic Neuropathy. Philadelphia: Saunders; 1987. pp. 140–145.
[10] Ziegler D, Zentai C, Perz S, Rathmann W, Haastert B, Meisinger C, Löwel H. Diminished heart rate variability (HRV) and prolonged QTc interval, but not increased QT dispersion (QTD) are predictors of mortality in the diabetic population. Diabetes 2004; 53 (2): A57.
[11] Ziegler D, Dannehl K, Mühlen H, Spüler M, Gries FA. Prevalence of cardiovascular autonomic dysfunction assessed by spectral analysis, vector analysis, and standard tests of heart rate variation and blood pressure responses at various stages of diabetic neuropathy. Diabet Med 1992; 9: 806-814.
[12] Boulton AJM, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE, Sosenko JM, Ziegler D. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005; 28: 956–962.
[13] The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia 1998; 41: 416–423.
[14] Vinik AI, Erbas T. Diabetic autonomic neuropathy. Handb Clin Neurol. 2013; 117: 279–294.
[15] Witte DR, Tesfaye S, Chaturvedi N, Eaton SE, Kempler P, Fuller JH, EURODIAB Prospective Complications Study Group. Risk factors for cardiac autonomic neuropathy in type 1 diabetes mellitus. Diabetologia 2005; 48: 164–171.
[16] Ziegler D, Zentai C, Perz S, Rathmann W, Haastert B, Meisinger C, Löwel H, KORA Study Group. Selective contribution of diabetes and other cardiovascular risk factors to cardiac autonomic dysfunction in the general population. Exp Clin Endocrinol Diabetes 2006; 114: 153–159.
[17] World Health Organization. Diabetes Programme. Available from: http://www. who.int/diabetes/en/

Chapter 30

[1] Gerber Y, Weston SA, Redfield MM, Chamberlain AM, Manemann SM, Jiang JR, Killian JM, Roger VL. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med 2015; 175 (6): 996-1004. doi:10.1001/ jamainternmed.2015.0924
[2] Singh RB, Takahashi T, Nakaoka T, Otsuka K,Toda E, Shin HH, Lee MK, Beeharry V, Hristova K, Fedacko J, Pella D, De Meester F, Wilson DW, Juneja LR, Martirosyan DM. Nutrition in transition from Homo sapiens to Homo economicus. The Open Nutra J 2013; 6: 6-17.
[3] Esposito K, Giugliano D. Diet and inflammation: a link to metabolic and cardiovascular diseases. Eur Heart J 2006; 27: 15-20.
[4] Handjieva-Darlenska T, Hristova K, and Singh RB. Antioxidant vitamins and the heart. World Heart J 2014;6:179-184.
[5] Singh RB, Niaz MA, Ahmad S, Rastogi SS, Singh U, Agarwal P. Dietary and serum levels of antioxidants and minerals in patients with acute myocardial infarction. Trace Elem Electro 1995; 12:148-152.
[6] Singh RB, Niaz MA, Sharma JP, Kumar R, Bishnoi I, Begum R. Plasma levels of antioxidant vitamins and oxidative stress in patients with acute myocardial infarction. Acta Cardiol 1994; 49: 441-452.
[7] Singh RB, Ghosh S, Niaz MA, Singh R, Beegum R, Chibo H, Shoumin Z, Postiglione A. Dietary intake, plasma levels of antioxidant vitamins and oxidative stress in relation to coronary artery disease in elderly subjects. Am J Cardiol 1995; 76: 1233-8.
[8] Luca F, Perry GH, Di Rienzo A. Evolutionary adaptations to dietary changes. Annu Rev Nutr 2010; 30: 291–314.
[9] Singh RB, Rastogi SS, Singh R, Ghosh S, Niaz MA. Effects of guava intake on serum total and high density lipoprotein cholesterol levels and on systemic blood pressure. Amer J Cardiol 1992; 70: 1287-91.
[10] Singh RB, Rastogi SS, Niaz MA, Ghosh S, Singh R: Effects of fat modified and fruits vegetable enriched diets on blood lipids in the Indian diet heart study. Am J Cardiol 1992; 70: 869-874.
[11] Singh RB, Rastogi SS, Verma R, Bolaki L, Singh R, Ghosh S. An Indian experiment with nutritional modulation in acute myocardial infarction. Am J Cardiol 1992; 69: 879-85.
[12] Singh RB, Fedacko J, Vargova V, Pella D, Niaz MA, Ghosh S. Effect of low w-6/w-3 fatty acid ratio Paleolithic Style Diet in patients with acute coronary syndromes: A randomized, single blind, controlled trial. World Heart J 2012; 4: 71-84.
[13] De Lorgeril M, Renaud S, Mamelle N, Salen P, Martin JL, Moniaud I, Guidollet J, Touboul P, Delaye J. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. The Lancet 1994; 343: 1454–1459.
[14] Singh RB, Dubnov G, Niaz MA, Ghosh S, Singh R, Rastogi SS, Manor O, Pella D, Berry EM. Effect of an Indo-Mediterranean diet on progression of coronary disease in high risk patients: a randomized single blind trial. Lancet 2002; 360: 1455-1461.
[15] Estruch R, Ros E, Salas-Salvado J, Covas M-I, Corella D, Aros F, Gomez-Gracia E, Ruiz-Gutierrez V, Fiol M, Lapetra J, Lamuela-Raventos RM, Serra-Majem L, Pinto X, Basora J, Munoz MA, Sorli JV, Martinez JA, Martinez-Gonzalez MA, for the PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013; February 25, 2013, doi: 10.1056/NEJMoa1200303.
[16] Singh RB, Niaz MA, Rastogi SS, Rastogi S. Usefulness of antioxidant vitamins in suspected acute myocardial infarction (the Indian experiment of infarct survival-3). Am J Cardiol 1996; 77: 232-236.
[17] Singh RB, Niaz MA, Agarwal P, Beegum R, Rastogi SS, Sachan DS. A randomized, double blind, placebo controlled trial of L-carnitine in suspected acute myocardial infarction. Postgrad Med J 1996; 72: 45-50.
[18] Moyer VA, United States Preventive Services Task Force. Vitamin, mineral, and multivitamin supplements for the primary prevention of cardiovascular disease and cancer: USPSTF statement. Ann Intern Med 2014; 160(8): 558-64. doi: 10.7326/M14-0198. available at: http://annals.org.
[19] Singh RB, Fedacko J, Pella D, Hristova K, Chaves H, Milovanovic B, Handjiev S, Takahashi T, De Meester F, Wilson DW, Elkilany G, Baathallah S.

Angiotensin converting enzyme; a possible risk promoter during transition from undernutrition to chronic diseases of affluence. World Heart J 2014; 6: 209-213.
[20] Ye M, Wysocki J, Naaz P, Salabat MR, LaPointe MS, Batlle D. Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice: a renoprotective combination? Hypertension 2004;43:1120-1125.
[21] Singh RB, De Meester F, Juneja L, Mechirova V, Pella D. New risk factors of heart failure. Eur Heart J 2007; 28 (8): 1038-1039. DOI: 10.1093/eurheartj/ehm006.
[22] Fedacko J, Singh RB, Gupta A, Hristova A, Toda E, Kumar A, Saxena M, Baby A, Singh A, Takahashi T, Wilson DW. Inflammatory mediators in chronic heart failure in north India. Acta Cardiol 2014; 69: 391-98.
[23] Hristova K, Singh RB, Fedacko J, Toda E, Kumar A, Saxena M, Baby A, Takahashi T, De Meester F, Wilson DW.

Causes and risk factors of congestive heart failure in India. World Heart J 2013; 5: 13-20.
[24] Esterbaur H, Cheeseman K. Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. Methods Enzymol 1990; 186: 407-21.
[25] Niato C, Kawamura M, Yamamoto Y. Lipid peroxides as the initiating factor of atherosclerosis. Ann NY Acad Sci 1993; 676: 27-45.
[26] Chopra RK, Goldman R, Sinatra ST, Bhagavan HN. Relative bioavailability of coenzyme Q formulations in human subjects. Int J Vit Nutr Res 1998; 68: 109-13.
[27] Edlund PO. Determination of coenzyme Q, alpha-tocopherol and cholesterol in biological samples by coupled-column liquid chromatography with coulometric and ultraviolet detection. J Chromatogr 1988; 425: 87-97.
[28] Singh RB, Hristova K, El-Kilany G, Takahashi T, Shehab A, Chaves H, Wilson DW, Rupini D, Gupta N, Gupta R. Nutritional modulators of chronic heart failure. The Open Nutra J 2015; 8: 1-4.
[29] Witte KK, Clark AL, Cleland JG. Chronic heart failure and micronutrients. J Am Coll Cardiol 2001; 37: 1765-74.
[30] El-Kilany G, Singh RB, Hristova K, Milovanovic B, Chaves H, Wilson DW, Saboo B, Mahashwari A. Beyond drug therapy, nutritional perspectives in the management of chronic heart failure. Editorial, World Heart J 2015; 7 (in press).
[31] Lee JH, Jarreau T, Prasad A, Lavie C, O Keefe J, Ventura H. Nutritional assessment in heart failure patients. Congest Heart Fail 2011; 17: 199-203. doi: 10.1111/j.1751-7133.2011.00239.x.
[32] Abbate A. The heart on fire: inflammasome and cardiomyopathy. Exp Physiol 2013; 98: 385.
[33] Kumar A, Singh RB, Saxena M, Niaz MA, Josh SR, Chattopadhyay P, Mechirova V, Pella D, Chopra R. Effect of carni Q-gel (ubiquinol and carnitine) on cytokines in patients with heart failure in the Tishcon study. Acta Cardiol 2007; 62: 349-354.
[34] Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER III, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RY, Turner MB, on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2015 update: a report from the American Heart Association. Circulation 2015; 131: e29-e322. doi: 10.1161/ CIR.0000000000000152

Chapter 31

[1] World Health Organization. Data and statistics: mortality and health status. [Accessed January 12, 2012]. http://www.who.int/research/en/
[2] Naghavi M, Wang H, Lozano R, Davis A et al. (712 authors). Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet. 2015; 385 (No. 9963): 117-171 doi: 10.1016/S0140-6736(14)61682-2.
[3] Shehab A, Galal Elkilany G, Singh RB, Hristova K, Chaves H, Cornelissen G, Otsuka K. Coronary risk factors in South West Asia. World Heart J 2015; 7:21-30.
[4] Zadeh SS, Pahlevanlo A, Rad NG, Jalili M, Singh RB, Wilczynska A, De Meester F, Wilson DW. Can diet and lifestyle factors and geomagnetic forces predispose aggression? The Open Nutra J 2011; 4:176-179.
[5] Singh RB, Hristova K, Gligorijevic T, De Meester F, Saboo B, Elkilany G, Takahashi T, Mahashwari A, Cornelissen G, Hadi NR, Mohammad BI, Chibisov S, Abramova M, Shastun S. Can circadian restriction of feeding modulate autonomic nervous system dysfunction and cardiometabolic risk? World Heart J 2015;7: 31-42.
[6] Rosengren A, Hawken S, Ounpuu S, Sliwa K, Zubaid M, Almahmeed WA, Blackett KN, Amom CS, Sato H, Ysuf S. Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases, 13648 controls from 52 countries (the INTERHEART Study): case control study. Lancet 2004; 364: 953-962.
[7] Xu T, Li W, Teo K, Wang XY, Liu LS, Yusuf S, INTER-HEART China Investigators. Association of psychological risk factors and acute myocardial infarction in China: the INTER-HEART China study. Chin Med J (Engl). 2011; 124 (14): 2083-2088.
[8] Nabi H, Kivimäki M, Batty GD, Shipley MJ, Britton A, Brunner EJ, Vahtera J, Lemogne C, Elbaz A, Singh-Manoux A. Increased risk of coronary heart disease among individuals reporting adverse impact of stress on their health: the Whitehall II prospective cohort study. Eur Heart J. 2013; 34 (34): 2697-2705. doi: 10.1093/eurheartj/eht216. Epub 2013 Jun 26.
[9] Singh RB, Anjum B, Garg R, Verma NS, Singh R, Mahdi AA, Singh RK, De Meester F, Wilczynska A, Dharwadkar S, Takahashi T, Wilson DW. Association of circadian disruption of sleep and night shift work with risk of cardiovascular disease. World Heart J 2012; 4: 23-32.
[10] Cornelissen G, Halberg F, Bakken EE, Wang Z, Tarquini R, Perfetto F, Laffi G, Maggioni C, Kumagai Y, Homolka P, Havelkova A, Dusek J, Svacinova H, Siegelova J, Fiser B. Chronobiology of high blood pressure. Scripta Medica (Brno). 2007; 80: 157–166.
[11] Singh RB, Cornelissen G, Siegelova J, Homolka P, Halberg F. About half weekly (circaseptan) pattern of blood pressure and heart rate in men and women of India. Scripta Medica (Brno) 2002; 75:125-128.
[12] Singh RB, Hristova K, Pella D, Fedacko J, Chaves H, Mondal RN, Milovanovic B, Cornelissen G, Halberg F, Wilson D. Extended consensus on guidelines for assessment of risk and management of hypertension. A scientific statement of the International College of Cardiology - thank you Dr Franz Halberg. World Heart J 2014; 6: 63-72.
[13] Singh RB, Cornelissen G, Kumar A, Bathina S, Halberg F. Larger circadian amplitude of heart rate associated with active prayer in Hindu Indians in Asia. World Heart J 2009; 1: 219-222.
[14] Singh RB, Niaz MA, Cornelissen G, Otsuka K, Siegelova J, Fiser B, Halberg F. Circadian rhythmicity of circulating vitamin concentrations. Scripta Medica (Brno) 2001; 74: 93-96.
[15] Halberg F, Cornelissen G, Sothern RB, Czaplicki J, Schwartzkopff O. Thirty-five-year climatic cycle in heliogeophysics, psychophysiology, military politics, and economics. Izvestiya, Atmospheric and Oceanic Physics 2010; 46 (7): 844-864. (Back translation from Geophysical Processes and Biosphere 2009; 8: 13-42).
[16] Cornelissen G, Halberg F, Breus T, Syutkina EV, Baevsky R, Weydahl A, Watanabe Y, Otsuka K, Siegelova J, Fiser B, Bakken EE. Non-photic solar associations of heart rate variability and myocardial infarction. J Atmos Solar-Terr Phys 2002; 64: 707-720.
[17] Vaccarino V, Goldberg J, Rooks C, Shah AJ, Veledar E, Faber TL, Votaw JR, Forsberg CW, Bremner JD. Post-traumatic stress disorder and incidence of coronary heart disease: A twin study. JAAC 2013; 62: 970-978.
[18] Assari S. Veterans and risk of heart disease in the United States: A cohort with 20 years of follow up. International J Prevent Medicine. 2014; 5: 703-709.
[19] Johnson AM, Rose KM, Elder GH Jr., Chambless LE, Kaufman JS, Heiss G, Military combat and risk of coronary heart disease and ischemic stroke in aging men: the Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol. 2010; 20 (2): 143.
[20] Dubnov G, Pella D, Singh RB. The effect of an alpha-linolenic acid rich diet on the circadian rhythm of cardiac events. World Heart J 2008; 1: 49-56.
[21] Singh RB, Halberg F, Cornelissen G, Siegelova J, Hristova J, Toda E, Takahashi T, Jan Fedacko J, Otsuka K. Personalized circadian timing of exercise. World Heart J 2013; 5: 79-90.
[22] Watanabe Y, Cornélissen G, Watanabe M, Watanabe F, Otsuka K, Ohkawa S-i, Kikuchi T, Halberg F. Effects of autogenic training and antihypertensive agents on circadian and circaseptan variation of blood pressure. Clin Exp Hypertens. 2003; 25: 405–412.
[23] Singh RB, Singh S, Fedacko J, Pella D, De Meester F. Pranayama: the power of breath. Int J Disab Human Dev 2009; 8: 141-153.
[24] Morgan N, Irwin MR, Chung M, Wang C. The effects of mind-body therapies on the immune system: meta-analysis. PLOS 2014. DOI: 10.1371/journal.pone.0100903.
[25] Cramer H, Lauche R, Dobos G. Characteristics of randomized controlled trials of yoga: a bibliometric analysis. BMC Complementary and Alternative Medicine 2014; 14: 328. doi: 10.1186 /1472-6882-14-328.
[26] Ciocchi S, Herry C, Grenier F, Wolff SBE, Letzkus JJ, Vlachos I, Ehrlich I, Sprengel R, Deisseroth K, Stadler MB, Müller C, Lüthi A. “Encoding of conditioned fear in central amygdala inhibitory circuits,” Nature, 2010; 468: 277-282.
[27] Paul-Labrador M, Polk D, Dwyer JH, Velasquez I, Nidich S, Rainforth M, Schneider R, Merz CN. Effects of a randomized controlled trial of transcendental meditation on components of the metabolic syndrome in subjects with coronary heart disease. Arch Intern Med 2006; 166:1218-1224.
[28] Bernardi I, Spadacini G, Bellwon J, Hajric R, Roskamm H, Frey AW. Effect of breathing rate on oxygen saturation and exercise performance in chronic heart failure. Lancet 1998; 351:1308-1311.
[29] Bernardi I, Gabutti A, Porta C, Spicuzza I. Slow breathing reduces chemoreflex response to hypoxia and hyercapnia and increases baroreflex sensitivity. J Hypertens 2001; 19: 2221-2229.
[30] Bernardi I, Wdowczyc-Szulc J, Valenti C, Castoldi S, Passino C, Spadacini G, Sleight P. Effects of controlled breathing, mental activity and mental stress with or without verbalization on heart rate variability. J Am Coll Cardiol 2000; 35: 1462-1469.
[31] Singh S, Singh G, Kartikey K, Singh RB. Effect of pranayama breathing patterns on naso-bronchial diseases: The power of breath. In Handbook of Pulmonary Medicine, Nova Science Publishers, NY 2009; 1-9.
[32] Singh RB, Beegom R, Rastogi V, Rastogi SS, Madhu V. Clinical characteristics of hypertension among patients of noninsulin dependent diabetes mellitus in North and South India. J Diab Assoc India 1996; 36: 45-50.
[33] Moodie R, Stuckler D, Monteiro C, Sheron N, Neal B, Thamarangsi T, Lincoln P, Casswel S on behalf of the Lancet NCD Group. Profits and pandemics: prevention of harmful effects of tobacco, alcohol, and ultra-processed food and drink industries. The Lancet 2013; 381 (9867): 670-679. (doi:10.1016/S0140-6736(12)62089).
[34] Bantle JP. Dietary fructose and metabolic syndrome and diabetes. J. Nutr. 2009; 139, 1263S–1268S.
[35] Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364 (9438): 937-952.
[36] Editorial. Veterans’ health care: a call of duty. Lancet 2015; 386: 1014.

Chapter 32

[1] Nintcheu-Fata S, Cornélissen G, Katinas G, Halberg F, Fiser B, Siegelova J, Masek M, Dusek J. Software for contour maps of moving least-squares spectra. Scripta medica (Brno) 2003; 76: 279-283.
[2] Katinas GS, Dementyev MV, Halberg F, Grambsch P, Sorokin AV, Cornélissen G. Evaluating the form of nonsinusoidal variations. World Heart J 2011; 3 (2): 135-149.
[3] Cornélissen G, Grambsch P, Halberg F. Editorial. World Heart J 2011; 3 (2): 123-134.
[4] Halberg F, Cornélissen G, Grambsch P, McCraty R, Beaty L, Siegelova J, Homolka P, Hillman DC, Finley J, Thomas F, Kino T, Revilla M, Schwartzkopff O. Personalized chronobiologic cybercare; other chronomics' progress by transdisciplinary cycles' congruences: Season's Appreciations 2009. J Appl Biomed 2011; 9: 1-34.
[5] Cornélissen G, Grambsch P, Sothern RB, Katinas G, Otsuka K, Halberg F. Congruent biospheric and solar-terrestrial cycles. J Appl Biomed 2011; 9: 63-102.
[6] Katinas GS, Chibisov SM. Chronome structure disturbances. Bulletin Scientific Journal of Peoples’ Friendship University of Russia Series Medical 2012;7: 122-123.
[7] Halberg F, Cornélissen G. Consensus concerning the chronome and the addition to statistical significance of scientific signification. Biochim Clin 1991; 15: 159-162.
[8] Halberg F, Carandente F, Cornélissen G, Katinas GS. Glossary of chronobiology. Chronobiologia 1977; 4 (Suppl. 1), 189 pp.
[9] Katinas GS, Chibisov SM, Schwartzkopff O, Cornélissen G, Halberg F. ~12-hour and ~84-hour oscillations during human adjustments to crossing time zones: more than waveform descriptors. Int J Geronto-Geriatrics 2010; 13 (1): 9-19.
[10] Katinas GS, Cornélissen G, Schwartzkopff O, Halberg F, Chibisov SM, Shastun SA, Dvornikov VE, Frolov VA. Visualization of amplitude-phase relationships in entrainment processes. Vestnik PFUR, seria Meditsina, 2012 (2): 13-22.

Selected Bibliography of G. S. Katinas

– Chronobiologic glossary. Internat. J. Chronobiol., 1973, v.1, 31 - 63. * F. Halberg et al. – Ultradian rhythms of cell proliferation in normal tissues (in Russian). Arch. Anat., 1974, v. 66, № 4, 44 – 49. – Transplant chronobiology. In: Chronobiology. Tokyo, Igaku Shoin LTD, 1974. 320 - 328. * F. Halberg et al.
– Der quantitative Wert der Eigenschaften des Gewebes als System. 71. Versammlung Anat. Gesellschaft, Kurzfassungen der Vortrage. Rostock, 1976, 114 - 116. – Method for natural periodisation of processes (in Russian). Arch. Anat., 1976, v. 71, № 9, 98 - 103. * V.L. Bykov. – Der quantitative Ausdruck der Gewebseigenschaften als System. Verh. Anat. Ges., 1977, Bd. 71, 291 - 295.
– Glossary of chronobiology. Chronobiologia, 1977 v. 4, Supplementum, 1 - 189. * F. Halberg et al. – Non-stationary data series and their computation at the investigations of the structure of an alive object (in Russian). In. Neuron microscopy in vivo (ed. by V.N. Majorov) L., Nauka, 1978, 136 - 149, 168 - 174.
– Biological rhythms and their adaptive dynamics. In: Ecological physiology of humans (a volume of Handbook of physiology (ed. by N.N. Vasilevsky, in Russian). L., Nauka, 1980, 468 - 528. * N.I. Moiseeva. – Structural levels of alive systems organization and biological rhythms (in Russian). In: Temporal factor in the functional organization of alive systems. L., 1980, 82 - 85. – Temporal and spatial tissue organization (in Russian, editor). L., 1981. – Zur Charakterisierung ultradianer Biorhithmen des Funktionzustandes einiger Gewebe bei adaptiven Reaktionen. In: Chronobiologie Chronomedizin. Vortrage des Deutsch-Sovietischen Symposium. Berlin, Akademie-Verlag, 1981, 511 - 526.
– Biological rhythms in tissue regeneration. In: 3. DDR - UdSSR Symp. Chronobiologie und Chronomedizin. Halle, 1986, 18 - 19. – General principles of tissue systems organization (in Russian). Arch. Anat., 1986, v. 91, № 10, 91 – 110.
– The ground concepts of chronobiology and chronomedicine (in Russian). In: Handbook of chronobiology and chronomedicine (ed. by F.I. Komarov). M., Meditsina, 1989, 17 - 29. *V.A.Jakovlev. – Mathematical methods of biorhythms analysis (in Russian). In: Handbook of chronobiology and chronomedicine (ed. by F.I. Komarov). M., Meditsina, 1989, 29 - 45. * V.P.Karp. – Organization of biorhythmological investigations (in Russian). In: Handbook of chronobiology and chronomedicine (ed. by F.I. Komarov). M., Meditsina, 1989, 45 - 51. * V.A.Jakovlev. – The problems of necessity to use mathematical methods in chronobiology and chronomedicine (in Russian). Problems of Chronobiology, 1990, v.1, № 1 - 2, 27 - 37. * V.P.Karp. – Computative methods of analysis in chronobiology and chronomedicine (in Russian). St-Pb., Vostochnaja corona, 1997, 1 - 116. * V.P. Karp.

Systolic blood pressure (SBP) speed and acceleration relate to the SBP-MESOR and the left ventricular mass index (LVMI). Katinas G., Cornélissen G., Chen C.H., Rhodus N., Schaffer E., Halberg F. 6 Convegno Nazionale de Chronobiologia, Chianciano, Italy, November 27-28, 1998, p. 30. – Chronomes: time structures as markers of endocrine rhythms separating age trends from disease risk syndromes. Halberg F., Cornélissen G., Katinas G.S., Herold M., Klotz W., Kreze E., Perfetto F., Tarquini R., Maggioni C., Chen C.H., Schwartzkopff O. Speaker presentation abstract, Serono Int. Symp. Endocrinology of Aging, Tempe, Arizona, Oct. 27-30, 1999, p.8. – Case report of coexisting elderly MESOR-hypertension and circadian amplitude-hypertension (CHAT). Katinas G.S., Cornélissen G., Irizarry R., Shaffer E., Homans D., Rhodus N., Schwartzkopff O., Sigelowa J., Palat M., Halberg F. Geronto-Geriatrics 2: 68-86, 1999. – Chronobiology: time structures, chronomes, gauge aging, disease risk syndromes and the cosmos. Halberg F., Cornélissen G., Chen C-H., Katinas G.S., Otsuka K., Watanabe Y., Herold M., Loeckinger A., Kreze A., Kreze E., Perfetto F., Tarquini R., Maggioni C., Sothern R.B., Schwartzkopff O. J. Anti-Aging Med. 2000; 3 67-90 [Serono

]. – The pineal gland and chronobiologic history: mind and spirit as feedsidewards in time structures for prehabilitation. Halberg F., Cornélissen G., Conti C., Maestroni C., Maggioni C., Perfetto F., Salti R., Tarquini R., Katinas G.S., Schwartzkopff O. In: Bartsch C., Bartsch H., Blask D.E., Cardinali D.P., Hrushesky W.J.M., Mecke W., editors. The Pineal Gland and Cancer: Neuroimmunoendocrine Mechanisms in Malignancy. Heidelberg: Springer, 2000: 66-116.

Feedsidewards: intermodulation (strictly) among time structures, chronomes, in and around us, and cosmo-vasculo-neuroimmunity. About ten-yearly changes: what Galileo missed and Schwabe found. Halberg F., Cornélissen G., Katinas G.S., Watanabe Y., Otsuka K., Maggioni C., Perfetto F., Tarquini R., Schwartzkopff O., Bakken E.E. In: Conti A., Maestroni G.J.M., McCann S.M., Sternberg E.M., Lipton J.M., Smith C.C. (eds.), Neuroimmunomodulation (Proc. 4-th International Society for Neuroimmunomodulation, Lugano, Switzerland, September 29-October 2, 1999). Ann NY Acad Sci 2000; 917: 348-376. – Cross-spectrally coherent ~ 10.5- and 21-year biological and physical cycles, magnetic storms and myocardial infarctions. Halberg F., Cornélissen G., Otsuka K., Watanabe Y., Katinas G.S., Burioka N., Delyukov A., Gorgo Y., Zhao Z.U., Weydahl A., Sothern R.B., Siegelova J., Fiser B., Dusek J., Syutkina E.V., Perfetto F., Tarquini R., Singh R.B., Lofstrom D., Lofstrom P., Johnson P.W.C., Schwartzkopff O., International BIOCOS Study Group. Invited presentation, NATO Advanced Study Institute on Space Storms and Space Wether Hazards, Crete, Greece, June 19-29, 2000. Neuroendocrinol Lett 2000; 21: 233-258. – Solar modulations of physiology, pathology and even morphology, and a broader chronoastrobiology? Halberg F., Cornélissen G., Sothern R.B., Faraone P., Breus T., Starbuck S., Watanabe Y., Otsuka K., Engebretson M., Burioka N., Katinas G.S., Delyukov A., Gorgo Y., Winget C., Holley D., Delmore P., Schwartzkopff O. In: Anastasiadis A., editor. NATO Advanced Study Institute on Space Storms and Space Wether Hazards, Crete, Greece, June 19-29, 2000: 24-25.

About-daily (circadian) and about-weekly (circaseptan) patterns of human salivary melatonin. Herold M., Cornélissen G., Rawson M-J. Katinas G.S., Alinder C., Bratteli C., Gubin D., Halberg F. J Anti-Aging Med 2000; 263-267. – Individualized combination chronotherapy of coexisting CHAT and MESOR-hypertension including diltiazem HCl. Katinas G.S., Cornélissen G., Homans D., Schaffer E., Rhodus N., Siegelova J., Machat R., Halberg F. Scripta medica (Brno) 2000; 73: 95-104. – About-weekly electrical potential, chloroplast migration and oxygen production changes of Acetabularia in continuous light. Katinas G.S., Hillman D., Siegelova J., Dusek J., Cornélissen G., Halberg F. MEFA 8-th International Fair of Medical Technology and Pharmacy, Brno, Czech Republic, 7-10 Nov 2000, abstract 20. – Near 10-year and longer periods modulate circadians: intersecting anti-aging and chronoastrobiological research. Halberg F., Cornélissen G., Watanabe Y., Otsuka K., Fiser B., Siegelova J., Mazankova V., Maggioni C., Sothern R.B., Katinas G.S., Syutkina E.V., Burioka N., Schwartzkopff O. J Gerontol Med Sci. 2001, v. 56A, p M304 – M324.
– About 8- and ~84-hour rhythms in endotheliocytes as in endothelin-1 and effect of trauma. Katinas G.S., Halberg F., Cornélissen G., Hawkins D., Bueva M.V., Korzhevsky D.E., Sapozhnikova L.R., Rhodus N., Schaffer E. Peptides, 2001, v. 22, p. 647 - 659.
Katinas G, Nintcheu-Fata S, Cornélissen G et al. (2002). Moving least squares spectra scrutinize chronomics in and around us; Abstract 14. Congress MEFA. Brno, Czech Rep.
Halberg F., Cornélissen G., Otsuka K., Wang Zh., Katinas G., Siegelova J., Homolka P., Prikryl P., S. Chibisov et al. Chronoastrobiology: proposal, nine conferences, heliogeomagnetics, transyears, near-weeks, near-decades, phylogenetic and ontogenetic memories//Biomedicine and Pharmacotherapy. — 2004. — Vol. 58. — P. S143-S180.
Katinas G, Sapozhnikova L, Aviño Marrades J et al. (2005). Circadian time of trauma affects formation of collagen in scar's connective tissue: a chronometaanalysis. Abstract, 3rd Intl Conf “Civilization diseases in the spirit of V.I. Vernadsky,” Moscow, PFUR: 118-120.
Halberg F., Cornélissen G., Katinas G., Tvildiani L., Gigolashvili M., Janashia K., Toba T., Revilla M., Regal Ph., Sothern R.B., Wendt H.W., Wang Zh., Zeman M., Jozsa R., Singh R.B., Mitsutake G., Chibisov S.M. et al. Chronobiology’s progress. Part I, Season’s appreciations 2004-2005: time-, frequency-, phase-, variable-, individual-, age-, and site-specific chronomics//Journal of Applied Biomedicine. — 2006. — Vol. 4. — P. 1-38.
Halberg F., Cornélissen G., Katinas G., Tvildiani L., Gigolashvili M., Janashia K., Toba T., Revilla M., Regal Ph., Sothern R.B., Wendt H.W., Wang Zh., Zeman M., Jozsa R., Singh R.B., Mitsutake G., Chibisov S.M. et al. Chronobiology’s progress. Part II, Chronomics for an immediately applicable biomedicine//Journal of Applied Biomedicine. — 2006. — Vol. 4. — P. 73-86.
Chibisov SM, Katinas GS Circadian rhythms of the heart before and after electrical cardioversion//Modern high technologies. - 2008. - № 6.
Chibisov S.M., Katinas G.S., Salvador Sanchez-de la Pena, Kirichek A.A., Chibisova A.S., Kirichek S.G. Monitoreo hemodinamico para estudiar el temblor auricular//Int. J. of Geronto-geriatrics. — 2009. — Vol. 13 — № 2. — P. 30-34.
Halberg F., Cornélissen G., Salty R., Perfetto F., Tarquini R., Stagi S., Hillman D.C., Katinas G.S., Hoogerwerf W.A., Carandente F., Otsuka K., Czaplicki J., Chibisov S.M., Scheving L.A., Syutkina E.V., Masalov A., Mitsutake G., Wang Zh., Wan Ch., Schwartzkopff O., Bakken E.E. CHRONOAUXOLOGY. Chronomics: trends and cycles in growth and cosmos rather than secularity./NICOMP, 2010. — 90 p.
Katinas GS, Chibisov SM, Schwartzkopff O et al. (2010). ~12-hour and ~84-hour oscillations during human adjustments to crossing time zones: more than waveform descriptors. Internat J Geronto-Geriatrics. 13, 1: 9-19.
Katinas GS, Dementyev MV, Halberg F et al. (2011). Evaluating the form of nonsinusoidal variations. World Heart J, 3(2): 135-149.
Katinas GS, Mamontov OV, Konrady AO et al. (2011). Optimization of chronotherapy of hypertension according to ambulatory blood pressure monitoring (ABPM) after modeling circadian rhythms (CR) by means of Sawittzky-Goley filters. 14th Соngг Intl Sос Holter Noninvasive Electrocardiology (ISHNE2011), Book of Abstracts. Moscow: 8.
Halberg F., Sothern R.B., Katinas G., Cornélissen G., Watanabe Y., Chibisov S.M., Shastun S.A., Frolov V.A. Why decades-long chronobiologically interpreted blood pressure and heart rate monitoring (C-ABPM) coperiodisms toward a chronousphere?//Вестник РУДН. Серия Медицина. — 2012. — № 1. — 27-36.
Katinas G.S., Cornélissen G., Schwartzkopff O., Halberg F., Chibisov S.M., Shastun S.A., Dvornikov V.E., Frolov V.A. Visualization of amplitude-phase relationships in entrainment processes//Вестник РУДН. – Серия медицина. – 2012. – № 2. – С. 13-22.
Chibisov SM, Katinas GS, Ragulskaya MV. Biorhythms and Space: Monitoring kosmobiosfernyh ties. M. Publ “Capital Print,” 2013, p. 442.

If you have any questions or comments with regards to this book, please fill out the form below. Thank you!

You have not viewed any product yet.